<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003352.pub4" GROUP_ID="ADDICTN" ID="465599092322320863" MERGED_FROM="" MODIFIED="2015-05-27 13:50:41 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;To do&lt;br&gt;-add contribution of reviewers&lt;br&gt;-add dates for all the search strategies in the abstract&lt;br&gt;-in the background add the reference for Giannini 1986&lt;/p&gt;&lt;p&gt;To check (corrections done by the editorial base)&lt;/p&gt;&lt;p&gt;-added dates of publication of protocol and review &lt;br&gt;-added synopsis&lt;br&gt;-added abstract background&lt;br&gt;-deleted (4) miscellaneous in the Background&lt;br&gt;-deleted (ii) where possible, perform meta-analytic synthesis...&lt;/p&gt;&lt;p&gt;Search Strategies:&lt;br&gt;-added the drug and alcohol group register;&lt;br&gt;Description of studies:&lt;br&gt;-added all the links to studies&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-05-27 14:44:56 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="31" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2015-05-27 14:44:56 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-02-28 12:35:37 +0100" MODIFIED_BY="Laura Amato">Dopamine agonists for the treatment of cocaine dependence</TITLE>
<CONTACT>
<PERSON ID="11445" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Laura</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Amato</LAST_NAME>
<SUFFIX/>
<POSITION>Joint Co-ordinating Editor</POSITION>
<EMAIL_1>l.amato@deplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390683060483</PHONE_1>
<PHONE_2/>
<FAX_1>+390683060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-05-27 14:48:55 +0200" MODIFIED_BY="Laura Amato">
<PERSON ID="6297" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Silvia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Minozzi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>minozzi.silvia@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11445" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Laura</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Amato</LAST_NAME>
<SUFFIX/>
<POSITION>Joint Co-ordinating Editor</POSITION>
<EMAIL_1>l.amato@deplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390683060483</PHONE_1>
<PHONE_2/>
<FAX_1>+390683060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6BDED43782E26AA2010A621ACB97CD51" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pier Paolo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pani</LAST_NAME>
<SUFFIX/>
<POSITION>Head</POSITION>
<EMAIL_1>pallolo@tin.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+39 349 3280112</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Social-Health Division</DEPARTMENT>
<ORGANISATION>Health District 8 (ASL 8) Cagliari</ORGANISATION>
<ADDRESS_1>Via Logudoro 17</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cagliari</CITY>
<ZIP>09127</ZIP>
<REGION>Sardinia</REGION>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 070 6093604</PHONE_1>
<PHONE_2/>
<FAX_1>+39 070 6093604</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="36961232586228493457110111093354" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Renata</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solimini</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>renata.solimini@iss.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Therapeutic Research and Medicines Evaluation</DEPARTMENT>
<ORGANISATION>Drug Abuse and Doping Unit, Istituto Superiore di Sanità</ORGANISATION>
<ADDRESS_1>viale Regina Elena 299</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00161</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 06 4990 3654</PHONE_1>
<PHONE_2/>
<FAX_1>+39 06 4990 2016</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11551" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Simona</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vecchi</LAST_NAME>
<SUFFIX/>
<POSITION>Research worker</POSITION>
<EMAIL_1>s.vecchi@deplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>39 0683060457</PHONE_1>
<PHONE_2/>
<FAX_1>39 0683060374</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1501071342372317310145724088396" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Franco</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>De Crescenzo</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>decrescenzo.franco@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Psychiatry and Psychology</DEPARTMENT>
<ORGANISATION>Catholic University of the Sacred Heart</ORGANISATION>
<ADDRESS_1>L.go A. Gemelli 8</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00168</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="84467130045058647163110111094021" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Piergiorgio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zuccaro</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>piergiorgio.zuccaro@iss.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Therapeutic Research and Medicines Evaluation</DEPARTMENT>
<ORGANISATION>Drug Abuse and Doping Unit, Istituto Superiore di Sanità</ORGANISATION>
<ADDRESS_1>viale Regina Elena 299</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00161</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 06 4990 2909</PHONE_1>
<PHONE_2/>
<FAX_1>+39 06 4990 2016</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6213" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Davoli</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinating Editor</POSITION>
<EMAIL_1>m.davoli@deplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>Lazio Regional Health Service</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00199</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 06 83060 444</PHONE_1>
<PHONE_2/>
<FAX_1>+39 06 83060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-05-11 11:18:06 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="12" MONTH="1" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="1" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="1" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-05-27 14:44:56 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-05-27 14:42:42 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>typo correction</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-05-27 14:44:56 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-05-27 14:44:52 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>We included one new trial, and conclusions were not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-27 14:44:56 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>We performed a new search up to 12 January 2015.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-03-31 12:13:14 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>New authors, new searches, new studies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-03-31 12:13:06 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>New authors, new searches, new studies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-30 15:06:20 +0200" MODIFIED_BY="Laura Amato">
<DATE DAY="21" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="25" MONTH="2" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-05-14 10:42:47 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2015-05-14 10:42:29 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-05-14 10:42:03 +0200" MODIFIED_BY="[Empty name]">
<NAME>Department of Epidemiology, Lazio Regional Health Service, ASL RM E</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-05-14 10:42:47 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-05-14 10:42:47 +0200" MODIFIED_BY="[Empty name]">
<NAME>Italian Drug Agency</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-05-27 14:42:00 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-05-27 14:42:00 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-05-11 12:38:34 +0200" MODIFIED_BY="[Empty name]">Dopamine agonists for the treatment of people who misuse cocaine</TITLE>
<SUMMARY_BODY MODIFIED="2015-05-27 14:42:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>A pharmacological agent with proven efficacy does not exist for treatment of cocaine misuse. Cocaine is an alkaloid derived from the erythroxylon coca leaf that is used as powder for intranasal or intravenous use or as crack, a free-base form which is smoked. Cocaine misuse is a major public health problem because its use can be associated with medical and psychosocial complications including the spread of infectious diseases (such as AIDS, hepatitis and tuberculosis), crime, violence and neonatal drug exposure. In this Cochrane Review we looked at the evidence on the efficacy and acceptability of dopamine agonists as a treatment, used either alone or in combination with any psychosocial intervention, for people addicted to cocaine.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched scientific databases and internet resources to identify randomised controlled trials (where participants are allocated at random to any dopamine agonist drug or placebo or another type of drug aimed to reduce use of cocaine. We also assessed dropout from treatment and frequency of side effects. We included adults of any gender, age or ethnicity.</P>
<P>
<B>Key results</B>
</P>
<P>We included 24 studies with 2147 participants, who were all addicted to cocaine. Most were men (82.%)with an average age of 37 years. The mean duration of the included trials was seven weeks (range 1.5 to 16 weeks) Twenty-two studies were conducted in USA, one in Brazil and one in Spain; all but four were outpatients.</P>
<P>The included trials studied the following drugs: amantadine, bromocriptine, L dopa/Carbidopa, pergolide, cabergoline hydergine, and pramipexole. All compared dopamine agonist versus placebo. Four studies compared amantidine versus antidepressants.</P>
<P>No differences were found between the drugs and placebo for any of the outcomes considered: dropout (moderate quality of evidence), abstinence (low quality of evidence), severity of dependence (low quality of evidence), adverse events (moderate quality of evidence). Antidepressants was found to be better than the dopamine agonist amantidine for abstinence, but this was based on two studies with very few participants and low quality of evidence. There is no current evidence supporting the clinical use of dopamine agonist medications in the treatment of cocaine misuse. The evidence is current to 12 January 2015.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-05-12 13:27:00 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-05-04 14:02:56 +0200" MODIFIED_BY="[Empty name]">
<P>Cocaine misuse is a disorder for which no pharmacological treatment of proven efficacy exists. Advances in neurobiology could guide future medication development.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-05-11 12:35:35 +0200" MODIFIED_BY="[Empty name]">
<P>To investigate the efficacy and acceptability of dopamine agonists alone or in combination with any psychosocial intervention for the treatment of of people who misuse cocaine.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-05-04 14:29:35 +0200" MODIFIED_BY="[Empty name]">
<P>We run the search on 12 January 2015. We searched the Cochrane Drugs and Alcohol Group (CDAG) Specialized Register, PubMed, EMBASE, CINAHL, PsycINFO, ICTRP, clinicaltrials.gov and screened reference lists.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-05-11 12:36:14 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing dopamine agonists alone or associated with psychosocial intervention with placebo, no treatment or other pharmacological interventions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-05-04 11:41:49 +0200" MODIFIED_BY="[Empty name]">
<P>We used standard Cochrane methodological procedures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-05-12 13:27:00 +0200" MODIFIED_BY="[Empty name]">
<P>Twenty four studies, including 2147 participants, met the inclusion criteria. Comparing any dopamine agonist versus placebo, we found no differences for any of the outcomes considered: dropout (moderate quality of evidence), abstinence (low quality of evidence), severity of dependence (low quality of evidence), adverse events (moderate quality of evidence). This was also observed when single dopamine agonists were compared against placebo. Comparing amantadine versus antidepressants, we found low quality of evidence that antidepressants performed better for abstinence (RR 0.25, 95% CI 0.12 to 0.53) based on two studies with 44 participants. No differences were found for dropout or adverse events, for both moderate quality of evidence.</P>
<P>The major flaws of the included studies concerned selection bias because most studies did not report information about sequence generation (80%) and allocation concealment methods (86%): half of the included studies were judged at unclear risk of performance bias and 62.5% at unclear risk of detection bias for what concerns subjective outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-05-04 14:06:57 +0200" MODIFIED_BY="[Empty name]">
<P>Current evidence from RCTs does not support the use of dopamine agonists for treating cocaine misuse. This absence of evidence may leave to clinicians the alternative of balancing the possible benefits against the potential adverse effects of the treatment. Even the potential benefit of combining a dopamine agonist with a more potent psychosocial intervention, which was suggested by the previous Cochrane Review (<A HREF="Soares 2003">Soares 2003</A>), is not supported by the results of this Cochrane Review update.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-05-14 10:35:33 +0200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-05-12 13:31:12 +0200" MODIFIED_BY="[Empty name]">
<P>Cocaine is an alkaloid derived from the leaf of erythroxylon coca. People commonly use it as a powder, for intranasal or intravenous use, or as crack, a free-base form which is smoked. Cocaine dependence is a major public health problem that is characterized by recidivism and a host of medical and psychosocial complications (<LINK REF="REF-UNODC-2014" TYPE="REFERENCE">UNODC 2014</LINK>). There is a wide and well documented range of consequences associated with acute and chronic use of this drug, such as medical, psychological and social problems, including the spread of infectious diseases (e.g. AIDS, hepatitis and tuberculosis), crime, violence and neonatal drug exposure (<LINK REF="REF-Higgins-1994" TYPE="REFERENCE">Higgins 1994</LINK>). Both injection and non-injection cocaine use can increase the risk of HIV infection through high risk injecting and sexual behaviours (<LINK REF="REF-Sorensen-1991" TYPE="REFERENCE">Sorensen 1991</LINK>). </P>
<P>The illicit use of cocaine has become a persistent health problem worldwide.</P>
<P>The annual prevalence of cocaine use on a global estimate is 0.4% (0.3 to 0.4%), with a higher annual prevalence in Oceania (1.5%) and North America (1.8%), and a lower annual prevalence in Asia (0.05%). The number of first-time users has declined in recent years due to a decrease in the global availability of cocaine, related to a one-quarter reduction in the cultivation of coca bush (<LINK REF="REF-UNODC-2014" TYPE="REFERENCE">UNODC 2014</LINK>)</P>
<P>Although cocaine prevalence figures are much lower than comparable figures for cannabis, the prevalence of use among young adults can be higher than the population average. </P>
<P>In Europe, lifetime prevalence for cocaine among 15- to 64-year-olds is 4.2% and ranges from 0.4% to 9.0%, with the highest levels being found in Spain (8.8%) and in United Kingdom (UK) (9.0%); recent use among 15- to 34-year-olds is 1.7% with Spain and UK having rates over 3% (<LINK REF="REF-EMCDDA-2014" TYPE="REFERENCE">EMCDDA 2014</LINK>).</P>
<P>In the USA, 0.6% of the population (1.5 million) currently uses cocaine and the lifetime prevalence for cocaine use is about 13.7% (<LINK REF="REF-SAMHSA-2014" TYPE="REFERENCE">SAMHSA 2014</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-05-12 13:33:43 +0200" MODIFIED_BY="[Empty name]">
<P>Cocaine dependence remains a disorder for which no pharmacological treatment of proven efficacy exists, although considerable advances in the neurobiology of this addiction could guide future medication development. The effect of this drug seems to rely on its ability to increase the availability of monoamines (dopamine, serotonin and noradrenaline) in the brain. An increase in dopamine levels in specific areas of the meso-limbic system, such as the nucleus accumbens, has been associated with the rewarding effect of drugs and self-administration behaviour in animal and human (<LINK REF="REF-Di-Chiara-1988" TYPE="REFERENCE">Di Chiara 1988</LINK>; <LINK REF="REF-Drevets-1999" TYPE="REFERENCE">Drevets 1999</LINK>; <LINK REF="REF-Drevets-2001" TYPE="REFERENCE">Drevets 2001</LINK>; <LINK REF="REF-Volkow-2003a" TYPE="REFERENCE">Volkow 2003a</LINK>). Specifically, the speed with which addictive drugs enter the brain and elevates dopamine levels in the nucleus accumbens seems to be positively correlated with addictive potential (<LINK REF="REF-Volkow-1995" TYPE="REFERENCE">Volkow 1995</LINK>; <LINK REF="REF-Volkow-2003b" TYPE="REFERENCE">Volkow 2003b</LINK>; <LINK REF="REF-Kimmel-2007" TYPE="REFERENCE">Kimmel 2007</LINK>). Among addictive drugs, cocaine is the most directly involved in the activation of dopaminergic system, since acute cocaine-induced increase of extracellular dopamine is due to the inhibition of its presynaptic reuptake through the blockade of its transporter (<LINK REF="REF-Self-1995" TYPE="REFERENCE">Self 1995</LINK>; <LINK REF="REF-Gold-1997" TYPE="REFERENCE">Gold 1997</LINK>; <LINK REF="REF-Wise-2005" TYPE="REFERENCE">Wise 2005</LINK>). On the contrary, chronic cocaine abuse leads to down-regulation of dopaminergic systems (<LINK REF="REF-Volkow-1997" TYPE="REFERENCE">Volkow 1997</LINK>; <LINK REF="REF-Gardner-1999" TYPE="REFERENCE">Gardner 1999</LINK>; <LINK REF="REF-Volkow-1999a" TYPE="REFERENCE">Volkow 1999a</LINK>; <LINK REF="REF-Volkow-2006" TYPE="REFERENCE">Volkow 2006</LINK>; <LINK REF="REF-Martinez-2009" TYPE="REFERENCE">Martinez 2009</LINK>; <LINK REF="REF-Volkow-2010" TYPE="REFERENCE">Volkow 2010</LINK>). Depression following post-cocaine use and cocaine craving may be linked to this down-regulation.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-05-12 13:31:51 +0200" MODIFIED_BY="[Empty name]">
<P>These pre-clinical findings are the theoretical foundations on which the use of dopamine agonists for the treatment of cocaine dependence is based. Given this knowledge, manipulation of dopamine transmission in the reward circuitry of the brain has been looked as the mainstay of the development of new medications for the treatment of cocaine addiction. More specifically, dopamine agonists or antagonists, acting on brain dopamine transporter or brain dopamine receptors, have been tested.</P>
<P>Use of dopamine agonists is based primarily on two reasons:</P>
<UL>
<LI>Slow-onset long acting dopamine agonists will have less addictive potential (<LINK REF="REF-Volkow-1999b" TYPE="REFERENCE">Volkow 1999b</LINK>; <LINK REF="REF-Volkow-2003b" TYPE="REFERENCE">Volkow 2003b</LINK>);</LI>
<LI>Dopamine agonists will ameliorate dopaminergic dysfunction, counter-acting mesolimbic dopaminergic down regulation consequent to chronic use of cocaine, thereby reducing craving and the risk of relapse (<LINK REF="REF-Gardner-1999" TYPE="REFERENCE">Gardner 1999</LINK>; <LINK REF="REF-Volkow-1999a" TYPE="REFERENCE">Volkow 1999a</LINK>; <LINK REF="REF-Volkow-2006" TYPE="REFERENCE">Volkow 2006</LINK>; <LINK REF="REF-Volkow-2010" TYPE="REFERENCE">Volkow 2010</LINK>).</LI>
</UL>
<P>Under this assumption, dopamine agonists may alleviate cocaine abstinence symptomatology, reduce craving and the risk of relapse.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-05-14 10:35:33 +0200" MODIFIED_BY="[Empty name]">
<P>Although effective pharmacotherapy is available for people who are heroin (<LINK REF="REF-Faggiano-2003" TYPE="REFERENCE">Faggiano 2003</LINK>; <LINK REF="REF-Mattick-2008" TYPE="REFERENCE">Mattick 2008</LINK>; <LINK REF="REF-Mattick-2009" TYPE="REFERENCE">Mattick 2009</LINK>) or alcohol dependent (<LINK REF="REF-Amato-2010" TYPE="REFERENCE">Amato 2010</LINK>; <LINK REF="REF-R_x00f6_sner-2010a" TYPE="REFERENCE">Rösner 2010a</LINK>; <LINK REF="REF-R_x00f6_sner-2010b" TYPE="REFERENCE">Rösner 2010b</LINK>), none currently exists for people who are cocaine dependent. This is despite three decades of clinical trials on the efficacy of pharmacological and psychosocial interventions to treat this syndrome.</P>
<P>Four Cochrane Reviews have been published on the efficacy of antipsychotics (<LINK REF="REF-Amato-2007" TYPE="REFERENCE">Amato 2007</LINK>), anticonvulsants (Minozzi 2015), antidepressants (<LINK REF="REF-Pani-2011" TYPE="REFERENCE">Pani 2011</LINK>) and psychostimulants (<LINK REF="REF-Castells-2010" TYPE="REFERENCE">Castells 2010</LINK>) for people with cocaine dependence but none found support for the efficacy of these treatments. Moreover, a Cochrane Review assessing the efficacy and safety of disulphiram (<LINK REF="REF-Pani-2010" TYPE="REFERENCE">Pani 2010</LINK>) has shown low evidence supporting its clinical use for the treatment of cocaine dependence.</P>
<P>One Cochrane Review has been published on the efficacy of psychosocial treatments for psychostimulants dependence (<LINK REF="REF-Knapp-2007" TYPE="REFERENCE">Knapp 2007</LINK>). It shows that existing treatments demonstrate modest outcomes at best. Therefore, there is still a need to develop and test different formats of existing treatment models and newer psychosocial interventions should be undertaken.</P>
<P>Cocaine dependence remains a disorder for which no pharmacological treatment of proved efficacy exists, although considerable advances in the neurobiology of this addiction could guide future medication development.</P>
<P>The former Cochrane Review on dopamine agonists for cocaine dependence was published in 2003 (<LINK REF="REF-Soares-2003" TYPE="REFERENCE">Soares 2003</LINK>) and updated in 2011 (<LINK REF="REF-Amato-2011" TYPE="REFERENCE">Amato 2011</LINK>). Moreover, the review on psychostimulants, which actually are dopamine agonists (<LINK REF="REF-Castells-2010" TYPE="REFERENCE">Castells 2010</LINK>), did not consider medications devoid of psychostimulant effect. Therefore, a review update is required to examine the effect of dopamine agonists that do not have psychostimulant effects..</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-05-12 13:34:11 +0200" MODIFIED_BY="[Empty name]">
<P>To investigate the efficacy and acceptability of dopamine agonists alone or in combination with any psychosocial intervention for the treatment of of people who misuse cocaine.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-05-12 13:37:28 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-05-04 13:57:52 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-05-04 13:57:52 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) which focused on the use of dopamine agonists for people who misuse cocaine.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-05-04 13:57:44 +0200" MODIFIED_BY="[Empty name]">
<P>Cocaine misusing as diagnosed by the Diagnostic and Statistical Manual of Mental Disorder (DSM IIIR; DSM IV; DSM-IV-R, DSM V) or by specialists. Trials including participants with additional diagnoses of substance dependence were also eligible. We excluded people under 18 years of age and pregnant women for the substantially different approach and clinical management of these people. We included people with comorbid mental health conditions and considered them in subgroup analyses.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-05-04 12:15:15 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Experimental</HEADING>
<UL>
<LI>Any dopamine agonist alone or in combination with any psychosocial intervention. We excluded psychostimulants.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<UL>
<LI>Placebo;</LI>
<LI>Other pharmacological interventions;</LI>
<LI>Any psychosocial intervention.</LI>
</UL>
<P>Furthermore, we considered different factors as confounders and accounted for them in the analyses whenever possible:</P>
<UL>
<LI>Setting (inpatient or outpatient treatment);</LI>
<LI>Starting dose/rate and pattern of dose reduction;</LI>
<LI>Scheduled duration of treatment;</LI>
<LI>Severity of dependence (duration of use, route of administration, frequency of consumption);</LI>
<LI>Health status;</LI>
<LI>Psychiatric comorbidity;</LI>
<LI>Other treatment offered (psychosocial support);</LI>
<LI>Social status;</LI>
<LI>Number of previous treatment attempts and previous treatment outcomes.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-05-04 12:15:22 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-05-04 12:15:22 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Dropouts as number of participants who did not complete the treatment;</LI>
<LI>Acceptability of the treatment as number of participants experiencing adverse effect;</LI>
<LI>Dropouts due to adverse effects;</LI>
<LI>Abstinence self reported or number of participants with urine samples negative for cocaine, or both;</LI>
<LI>Results at follow-up as number of participants abstinent at follow-up.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-05-04 12:15:22 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Craving as measured by validated scales e.g. Brief Substance Craving Scale (BSCS) or Visual Analog Scale (VAS);</LI>
<LI>Severity of dependence as measured by validated scales e.g. Addiction Severity Index (ASI);</LI>
<LI>Clinical Global valuation as measured by validated scales e.g. Clinical Global Impression Subjective -Scale (CGI-S) or Clinical Global Impression -Observer Scale (CGI-O), Severity of Dependence Scale (SDS);</LI>
<LI>Psychiatric symptoms/psychological distress diagnosed using standard instruments e.g. Diagnostic and Statistical Manual of Mental Disorders (DSM) or measured by validated scales e.g. Hamilton Depression Rating Scale (HDRS), Profile of Mood States Scale (POMSS), or Positive and Negative Syndrome Scale (PANSS).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-05-04 13:52:37 +0200" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-05-04 13:52:37 +0200" MODIFIED_BY="[Empty name]">
<P>In <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> we have detailed the search methods used in the previous version of this review (<LINK REF="REF-Amato-2011" TYPE="REFERENCE">Amato 2011</LINK>). <LINK REF="REF-Amato-2011" TYPE="REFERENCE">Amato 2011</LINK> included searches up to June 2011.</P>
<P>For this update, we searched the following electronic databases up to 13 January 2015:</P>
<OL>
<LI>CDAG Specialized Register (January 2015);</LI>
<LI>CENTRAL (the Cochrane Library, Issue 1, January 2015);</LI>
<LI>MEDLINE (PubMed) (June 2011 to 12 January 2015);</LI>
<LI>EMBASE (Elsevier, EMBASE.com) (June 2011 to 12 January 2015);</LI>
<LI>CINAHL (EBSCO Host) (June 2011 to 12 January 2015);</LI>
<LI>Web of Science (June 2011 to 12 January 2015).</LI>
</OL>
<P>In addition, we searched for ongoing clinical trials and unpublished studies via internet searches on the following websites on 12 January 2015:</P>
<UL>
<LI>ClinicalTrials.gov: <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>;</LI>
<LI>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) <A HREF="http://www.who.int/ictrp/en/">www.who.int/ictrp/en/</A>.</LI>
</UL>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for the search terms we used in this Cochrane Review update.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-05-04 12:16:00 +0200" MODIFIED_BY="[Empty name]">
<P>We also searched:</P>
<UL>
<LI>Reference lists of all relevant papers to identify further studies;</LI>
<LI>Conference proceedings likely to contain trials relevant to the review;</LI>
<LI>We contacted investigators seeking information about unpublished or incomplete trials.</LI>
</UL>
<P>All searches included non-English language literature and we assessed studies with English abstracts for inclusion. When considered likely to meet inclusion criteria, studies were translated.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-05-12 13:37:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2015-05-12 13:36:13 +0200" MODIFIED_BY="[Empty name]">
<P>For the previous update of this review, two review authors (SV, RS) independently screened the titles and abstracts of all publications obtained through the search strategy. We obtained all potentially eligible studies as full text articles. Three review authors (SV, RS, SM) independently assessed these for inclusion. In doubtful or controversial cases, we discussed all identified discrepancies and reached consensus on all items.</P>
<P>For this update, two review authors (SM, FDC) independently screened the titles and abstracts and assessed the full text of potentially eligible studies. In doubtful or controversial cases, we discussed all identified discrepancies and reached consensus on all items.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-05-12 13:36:34 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors (LA, SM) assessed study quality according to the criteria indicated in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and extracted data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-05-12 13:36:57 +0200" MODIFIED_BY="[Empty name]">
<P>We performed 'Risk of bias' assessments for included RCTs and CCTs using the criteria recommended by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The recommended approach for 'Risk of bias' assessment in studies included in a Cochrane Review is a two-part tool, addressing specific domains, namely sequence generation and allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome assessor (detection bias), incomplete outcome data (attrition bias) and selective outcome reporting (reporting bias). The first part of the tool involves describing what was reported to have happened in the included study. The second part of the tool involves assigning a judgement relating to the risk of bias for that entry, in terms of 'low', 'high' or 'unclear' risk. We used the criteria indicated by <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK> and adapted to the addiction field (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for details).</P>
<P>We addressed the domains of sequence generation and allocation concealment (avoidance of selection bias) in the tool by a single entry for each study.</P>
<P>We considered blinding of participants and outcome assessor (avoidance of detection bias) separately for objective outcomes (e.g. dropout, abstinence measured by urine-analysis, subjects relapsed at the end of follow-up) and subjective outcomes (e.g. duration and severity of signs and symptoms of withdrawal, craving, patient self-reported use of substance, side effects, psychiatric symptoms, clinical global valuation).</P>
<P>Incomplete outcome data (avoidance of attrition bias) was considered for all outcomes except for dropout from the treatment, which is very often the primary outcome measure in trials on addiction (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for a detailed description on how we assessed the risk of bias in this review).</P>
<SUBSECTION>
<HEADING LEVEL="3">Grading of evidence</HEADING>
<P>We assessed the overall quality of the evidence for the primary outcome using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. The GRADE Working Group developed a system for grading the quality of evidence (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>; <LINK REF="REF-Sch_x00fc_nemann-2006" TYPE="REFERENCE">Schünemann 2006</LINK>; <LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>) which takes into account issues not only related to internal validity but also to external validity, such as directness of results. The 'Summary of findings' tables present the main findings of a review in a transparent and simple tabular format. In particular, they provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined and the sum of available data on the main outcomes.</P>
<P>The GRADE system uses the following criteria for assigning grades of evidence:</P>
<UL>
<LI>High: further research is very unlikely to change our confidence in the estimate of effect;</LI>
<LI>Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate;</LI>
<LI>Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate;</LI>
<LI>Very low: any estimate of effect is very uncertain.</LI>
</UL>
<P>Quality of the evidence may be downgraded for the following reasons:</P>
<UL>
<LI>Serious (-1) or very serious (-2) limitation to study quality;</LI>
<LI>Important inconsistency (-1);</LI>
<LI>Some (-1) or major (-2) uncertainty about directness;</LI>
<LI>Imprecise or sparse data (-1);</LI>
<LI>High probability of reporting bias (-1).</LI>
</UL>
<P>Quality of the evidence may be upgraded for the following reasons:</P>
<UL>
<LI>Strong evidence of association - significant relative risk of &gt; 2 (&lt; 0.5) based on consistent evidence from two or more observational studies, with no plausible confounders (+1);</LI>
<LI>Very strong evidence of association - significant relative risk of &gt; 5 (&lt; 0.2) based on direct evidence with no major threats to validity (+2);</LI>
<LI>Evidence of a dose response gradient (+1);</LI>
<LI>All plausible confounders would have reduced the effect (+1).</LI>
</UL>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-05-12 13:37:02 +0200" MODIFIED_BY="[Empty name]">
<P>We analysed dichotomous outcomes (dropouts, abstinence, abstinence at follow-up, side effects) by calculating the relative risk (RR) for each trial, with the uncertainty in each result being expressed by their confidence intervals (CIs). Continuous outcomes (craving, severity of dependence, clinical valuation, psychiatric symptoms) were analysed by calculating the standardised mean difference (SMD) with 95% CIs. We did not use data presented as number of positive urine tests over the total number of tests in the experimental and control group as measure of substance use. We made this decision because using the number of tests instead of the number of subjects as the unit of the analysis violates the hypothesis of independence among observations. In fact, the results of test done for each participants are not independent. When studies reported number of missing urine stated that they were considered as positive, we included them in the analysis. All but adverse events were computed using intention-to-treat (ITT) principles.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-05-12 13:37:07 +0200" MODIFIED_BY="[Empty name]">
<P>If all arms in a multi-arm trial were included in the meta-analysis and one treatment arm was included more than once in some comparisons, then we divided the number of events and the number of participants in that arm by the number of treatment comparisons made. This method avoids the multiple use of participants in the pooled estimate of treatment effect while retaining information from each arm of the trial. It compromises the precision of the pooled estimate slightly.</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-05-12 13:37:11 +0200" MODIFIED_BY="[Empty name]">
<P>We tested the presence of heterogeneity between trials using the I² statistic and with Chi² test. A P value &lt; 0.1 and an I<SUP>2 </SUP>statistic value &gt; 50% indicated significant heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-05-12 13:37:16 +0200" MODIFIED_BY="[Empty name]">
<P>We used funnel plots (plot of the effect estimate from each study against the sample size or effect standard error) to assess the potential for bias related to the size of included trials.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-05-12 13:37:22 +0200" MODIFIED_BY="[Empty name]">
<P>We combined the outcomes from the individual trials through meta-analysis where possible (comparability of intervention and outcomes between trials) using a random-effect models because we expected a certain degree of heterogeneity among trials. For the abstinence rate we used the number of randomised patients as the denominator, assuming that people who dropped out continued to use cocaine.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-05-12 13:37:28 +0200" MODIFIED_BY="[Empty name]">
<P>To incorporate the 'Risk of bias' assessment in the review process, we first plotted intervention effects estimates stratified for risk of bias for each relevant domain. If differences in results were present among studies at different risk of bias, we performed a sensitivity analysis excluding studies at high risk of bias from the analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-05-14 10:45:13 +0200" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of studies see the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' tables.</P>
<SEARCH_RESULTS MODIFIED="2015-05-14 10:45:13 +0200" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane Review first published in 2001 (<LINK REF="REF-Soares-2003" TYPE="REFERENCE">Soares 2003</LINK>). In the first edition of this review we identified 442 reports. We excluded 392 on basis of title and abstract. We retrieved50 articles for more detailed evaluation, 27 of which we excluded after reading the full text. The remaining 23 studies satisfied all the inclusion criteria (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>In this update, we identified 220 records after bibliographic searches and removal of duplicates. We excluded 213 records on the basis of title and article. We retrieved the full text of seven articles for more detailed evaluation. We excluded five articles after full text evaluation. Two articles, related to one study, met the inclusion criteria (see Figure 2).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-05-14 09:27:45 +0200" MODIFIED_BY="[Empty name]">
<P>Twenty-four studies, 2147 participants, met the inclusion criteria for this Cochrane Review (for details see the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial duration</HEADING>
<P>The mean duration of the trials was seven weeks (range 1.5 to 16 weeks).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment regimes and setting</HEADING>
<P>The included studies considered the dopamine agonists of amantadine, bromocriptine, cabergoline, hydergine, L dopa/carbidopa, pergolide and pramipexole:</P>
<UL>
<LI>
<U>Amantadine</U>: 10 studies compared amantadine with placebo (<LINK REF="STD-Giannini-1989" TYPE="STUDY">Giannini 1989</LINK>; <LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Handelsman-1995" TYPE="STUDY">Handelsman 1995</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-P_x00e9_rez-de-los-Cobos-2001" TYPE="STUDY">Pérez de los Cobos 2001</LINK>; <LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>; <LINK REF="STD-Kampman-2006" TYPE="STUDY">Kampman 2006</LINK> ), four studies with the antidepressant desipramine (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Oliveto-1995" TYPE="STUDY">Oliveto 1995</LINK>), one study with the antidepressant fluoxetine (<LINK REF="STD-Oliveto-1995" TYPE="STUDY">Oliveto 1995</LINK>), one with the beta-adrenergic antagonist propanolol (<LINK REF="STD-Kampman-2006" TYPE="STUDY">Kampman 2006</LINK>). The mean dosage of amantadine was 267 mg/day (range 100 to 400 mg/day);</LI>
<LI>
<U>Bromocriptine:</U> bromocriptine was considered in five studies compared with placebo (<LINK REF="STD-Giannini-1989" TYPE="STUDY">Giannini 1989</LINK>; <LINK REF="STD-Moscovitz-1993" TYPE="STUDY">Moscovitz 1993</LINK>; <LINK REF="STD-Eiler-1995" TYPE="STUDY">Eiler 1995</LINK>; <LINK REF="STD-Handelsman-1997" TYPE="STUDY">Handelsman 1997</LINK>; <LINK REF="STD-Gorelick-2006" TYPE="STUDY">Gorelick 2006</LINK>), the mean dosage of bromocriptine was 6.2 mg/day (range 2.5 to 10 mg/day);</LI>
<LI>L-dopa<U>/carbidopa:</U> six studies compared L-dopa/Carbidopa with placebo (<LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>; <LINK REF="STD-Mooney-2007a" TYPE="STUDY">Mooney 2007a</LINK>; <LINK REF="STD-Mooney-2007b" TYPE="STUDY">Mooney 2007b</LINK>; <LINK REF="STD-Schmitz-2008" TYPE="STUDY">Schmitz 2008</LINK>; <LINK REF="STD-Schmitz-2010" TYPE="STUDY">Schmitz 2010</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>), the mean dosages of these drug were respectively 545 mg/183 mg/day (range 75 mg/100 mg to 800 mg/200 mg/day). <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK> also compared L-dopa/carbidopa with naltrexone and modafinil;</LI>
<LI>
<U>Pergolide:</U> two studies (<LINK REF="STD-Malcolm-2000" TYPE="STUDY">Malcolm 2000</LINK>; <LINK REF="STD-Focchi-2005" TYPE="STUDY">Focchi 2005</LINK>) compared pergolide with placebo and the mean dosage was 0.2 mg/day (range 0.1 to 0.5 mg/day);</LI>
<LI>Single studies considered the other three dopamine agonists: cabergoline (0.5 mg/week) and hydergine (3 mg) were considered in <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>, a study with four arms that also compared L-dopa/carbidopa and placebo. <LINK REF="STD-Ciraulo-2005" TYPE="STUDY">Ciraulo 2005</LINK> considered pramipexole and compared it at a dosage of 1.5 mg with placebo and the antidepressant venlafaxine.</LI>
</UL>
<P>In 16 studies, psychosocial interventions were added to the pharmacological one: cognitive behavioural therapy (<LINK REF="STD-Handelsman-1997" TYPE="STUDY">Handelsman 1997</LINK>; <LINK REF="STD-Kampman-2006" TYPE="STUDY">Kampman 2006</LINK>; <LINK REF="STD-Schmitz-2008" TYPE="STUDY">Schmitz 2008</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>), counselling sessions (<LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>; <LINK REF="STD-Mooney-2007a" TYPE="STUDY">Mooney 2007a</LINK>; <LINK REF="STD-Mooney-2007b" TYPE="STUDY">Mooney 2007b</LINK>), contingency management (<LINK REF="STD-Schmitz-2008" TYPE="STUDY">Schmitz 2008</LINK>; <LINK REF="STD-Schmitz-2010" TYPE="STUDY">Schmitz 2010</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>), group relapse prevention therapy (<LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Oliveto-1995" TYPE="STUDY">Oliveto 1995</LINK>) and interpersonal psychotherapy (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>).</P>
<P>Twenty-one studies were conducted in outpatient settings and four were performed in inpatient settings.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>All participants were addicted to cocaine according to DSM criteria (DSM IIIR; DSM IV; DSM-IV-R; five studies (<LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Handelsman-1995" TYPE="STUDY">Handelsman 1995</LINK>; <LINK REF="STD-Oliveto-1995" TYPE="STUDY">Oliveto 1995</LINK>; <LINK REF="STD-Handelsman-1997" TYPE="STUDY">Handelsman 1997</LINK>; <LINK REF="STD-P_x00e9_rez-de-los-Cobos-2001" TYPE="STUDY">Pérez de los Cobos 2001</LINK>) enrolled patients with also opioid dependence in methadone maintenance therapy. Most participants were male (82%), with a mean age of 37 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial location (country)</HEADING>
<P>Twenty-two studies were conducted in the USA, one in Brazil and one in Spain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons</HEADING>
<OL>
<LI>Any dopamine agonist versus placebo;</LI>
<LI>Amantadine versus placebo;</LI>
<LI>Bromocriptine versus placebo;</LI>
<LI>L dopa/carbidopa versus placebo;</LI>
<LI>Amantadine versus antidepressants.</LI>
</OL>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-05-04 12:17:21 +0200" MODIFIED_BY="[Empty name]">
<P>We excluded 32 studies from this review for the following reasons: inappropriate outcome measures (13 studies); inappropriate study design (six studies); inappropriate type of intervention considered (nine studies), comparisons considered not in the inclusion criteria (two studies), study design and outcomes not in the inclusion criteria (two studies). See the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for further details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]">
<P>We have presented judgements for each 'Risk of bias' item for each included study (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and as percentages across all included studies (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2015-05-12 13:49:37 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>Only five included studies (20.8%) used an adequate method of sequence generation. We classifed all other included studies at unclear risk of bias because the trial authors gave no information about the method used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Only four included studies (16.6%) used an adequate method of allocation concealment. The remaining studies were classified at unclear risk of bias because no information was given about the method used.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2015-05-12 13:49:48 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Performance bias</HEADING>
<P>All but two trials adopted a double-blind design. <LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK> and <LINK REF="STD-Focchi-2005" TYPE="STUDY">Focchi 2005</LINK> were both single-blinded and judged at high risk of bias for subjective outcomes. Ten trials (41.6%) gave detailed information about the way to maintain blinding and were judged at low risk of bias. We considered the remaining trials at unclear risk for subjective outcomes. We judged all included studies at low risk of performance bias for objective outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Detection bias</HEADING>
<P>Two studies were single blinded and were judged at high risk of detection bias (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Focchi-2005" TYPE="STUDY">Focchi 2005</LINK>). Seven trials (29.1%) stated that outcome assessors were blinded. We judged all other included studies at unclear risk of detection bias.</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-05-12 13:49:52 +0200" MODIFIED_BY="[Empty name]">
<P>Seventeen included studies (70.8%) were judged at low risk of attrition bias or because the ITT principle was used or because there were few lost at follow-up, balanced between groups and reason for dropout were reported. We judged six studies at high risk of attrition bias (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Moscovitz-1993" TYPE="STUDY">Moscovitz 1993</LINK>; <LINK REF="STD-Eiler-1995" TYPE="STUDY">Eiler 1995</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-Malcolm-2000" TYPE="STUDY">Malcolm 2000</LINK>; <LINK REF="STD-Gorelick-2006" TYPE="STUDY">Gorelick 2006</LINK>) and one at unclear risk (<LINK REF="STD-Focchi-2005" TYPE="STUDY">Focchi 2005</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-05-12 13:49:59 +0200" MODIFIED_BY="[Empty name]">
<P>We considered 20/24 (83.3%) of the included studies at low risk of reporting bias. Two were judged at high risk (<LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>) and two at unclear risk (<LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Oliveto-1995" TYPE="STUDY">Oliveto 1995</LINK>).</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Dopamine agonist versus placebo</HEADING>
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Dropouts</HEADING>
<P>Twenty trials, 1656 participants, examined this outcome (<LINK REF="STD-Giannini-1989" TYPE="STUDY">Giannini 1989</LINK>; <LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Moscovitz-1993" TYPE="STUDY">Moscovitz 1993</LINK>; <LINK REF="STD-Eiler-1995" TYPE="STUDY">Eiler 1995</LINK>; <LINK REF="STD-Handelsman-1995" TYPE="STUDY">Handelsman 1995</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-Handelsman-1997" TYPE="STUDY">Handelsman 1997</LINK>; <LINK REF="STD-Malcolm-2000" TYPE="STUDY">Malcolm 2000</LINK>; <LINK REF="STD-P_x00e9_rez-de-los-Cobos-2001" TYPE="STUDY">Pérez de los Cobos 2001</LINK>; <LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>; <LINK REF="STD-Ciraulo-2005" TYPE="STUDY">Ciraulo 2005</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>; <LINK REF="STD-Gorelick-2006" TYPE="STUDY">Gorelick 2006</LINK>; <LINK REF="STD-Kampman-2006" TYPE="STUDY">Kampman 2006</LINK>; <LINK REF="STD-Mooney-2007a" TYPE="STUDY">Mooney 2007a</LINK>; <LINK REF="STD-Mooney-2007b" TYPE="STUDY">Mooney 2007b</LINK>; <LINK REF="STD-Schmitz-2008" TYPE="STUDY">Schmitz 2008</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>) showing no difference between the two treatments, RR 1.04, (95% CI 0.94 to 1.14); moderate quality of evidence. <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. Sensitivity analysis excluding studies at high risk of attrition bias did not change results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Adverse events as number of participants with at least one adverse event</HEADING>
<P>Seven studies, 252 participants, reported on this outcome (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Moscovitz-1993" TYPE="STUDY">Moscovitz 1993</LINK>; <LINK REF="STD-P_x00e9_rez-de-los-Cobos-2001" TYPE="STUDY">Pérez de los Cobos 2001</LINK>; <LINK REF="STD-Gorelick-2006" TYPE="STUDY">Gorelick 2006</LINK>; <LINK REF="STD-Kampman-2006" TYPE="STUDY">Kampman 2006</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>) we detected no difference between the two treatments, RR 1.27 (95% CI 0.66 to 2.44); moderate quality of evidence ; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Abstinence (objective)</HEADING>
<P>Eleven trials, 731 participants, reported this outcome (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Moscovitz-1993" TYPE="STUDY">Moscovitz 1993</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>; <LINK REF="STD-Focchi-2005" TYPE="STUDY">Focchi 2005</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>; <LINK REF="STD-Mooney-2007a" TYPE="STUDY">Mooney 2007a</LINK>; <LINK REF="STD-Mooney-2007b" TYPE="STUDY">Mooney 2007b</LINK>; <LINK REF="STD-Schmitz-2008" TYPE="STUDY">Schmitz 2008</LINK>; ) and we detected no difference between the two treatments, RR 1.12 (95% CI 0.85 to 1.47); low quality of evidence; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>. Sensitivity analysis excluding studies at high risk of attrition bias did not affect the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Abstinence at follow-up (objective)</HEADING>
<P>We detected no difference between the two treatments after analysis of the results of four included studies, 136 participants, that reported on this outcome (<LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>): RR 1.10 (95% CI 0.61 to 1.98); low quality of evidence; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Severity of dependence (measured as difference before and after treatment)</HEADING>
<P>Based on four included studies, 202 participants, (<LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Ciraulo-2005" TYPE="STUDY">Ciraulo 2005</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>; <LINK REF="STD-Kampman-2006" TYPE="STUDY">Kampman 2006</LINK>), there was a statistically significant result in favour of placebo treatment: SMD 1.69 (95% CI 0.17 to 3.20); low quality of evidence; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Dropouts due to adverse effects</HEADING>
<P>Based on the results of four studies, 368 participants (<LINK REF="STD-Mooney-2007a" TYPE="STUDY">Mooney 2007a</LINK>; <LINK REF="STD-Mooney-2007b" TYPE="STUDY">Mooney 2007b</LINK>; <LINK REF="STD-Schmitz-2008" TYPE="STUDY">Schmitz 2008</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>), we did not detect no difference between the two treatments, RR 1.21 (95% CI 0.27 to 5.38); <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Craving at the end of treatment</HEADING>
<P>Three studies, 151 participants, reported on this outcome (<LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>; <LINK REF="STD-Ciraulo-2005" TYPE="STUDY">Ciraulo 2005</LINK>; <LINK REF="STD-Focchi-2005" TYPE="STUDY">Focchi 2005</LINK>). We detected no differences between treatments: SMD 0.20 (95% CI -0.35 to 0.74); <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8 Clinical global evaluation at the end of the treatment</HEADING>
<P>Two studies, 70 participants, reported this outcome (<LINK REF="STD-Ciraulo-2005" TYPE="STUDY">Ciraulo 2005</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>) and we detected no difference between treatments: SMD -0.04 (95% CI -0.50 to 0.43); <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.9 Depression (measured as difference before and after treatment)</HEADING>
<P>We included five studies, 292 participants in this analysis (<LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Handelsman-1995" TYPE="STUDY">Handelsman 1995</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-Focchi-2005" TYPE="STUDY">Focchi 2005</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>) and detected no difference between treatments: SMD 0.47 (95% CI -0.35 to 1.28); <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Amantadine versus placebo</HEADING>
<P>See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Dropouts</HEADING>
<P>Nine studies, 484 participants, reported on this outcome (<LINK REF="STD-Giannini-1989" TYPE="STUDY">Giannini 1989</LINK>; <LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Handelsman-1995" TYPE="STUDY">Handelsman 1995</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-P_x00e9_rez-de-los-Cobos-2001" TYPE="STUDY">Pérez de los Cobos 2001</LINK>; <LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>; <LINK REF="STD-Kampman-2006" TYPE="STUDY">Kampman 2006</LINK>). We detected no difference between treatments, RR 0.98 (95% CI 0.77 to 1.26); moderate quality of evidence; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Adverse events as number of participants with at least one adverse event</HEADING>
<P>Four studies, 275 participants, were included in this analysis (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-P_x00e9_rez-de-los-Cobos-2001" TYPE="STUDY">Pérez de los Cobos 2001</LINK>). We detected no difference between treatments, RR 1.19 (95% CI 0.69 to 2.06); moderate quality of evidence; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Abstinence (objective)</HEADING>
<P>Five studies, 275 participants, reported on this outcome (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Kampman-1996" TYPE="STUDY">Kampman 1996</LINK>; <LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>) and we detected no difference between treatments,RR 1.13, (95% CI 0.59 to 2.13); low quality of evidence; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Abstinence at follow-up (objective)</HEADING>
<P>We included three studies , 76 participants, in this analysis (<LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Shoptaw-2002" TYPE="STUDY">Shoptaw 2002</LINK>) and detected no difference between treatments, RR 1.49 (95% CI 1.03 to 2.15); moderate quality of evidence; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Severity of dependence (measured as difference before and after the treatment)</HEADING>
<P>Two studies, 102 participants, reported on this outcome (<LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Kampman-2006" TYPE="STUDY">Kampman 2006</LINK>). No difference was detected between treatments, SMD 0.39 (95% CI -0.00 to 0.79); <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Depression (measured as difference before and after the treatment)</HEADING>
<P>We included two studies, 109 participants, in this analysis (<LINK REF="STD-Alterman-1992" TYPE="STUDY">Alterman 1992</LINK>; <LINK REF="STD-Handelsman-1995" TYPE="STUDY">Handelsman 1995</LINK>). There was no difference between treatments, SMD -0.30 (95% CI -1.33 to 0.74); <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Bromocriptine versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Dropouts</HEADING>
<P>Five studies, 242 participants, (<LINK REF="STD-Giannini-1989" TYPE="STUDY">Giannini 1989</LINK>; <LINK REF="STD-Moscovitz-1993" TYPE="STUDY">Moscovitz 1993</LINK>; <LINK REF="STD-Eiler-1995" TYPE="STUDY">Eiler 1995</LINK>; <LINK REF="STD-Handelsman-1997" TYPE="STUDY">Handelsman 1997</LINK>; <LINK REF="STD-Gorelick-2006" TYPE="STUDY">Gorelick 2006</LINK>) and there was no difference between treatments, RR 1.00 (95% CI 0.73 to 1.38); <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Adverse events as number of participants with at least one adverse event</HEADING>
<P>We included two studies, 89 participants, in this analysis (<LINK REF="STD-Moscovitz-1993" TYPE="STUDY">Moscovitz 1993</LINK>; <LINK REF="STD-Gorelick-2006" TYPE="STUDY">Gorelick 2006</LINK>) and detected no difference between treatments, RR 0.92 (95% CI 0.38 to 2.22); <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. L dopa/carbidopa versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Dropouts</HEADING>
<P>Four studies, 262 participants, reported this outcome (<LINK REF="STD-Mooney-2007a" TYPE="STUDY">Mooney 2007a</LINK>; <LINK REF="STD-Mooney-2007b" TYPE="STUDY">Mooney 2007b</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>) and there was no difference between treatments, RR 0.95 (95% CI 0.78 to 1.17); <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Dropouts due to adverse effects</HEADING>
<P>We included four studies, 368 participants, in this analysis (<LINK REF="STD-Mooney-2007a" TYPE="STUDY">Mooney 2007a</LINK>; <LINK REF="STD-Mooney-2007b" TYPE="STUDY">Mooney 2007b</LINK>; <LINK REF="STD-Schmitz-2008" TYPE="STUDY">Schmitz 2008</LINK>; <LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>). We did not detect any difference between treatments, RR 1.21 (95% CI 0.27 to 5.38); <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Abstinence (objective)</HEADING>
<P>Four studies, 355 participants, reported on this outcome (<LINK REF="STD-Mooney-2007a" TYPE="STUDY">Mooney 2007a</LINK>; <LINK REF="STD-Mooney-2007b" TYPE="STUDY">Mooney 2007b</LINK>; <LINK REF="STD-Shoptaw-2005" TYPE="STUDY">Shoptaw 2005</LINK>; <LINK REF="STD-Schmitz-2008" TYPE="STUDY">Schmitz 2008</LINK>) and we detected no difference between treatments, RR 1.11 (95% CI 0.80 to 1.52); <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Amantadine versus antidepressants</HEADING>
<P>See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>.</P>
<P>The antidepressants considered in the studies were desipramine (four trials: <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Oliveto-1995" TYPE="STUDY">Oliveto 1995</LINK>; <LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>) and fluoxetine (one trial: <LINK REF="STD-Oliveto-1995" TYPE="STUDY">Oliveto 1995</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">5.1 Dropouts</HEADING>
<P>We included four studies, 153 participants, in this analysis (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>; <LINK REF="STD-Kosten-1992" TYPE="STUDY">Kosten 1992</LINK>; <LINK REF="STD-Oliveto-1995" TYPE="STUDY">Oliveto 1995</LINK>) and detected no difference between treatments, RR 0.86 (95% CI 0.48 to 1.53); moderate quality of evidence; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.2 Adverse events as number of participants with at least one adverse event</HEADING>
<P>Two studies, 44 participants, reported this outcome (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>) and we did not detect any difference between treatments, RR 0.56 (95% CI 0.18 to 1.77); low quality of evidence; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.3 Abstinence (objective)</HEADING>
<P>Based on two studies, 68 participants, (<LINK REF="STD-Weddington-1991" TYPE="STUDY">Weddington 1991</LINK>; <LINK REF="STD-Kolar-1992" TYPE="STUDY">Kolar 1992</LINK>), the result was in favour of antidepressants, RR 0.25 (95% CI 0.12 to 0.53); low quality of evidence; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. L-dopa/carbidopa versus naltrexone or modafinil</HEADING>
<P>One study (<LINK REF="STD-Schmitz-2014" TYPE="STUDY">Schmitz 2014</LINK>) reported that there were no difference in retention between L-dopa and modafinil (14/25 and 9/22 respectively) and between L-dopa and naltrexone (14/25 and 9/16 respectively).<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-05-14 10:22:10 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-05-14 10:20:29 +0200" MODIFIED_BY="[Empty name]">
<P>Twenty-four studies, including a total of 2147 participants, met the inclusion criteria for this review. However, the large variety of outcomes and rating scales considerably limited a quantitative synthesis of data. We could not synthesize a large amount of information.</P>
<P>Comparing any dopamine agonist versus placebo, we found moderate to low quality of evidence that there were no significant differences for any of the outcomes considered (dropout, abstinence, craving, severity of dependence depression adverse events). This also occurred when single dopamine agonists were compared against placebo.</P>
<P>Comparing amantadine versus antidepressants (desipramine in four comparisons and fluoxetine in one comparison), we found low quality of evidence that antidepressants performed better for abstinence, but results were from only two studies with 44 participants. The other two outcomes considered did not show statistically significant differences, although dropouts and adverse events tended to be more common in the antidepressant group.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-05-14 10:20:35 +0200" MODIFIED_BY="[Empty name]">
<P>As seen for other treatments, the trials included in this review had important differences in psychiatric and substance use diagnoses, definitions of outcomes variables and varying amounts of psychotherapy provided in conjunction with medications. These discrepancies have two consequences: data are more generalizable, but there is a clear limitation for pooling data.</P>
<P>Besides the limits in external validity due to the general requirement of RCTs in terms of strict inclusion criteria, highly homogenous study groups, limitations in dose adjustment, etc., the types of participants (adults abusers/dependents on cocaine or on cocaine and opioids) are quite representative of the general population of cocaine addicts. Moreover, the interventions and the outcomes investigated (dropouts, abstinence, adverse events) are important to populations, practitioners and decision makers, and relevant for the context of current practice. However, an important limitation to the generalization of the evidence is trial location. Despite our systematic bibliographical search, only two out of 23 included studies were conducted outside of the USA. It should be considered that different social contexts can influence the severity of dependence and the availability to enter an experimental design. Also different clinical contests can differentially influence participant selection to the trials and the results of the treatment, acting as an effect modifier in the estimation of efficacy of treatment.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-05-14 10:22:10 +0200" MODIFIED_BY="[Empty name]">
<P>Regarding risk of bias of the included trials, only 20.8% used an adequate method of sequence generation and the 17% an adequate method of allocation concealment. We judged the other studies were at unclear risk because the trial authors did not provide details. Only 41% of included trials described an adequate method to maintain blinding. Only 21% of included trials declared that outcome assessors were blinded. We judged all but two of the other at unclear risk of bias for subjective outcomes. We considered 83.3% of the included studies at low risk of reporting bias. We judged 70.8% at low risk of attrition bias or because the ITT principle was used or there were few participants lost at follow-up, balanced between groups and reason for dropout were reported.</P>
<P>Finally, the great heterogeneity of the scales used in the primary studies and the way in which results were reported meant it was not possible at times to undertake a cumulative analysis.</P>
<P>The quality of evidence using GRADE was judged from moderate to low, see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>
</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-05-14 10:22:17 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-05-14 10:22:17 +0200" MODIFIED_BY="[Empty name]">
<P>In spite of theoretical foundations on which the use of dopamine agonists for the treatment of cocaine dependence is based on (<LINK REF="REF-Gardner-1999" TYPE="REFERENCE">Gardner 1999</LINK>; <LINK REF="REF-Volkow-1999a" TYPE="REFERENCE">Volkow 1999a</LINK>; <LINK REF="REF-Volkow-1999b" TYPE="REFERENCE">Volkow 1999b</LINK>; <LINK REF="REF-Volkow-2003b" TYPE="REFERENCE">Volkow 2003b</LINK>; <LINK REF="REF-Gorelick-2004" TYPE="REFERENCE">Gorelick 2004</LINK>; <LINK REF="REF-Volkow-2006" TYPE="REFERENCE">Volkow 2006</LINK>; <LINK REF="REF-Rush-2009" TYPE="REFERENCE">Rush 2009</LINK>; <LINK REF="REF-Rush-2010" TYPE="REFERENCE">Rush 2010</LINK>; <LINK REF="REF-Volkow-2010" TYPE="REFERENCE">Volkow 2010</LINK>), current evidence from RCTs does not support the use of dopamine agonists for treating people with cocaine dependence.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-05-14 10:22:17 +0200" MODIFIED_BY="[Empty name]">
<P>This Cochrane Review shows that direct dopamine agonists alone do not appear to be efficacious. Nevertheless, their use in combination with indirect dopamine agonists, which have shown mixed results for the treatment of cocaine dependence, could be justifiable if laboratory studies demonstrate a reduction in cocaine craving or cocaine reinforcing effects.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-05-14 10:23:07 +0200" MODIFIED_BY="[Empty name]">
<P>We thank Zuzana Mitrova, managing editor of Cochrane Drugs and Alcohol Group, for her help during the editorial process.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-05-14 10:32:18 +0200" MODIFIED_BY="[Empty name]">
<P>Silvia Minozzi have no interests to declare relating to this work.</P>
<P>Laura Amato have no interests to declare relating to this work.</P>
<P>Pier Paolo Pani have no interests to declare relating to this work.</P>
<P>Roberta Solimini have no interests to declare relating to this work.</P>
<P>Simona Vecchi have no interests to declare relating to this work.</P>
<P>Franco De Crescenzo have no interests to declare relating to this work.</P>
<P>Pier Giorgio Zuccaro have no interests to declare relating to this work.</P>
<P>Marina davoli have no interests to declare relating to this work.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-05-14 10:26:56 +0200" MODIFIED_BY="[Empty name]">
<P>For the 2011 update,two review authors (SV, RS) developed the literature search strategy. Two review authors (SV, RS) inspected the search hits by reading titles and abstracts. We obtained each potentially relevant study located in the search in full text. Two review authors (LA, SM) independently assessed each article for inclusion. We resolved any disagreements by discussion between all review authors. Two review authors (SM, LA) assessed quality of the included trials. Two review authors (LA, SM) extracted data independently . Any disagreement was resolved by discussion between all review authors. PPP wrote the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> section and participated to results's discussion. MD and PGZ commented on and amended the review text.</P>
<P>For this review update, SM and FDC inspected the search hits by reading titles and abstracts. We obtained each potentially relevant study in full text and two review authors (SM, FDC) independently assessed articles for inclusion or exclusion.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-05-04 14:33:51 +0200" MODIFIED_BY="[Empty name]">
<P>This Cochrane Review is a substantial update, which has been performed by a new review author team several years after the first published version of the review (<LINK REF="REF-Soares-2003" TYPE="REFERENCE">Soares 2003</LINK>). We changed the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section substantially in accordance with developments within Cochrane.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-05-04 12:17:59 +0200" MODIFIED_BY="[Empty name]">
<P>The review authors of the first published version of this review (<LINK REF="REF-Soares-2003" TYPE="REFERENCE">Soares 2003</LINK>) did not update this review and did not respond to our reminders to update it. The topic is considered relevant and therefore we decided to withdraw the review and make it available to a new author team.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-05-14 10:36:17 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-05-14 10:33:52 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-05-04 14:35:40 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alterman-1992" MODIFIED="2015-05-04 11:47:21 +0200" MODIFIED_BY="[Empty name]" NAME="Alterman 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-04 11:47:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alterman AI, Droba M, Antelo RE, Cornish JW, Sweeney KK, Parikh GA, et al</AU>
<TI>Amantadine may facilitate detoxification of cocaine abusers</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>1</NO>
<PG>19-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ciraulo-2005" MODIFIED="2015-05-03 18:50:08 +0200" MODIFIED_BY="[Empty name]" NAME="Ciraulo 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-05-03 18:50:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciraulo DA, Sarid-Segal O, Knapp CM, Ciraulo AM, LoCastro J, Bloch DA, et al</AU>
<TI>Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>Suppl 1</NO>
<PG>12-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eiler-1995" MODIFIED="2015-05-04 11:47:34 +0200" MODIFIED_BY="[Empty name]" NAME="Eiler 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-05-04 11:47:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eiler K, Schaefer MR, Salstrom D, Lowery R</AU>
<TI>Double-blind comparison of bromocriptine and placebo in cocaine withdrawal</TI>
<SO>American Journal of Drug and Alcohol Abuse</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>1</NO>
<PG>65-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Focchi-2005" MODIFIED="2015-05-04 11:47:41 +0200" MODIFIED_BY="[Empty name]" NAME="Focchi 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-05-04 11:47:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Focchi GR, Leite MC, Andrade AG, Scivoletto S</AU>
<TI>Use of dopamine agonist pergolide in outpatient treatment of cocaine dependence</TI>
<SO>Substance Use and Misuse</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>8</NO>
<PG>1169-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannini-1989" MODIFIED="2015-05-04 11:47:03 +0200" MODIFIED_BY="[Empty name]" NAME="Giannini 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-05-04 11:47:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannini AJ, Folts DJ, Feather JN, Sullivan BS</AU>
<TI>Bromocriptine and amantadine in cocaine detoxification</TI>
<SO>Psychiatry Research</SO>
<YR>1989</YR>
<VL>29</VL>
<NO>1</NO>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorelick-2006" MODIFIED="2015-05-04 11:47:12 +0200" MODIFIED_BY="[Empty name]" NAME="Gorelick 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-04 11:47:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorelick DA, Wilkins JN</AU>
<TI>Bromocriptine treatment for cocaine addiction: association with plasma prolactin levels</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>2</NO>
<PG>189-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Handelsman-1995" MODIFIED="2015-05-04 11:47:49 +0200" MODIFIED_BY="[Empty name]" NAME="Handelsman 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-05-04 11:47:49 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Handelsman L, Limpitlaw L, Williams D, Schmeidler J, Paris P, Stimmel B. Amantadine does not reduce cocaine-dependent methadone maintenance patients. Drug and alcohol Dependence. 1995;39:173-180.&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 11:47:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Handelsman L, Limpitlaw L, Williams D, Schmeidler J, Paris P, Stimmel B</AU>
<TI>Amantadine does not reduce cocaine-dependent methadone maintenance patients</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1995</YR>
<VL>39</VL>
<NO>3</NO>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Handelsman-1997" MODIFIED="2015-05-04 11:48:02 +0200" MODIFIED_BY="[Empty name]" NAME="Handelsman 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-05-04 11:48:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Handelsman L, Rosenblum A, Palij M, Magura S, Foote J, Lovejoy M, et al</AU>
<TI>Bromocriptine for cocaine dependence - a controlled clinical trial</TI>
<SO>American Journal on Addictions</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>1</NO>
<PG>54-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kampman-1996" MODIFIED="2015-05-04 11:48:11 +0200" MODIFIED_BY="[Empty name]" NAME="Kampman 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-03-30 12:52:27 +0200" MODIFIED_BY="Laura Amato" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kampman K, Volpicelli, Alterman A, Cornish J, Weinrieb R, Epperson L, et al</AU>
<TI>Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1996</YR>
<VL>41</VL>
<PG>25-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-04 11:48:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kampman KM, Volpicelli JR, Alterman AI, Cornish J, O'Brien CP</AU>
<TI>Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>12</NO>
<PG>2052-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kampman-2006" MODIFIED="2015-05-04 11:48:25 +0200" MODIFIED_BY="[Empty name]" NAME="Kampman 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-04 11:48:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kampman KM, Dackis C, Lynch KG, Pettinati H, Tirado C, Gariti P, et al</AU>
<TI>A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>2</NO>
<PG>129-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolar-1992" MODIFIED="2015-05-04 11:48:32 +0200" MODIFIED_BY="[Empty name]" NAME="Kolar 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-04 11:48:32 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kolar AF, Brown BS, Weddington WW, Haertzen CC, Michaelson BS, Jaffe JH. Treatment of Cocaine Dependence in Methadone Maintenance Clients: A Pilot Study Comparing the Efficacy of Desipramine and Amantadine. The International Journal of the Addictions. 1992; 27(7): 849-868.&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 11:48:32 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolar AF, Brown BS, Weddington WW, Haertzen CC, Michaelson BS, Jaffe JH</AU>
<TI>Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine</TI>
<SO>International Journal of the Addictions</SO>
<YR>1992</YR>
<VL>27</VL>
<NO>7</NO>
<PG>849-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosten-1992" MODIFIED="2015-05-04 11:59:31 +0200" MODIFIED_BY="[Empty name]" NAME="Kosten 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-04 11:59:14 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kosten TR, Morgan CM, FalcioneJ, Schottenfeld RS. Pharmacotherapy for Cocaine-Abusing Methadone-Maintened Patients Using Amantadine or Desipramine. Archives of General Psychiatry 1992; 49: 894-898.&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 11:59:14 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kosten TR, Morgan CM, FalcioneJ, Schottenfeld RS</AU>
<TI>Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>11</NO>
<PG>894-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-04 11:59:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leal J, Ziedonis D, Kosten T</AU>
<TI>Antisocial personality as a prognostic for pharmacotherapy of cocaine dependence</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-04 11:59:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziedonis DM, Kosten TR</AU>
<TI>Depression as a prognostic for pharmacological treatment of cocaine dependence</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1991</YR>
<VL>27</VL>
<NO>3</NO>
<PG>337-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-2000" MODIFIED="2015-05-04 11:59:47 +0200" MODIFIED_BY="[Empty name]" NAME="Malcolm 2000" YEAR="1997">
<REFERENCE MODIFIED="2015-05-03 19:02:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Herron J, Sutherland SE, Brady KT</AU>
<TI>Adverse outcomes in a controlled trial of pergolide for cocaine dependence</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>1</NO>
<PG>81-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-04 11:59:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Kajdasz DK, Herron J, Anton RF, Brady KT</AU>
<TI>A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2000</YR>
<VL>60</VL>
<NO>2</NO>
<PG>161-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-04 11:59:47 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Malcolm R, Moore JW, Kajdasz DK, Cochrane CE. Pergolyde Mesylate Adverse events occurring in the treatment of cocaine dependence. The American Journal on Addictions 1997;6:117-123.&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 11:59:47 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Moore JW, Kajdasz DK, Cochrane CE</AU>
<TI>Pergolyde mesylate. Adverse events occurring in the treatment of cocaine dependence</TI>
<SO>American Journal on Addictions</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>2</NO>
<PG>117-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mooney-2007a" MODIFIED="2015-05-04 11:59:55 +0200" MODIFIED_BY="[Empty name]" NAME="Mooney 2007a" YEAR="2007">
<REFERENCE MODIFIED="2015-05-04 11:59:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mooney ME, Schmitz JM, Moeller FG, Grabowski J</AU>
<TI>Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2007</YR>
<VL>88</VL>
<NO>2-3</NO>
<PG>214-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mooney-2007b" MODIFIED="2015-05-04 12:00:05 +0200" MODIFIED_BY="[Empty name]" NAME="Mooney 2007b" YEAR="">
<REFERENCE MODIFIED="2015-05-04 12:00:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mooney ME, Schmitz JM, Moeller FG, Grabowski J</AU>
<TI>Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2007</YR>
<VL>88</VL>
<NO>2-3</NO>
<PG>214-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moscovitz-1993" MODIFIED="2015-05-04 12:00:12 +0200" MODIFIED_BY="[Empty name]" NAME="Moscovitz 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-05-04 12:00:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moscovitz H, Brookof D, Nelson L</AU>
<TI>A randomized trial of bromocriptine for cocaine users presenting to the emergency department</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliveto-1995" MODIFIED="2015-05-04 12:00:19 +0200" MODIFIED_BY="[Empty name]" NAME="Oliveto 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-05-04 12:00:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliveto A, Kosten TR, Schottenfeld R, Falcioni J, Ziedonis D</AU>
<TI>Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>1995</YR>
<VL>12</VL>
<NO>6</NO>
<PG>423-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-P_x00e9_rez-de-los-Cobos-2001" MODIFIED="2015-05-04 12:01:07 +0200" MODIFIED_BY="[Empty name]" NAME="Pérez de los Cobos 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-05-04 12:01:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pérez de los Cobos J, Duro P, Trujols J, Tejero A, Batlle F, Ribalta E, et al</AU>
<TI>Methadone tapering plus amantadine to detoxify heroin-dependent inpatients with or without an active cocaine use disorder: two randomised controlled trials</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2001</YR>
<VL>63</VL>
<NO>2</NO>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz-2008" MODIFIED="2015-05-04 12:01:01 +0200" MODIFIED_BY="[Empty name]" NAME="Schmitz 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-04 12:01:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz JM, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J</AU>
<TI>Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2008</YR>
<VL>94</VL>
<NO>1-3</NO>
<PG>142-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz-2010" MODIFIED="2015-05-03 19:13:51 +0200" MODIFIED_BY="[Empty name]" NAME="Schmitz 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-03 19:13:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz JM, Lindsay JA, Stotts AL, Green CE, Moeller FG</AU>
<TI>Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets</TI>
<SO>Experimental and Clinical Psychopharmacology  </SO>
<YR>2010</YR>
<VL>18</VL>
<NO>3</NO>
<PG>238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz-2014" MODIFIED="2015-05-04 14:22:02 +0200" MODIFIED_BY="[Empty name]" NAME="Schmitz 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-04 14:21:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schmitz J, Green CE, Stotts AL, Moeller FG</AU>
<TI>Screening medication for cocaine dependence treatment using a pre-randomisation, abstinence-induction procedure. Abstract no: 591</TI>
<SO>Proceedings of the 74th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 9-14, Palm Springs, CA</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-03 19:21:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz JM, Green CE, Stotts AL, Lindsay JA, Rathnayaka NS, Grabowski J, et al</AU>
<TI>A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2014</YR>
<VL>136</VL>
<PG>100-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoptaw-2002" MODIFIED="2015-05-04 12:01:20 +0200" MODIFIED_BY="[Empty name]" NAME="Shoptaw 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-05-04 12:01:20 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoptaw S, Kintaudi PC, Charuvastra C, Ling W</AU>
<TI>A screening trial of amantadine as a medication for cocaine dependence</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2002</YR>
<VL>66</VL>
<NO>3</NO>
<PG>217-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoptaw-2005" MODIFIED="2015-05-04 14:35:40 +0200" MODIFIED_BY="[Empty name]" NAME="Shoptaw 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-05-03 19:16:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elkashef A, Holmes TH, Bloch DA, Shoptaw S, Kampman K, Reid MS, et al</AU>
<TI>Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>Suppl 1</NO>
<PG>91-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-03 19:17:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kampman KM, Leiderman D, Holmes T, LoCastro J, Bloch DA, Reid MS, et al</AU>
<TI>Cocaine Rapid Efficacy Screening Trials (CREST): Lessons learned</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>Suppl 1</NO>
<PG>102-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-03 19:17:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leiderman DB, Shoptaw S, Montgomery A, Bloch DA, Elkashef A, LoCastro J, et al</AU>
<TI>Cocaine Rapid Efficacy Screening TrialCREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>Suppl 1</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-04 14:35:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shoptaw S, Watson DW, Reiber C, Rawson RA, Montgomery MA, Majewska MD, et al</AU>
<TI>Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>Suppl 1</NO>
<PG>78-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weddington-1991" MODIFIED="2015-05-04 12:01:29 +0200" MODIFIED_BY="[Empty name]" NAME="Weddington 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-05-04 12:01:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Weddington WW, Brown BS, Haertzen CA, Hess JM, Mahaffey JR, Kolar AF, Jaffe JH. Comparison of Amantadine Combined with Psychotherapy for Treatment of Cocaine Dependence. Am J Drug Alcohol Abuse. 1991;17:137-152.&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 12:01:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weddington WW Jr, Brown BS, Haertzen CA, Hess JM, Mahaffey JR, Kolar AF, et al</AU>
<TI>Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence</TI>
<SO>American Journal of Drug and Alcohol Abuse</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>2</NO>
<PG>137-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-05-14 10:33:52 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-2003" MODIFIED="2015-05-04 12:02:07 +0200" MODIFIED_BY="[Empty name]" NAME="Collins 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-05-04 12:02:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins ED, Vosburg SK, Hart CL, Haney M, Foltin RW</AU>
<TI>Amantadine does not modulate reinforcing, subjective, or cardiovascular effects of cocaine in humans</TI>
<SO>Pharmacology, Biochemistry, and Behavior</SO>
<YR>2003</YR>
<VL>76</VL>
<NO>3-4</NO>
<PG>401-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-2006" MODIFIED="2015-05-04 12:01:37 +0200" MODIFIED_BY="[Empty name]" NAME="Collins 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-04 12:01:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins ED, Vosburg SK, Ward AS, Haney M, Foltin RW</AU>
<TI>Memantine increases cardiovascular but not behavioral effects of cocaine in methadone-maintained humans</TI>
<SO>Pharmacology, Biochemistry, and Behavior</SO>
<YR>2006</YR>
<VL>83</VL>
<NO>1</NO>
<PG>47-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunningham-2010" MODIFIED="2015-05-14 10:33:43 +0200" MODIFIED_BY="[Empty name]" NAME="Cunningham 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-04 14:22:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cunningham KA, Carbone CL, Anastasio NC, Harper TA, Moeller FG, Ware DL, et al</AU>
<TI>Dopamine beta hidroxylase inhibitor SYN117 decreases subjective effects of cocaine</TI>
<SO>Proceedings of the 72th Annual Scientific Meeting of the College on Problems of Drug Dependence; 2010 June 12-17; Scottsdale, Arizona</SO>
<YR>2010</YR>
<PG>34</PG>
<CY>Scottsdale, Arizona. USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dackis-1985" MODIFIED="2015-05-04 12:01:51 +0200" MODIFIED_BY="[Empty name]" NAME="Dackis 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-05-04 12:01:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dackis CA, Gold MS</AU>
<TI>Bromocriptine as treatment of cocaine abuse</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>8438</NO>
<PG>1151-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dackis-1986" MODIFIED="2015-05-04 12:02:00 +0200" MODIFIED_BY="[Empty name]" NAME="Dackis 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-05-04 12:02:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dackis CA, Gold MS, Sweeney DR, Byron JP Jr, Climko R</AU>
<TI>Single-dose bromocriptine reverses cocaine craving</TI>
<SO>Psychiatry Research</SO>
<YR>1986</YR>
<VL>20</VL>
<NO>4</NO>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elkashef-2003" MODIFIED="2015-05-14 10:33:52 +0200" MODIFIED_BY="[Empty name]" NAME="Elkashef 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-01 09:59:28 +0200" MODIFIED_BY="Laura Amato" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Elkashef A, Fudala P, Gorgon L, Li S, Chiang N, Vocci F</AU>
<TI>Transdermal selegiline for the treatment of cocaine dependence</TI>
<SO>Proceedings of the 65th Annual Scientific Meeting of the College on Problems of Drug Dependence</SO>
<YR>2003</YR>
<CY>Bal Harbour, Florida, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ersche-2011a" MODIFIED="2015-05-04 12:13:37 +0200" MODIFIED_BY="[Empty name]" NAME="Ersche 2011a" YEAR="2011">
<REFERENCE MODIFIED="2015-05-04 12:13:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ersche KD, Roiser JP, Abbott S, Craig KJ, Müller U, Suckling J, et al</AU>
<TI>Response perseveration in stimulant dependence Is associated with striatal dysfunction and can be ameliorated by a D(2/3) receptor agonist</TI>
<SO>Biological Psychiatry</SO>
<YR>2011</YR>
<VL>70</VL>
<NO>8</NO>
<PG>754-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ersche-2011b" MODIFIED="2015-05-03 19:29:20 +0200" MODIFIED_BY="[Empty name]" NAME="Ersche 2011b" YEAR="2011">
<REFERENCE MODIFIED="2015-05-03 19:27:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ersche KD, Roiser JP, Lucas M, Domenici E, Robbins TW, Bullmore ET</AU>
<TI>Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment</TI>
<SO>Psychopharmacology</SO>
<YR>2011</YR>
<VL>214</VL>
<NO>4</NO>
<PG>779-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Extein-1989" MODIFIED="2015-05-04 12:13:44 +0200" MODIFIED_BY="[Empty name]" NAME="Extein 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-05-04 12:13:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Extein IL, Gross DA, Gold MS</AU>
<TI>Bromocriptine treatment of cocaine withdrawal symptoms</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>3</NO>
<PG>403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fairbairn-2008" MODIFIED="2015-05-04 12:13:54 +0200" MODIFIED_BY="[Empty name]" NAME="Fairbairn 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-04 12:13:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fairbairn CE, Dundon WD, Xie H, Plebani JG, Kampman KM, Lynch KG</AU>
<TI>Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial</TI>
<SO>American Journal on Addictions</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>5</NO>
<PG>387-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gawin-1985" MODIFIED="2015-05-04 12:14:01 +0200" MODIFIED_BY="[Empty name]" NAME="Gawin 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-05-04 12:14:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gawin F, Riordan C, Kleber H</AU>
<TI>Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative report</TI>
<SO>American Journal of Drug and Alcohol Abuse</SO>
<YR>1985</YR>
<VL>11</VL>
<NO>3-4</NO>
<PG>193-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gawin-1989" MODIFIED="2015-05-04 12:14:07 +0200" MODIFIED_BY="[Empty name]" NAME="Gawin 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-05-04 12:14:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gawin FH, Morgan C, Kosten TR, Kleber HD</AU>
<TI>Double-blind evaluation of the effect of acute amantadine on cocaine craving</TI>
<SO>Psychopharmacology</SO>
<YR>1989</YR>
<VL>97</VL>
<NO>3</NO>
<PG>402-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haney-1999" MODIFIED="2015-05-04 12:23:57 +0200" MODIFIED_BY="[Empty name]" NAME="Haney 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-05-04 12:23:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haney M, Collins ED, Ward AS, Foltin RW, Fischman MW</AU>
<TI>Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans</TI>
<SO>Psychopharmacology</SO>
<YR>1999</YR>
<VL>143</VL>
<NO>1</NO>
<PG>102-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2006" MODIFIED="2015-05-03 19:32:17 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-03 19:32:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, Roache JD, Ait-Daoud N, Javors MA, Harrison JM, Elkashef A, et al</AU>
<TI>A preliminary randomised, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>3</NO>
<PG>256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kjome-2010" MODIFIED="2015-05-04 12:23:37 +0200" MODIFIED_BY="[Empty name]" NAME="Kjome 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-04 12:23:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kjome K, Moeller F, Steinberg J, Bandak S, Lane S, Ma L, et al</AU>
<TI>Physiological and behavioral effects of SYN-115, a novel Adenosine2A antagonist in cocaine dependent subjects</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>35</VL>
<PG>S143-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosten-2005" MODIFIED="2015-05-04 12:23:49 +0200" MODIFIED_BY="[Empty name]" NAME="Kosten 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-05-04 12:23:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A</AU>
<TI>Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response</TI>
<SO>American Journal on Addictions</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>1</NO>
<PG>8-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-1992" MODIFIED="2015-05-04 12:24:43 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-04 12:24:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Bauer LO</AU>
<TI>Bromocriptine and cocaine cue reactivity in cocaine-dependent patients</TI>
<SO>British Journal of Addiction</SO>
<YR>1992</YR>
<VL>87</VL>
<NO>11</NO>
<PG>1537-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumor-1989" MODIFIED="2015-05-04 12:24:49 +0200" MODIFIED_BY="[Empty name]" NAME="Kumor 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-05-04 12:24:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumor K, Sherer M, Jaffe J</AU>
<TI>Effects of bromocriptine pretreatment on subjective and psychological responses to I.V. cocaine</TI>
<SO>Pharmacology, Biochemistry, and Behaviour</SO>
<YR>1989</YR>
<VL>33</VL>
<NO>4</NO>
<PG>829-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2014" MODIFIED="2015-05-04 12:24:56 +0200" MODIFIED_BY="[Empty name]" NAME="Liu 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-04 12:24:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu S, Green CE, Lane SD, Kosten TR, Moeller FG, Nielsen DA, et al</AU>
<TI>The influence of dopamine ß-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study</TI>
<SO>Pharmacogenetics and Genomics</SO>
<YR>2014</YR>
<VL>24</VL>
<NO>7</NO>
<PG>370-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-1994" MODIFIED="2015-05-04 12:25:03 +0200" MODIFIED_BY="[Empty name]" NAME="Malcolm 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-05-04 12:25:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Phillips JD, Brady KT, Roberts JR</AU>
<TI>A comparison of pergolide and bromocriptine in the initial rehabilitation of cocaine dependence</TI>
<SO>American Journal on Addictions</SO>
<YR>1994</YR>
<VL>3</VL>
<NO>2</NO>
<PG>144-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDougle-1992" MODIFIED="2015-05-03 19:41:12 +0200" MODIFIED_BY="[Empty name]" NAME="McDougle 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-03 19:41:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Price LH, Palumbo JM, Kosten TR, Heninger GR, Kleber HD</AU>
<TI>Dopaminergic responsivity during cocaine abstinence: a pilot study</TI>
<SO>Psychiatric Research</SO>
<YR>1992</YR>
<VL>43</VL>
<NO>1</NO>
<PG>77-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montoya-2002" MODIFIED="2015-05-04 12:25:30 +0200" MODIFIED_BY="[Empty name]" NAME="Montoya 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-05-04 12:25:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montoya ID, Preston KL, Rothman R, Gorelick DA</AU>
<TI>Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence</TI>
<SO>American Journal of Alcohol and Drug and Abuse</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>1</NO>
<PG>189-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-1988" MODIFIED="2015-05-04 12:25:19 +0200" MODIFIED_BY="[Empty name]" NAME="Morgan 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-05-04 12:25:19 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Morgan C, Kosten T, Gawin F, Kleber H. A pilot study of amantadine for ambulatory withdrawal for cocaine dependence. 1988:81-85.&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 12:25:19 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan C, Kosten T, Gawin F, Kleber H</AU>
<TI>A pilot study of amantadine for ambulatory withdrawal for cocaine dependence</TI>
<SO>NIDA Research Monograph</SO>
<YR>1988</YR>
<VL>81</VL>
<PG>81-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Preston-1992" MODIFIED="2015-05-04 12:25:44 +0200" MODIFIED_BY="[Empty name]" NAME="Preston 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-04 12:25:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preston KL, Sullivan JT, Strain EC, Bigelow GE</AU>
<TI>Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1992</YR>
<VL>262</VL>
<NO>1</NO>
<PG>279-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robbins-1992" MODIFIED="2015-05-04 12:25:51 +0200" MODIFIED_BY="[Empty name]" NAME="Robbins 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-04 12:25:51 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Robbins SJ, Ehrman RN, Childress AR, O'Brien CP.Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. Addictive Behaviors 1992;17:491-499.&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 12:25:51 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robbins SJ, Ehrman RN, Childress AR, O'Brien CP</AU>
<TI>Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride</TI>
<SO>Addictive Behaviors</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>5</NO>
<PG>491-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rotheram_x002d_Fuller-2007" MODIFIED="2015-05-04 12:25:59 +0200" MODIFIED_BY="[Empty name]" NAME="Rotheram-Fuller 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-04 12:25:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rotheram-Fuller E, De La Garza R 2nd, Mahoney JJ 3rd, Shoptaw S, Newton TF</AU>
<TI>Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination</TI>
<SO>Psychiatry Research</SO>
<YR>2007</YR>
<VL>152</VL>
<NO>2-3</NO>
<PG>205-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoptaw-2008" MODIFIED="2015-05-04 12:26:36 +0200" MODIFIED_BY="[Empty name]" NAME="Shoptaw 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-04 12:26:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Kao UH, Wang PC, Bholat MA, et al</AU>
<TI>Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>1</NO>
<PG>13-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sule-2008" MODIFIED="2015-05-03 19:45:03 +0200" MODIFIED_BY="[Empty name]" NAME="Sule 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-03 19:45:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sule A, Shah M, Kelly K</AU>
<TI>Potential use of dopamine  partial  agonists in cocaine addiction</TI>
<SO>Progress in Neurology and Psychiatry</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>2</NO>
<PG>6-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tennant-1987" MODIFIED="2015-05-04 12:26:16 +0200" MODIFIED_BY="[Empty name]" NAME="Tennant 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-05-04 12:26:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tennant FS Jr, Sagherian AA</AU>
<TI>Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1987</YR>
<VL>147</VL>
<NO>1</NO>
<PG>109-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tennant-1990" MODIFIED="2015-05-04 12:26:23 +0200" MODIFIED_BY="[Empty name]" NAME="Tennant 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-05-04 12:26:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tennant F</AU>
<TI>Clinical trial of multiple treatment agents for cocaine dependence: a placebo-control; elimination study</TI>
<SO>NIDA Research Monograph</SO>
<YR>1990</YR>
<VL>105</VL>
<PG>512-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winhusen-2007" MODIFIED="2015-05-03 19:47:27 +0200" MODIFIED_BY="[Empty name]" NAME="Winhusen 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-03 19:47:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winhusen T, Somoza E, Sarid-Segal O, Goldsmith RJ, Harrer JM, Coleman FS, et al</AU>
<TI>A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence</TI>
<SO>Drug and Alcohol Dependence  </SO>
<YR>2007</YR>
<VL>91</VL>
<NO>2-3</NO>
<PG>205-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfsohn-1993" MODIFIED="2015-05-04 12:26:29 +0200" MODIFIED_BY="[Empty name]" NAME="Wolfsohn 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-05-04 12:26:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolfsohn R, Sanfilipo M, Angrist B</AU>
<TI>A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1993</YR>
<VL>9</VL>
<NO>1</NO>
<PG>49-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-04-01 12:31:44 +0200" MODIFIED_BY="Laura Amato"/>
<ONGOING_STUDIES MODIFIED="2011-04-01 12:31:59 +0200" MODIFIED_BY="Laura Amato"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-05-14 10:36:17 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-05-14 10:36:17 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amato-2007" MODIFIED="2011-05-02 13:37:21 +0200" MODIFIED_BY="[Empty name]" NAME="Amato 2007" TYPE="COCHRANE_REVIEW">
<AU>Amato L, Minozzi S, Pani PP, Davoli M</AU>
<TI>Antipsychotic medication for cocaine dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006306.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Amato-2010" MODIFIED="2015-05-03 20:16:38 +0200" MODIFIED_BY="[Empty name]" NAME="Amato 2010" TYPE="COCHRANE_REVIEW">
<AU>Amato L, Minozzi S, Vecchi S, Davoli M</AU>
<TI>Benzodiazepines for alcohol withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-05-03 20:16:38 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-03 20:16:38 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005063.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Atkins-2004" MODIFIED="2015-05-04 12:27:05 +0200" MODIFIED_BY="[Empty name]" NAME="Atkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castells-2010" MODIFIED="2015-05-04 12:27:12 +0200" MODIFIED_BY="[Empty name]" NAME="Castells 2010" TYPE="COCHRANE_REVIEW">
<AU>Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D</AU>
<TI>Efficacy of psychostimulant drugs for cocaine dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-05-03 20:17:15 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-03 20:17:15 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007380.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Di-Chiara-1988" MODIFIED="2015-05-04 12:27:21 +0200" MODIFIED_BY="[Empty name]" NAME="Di Chiara 1988" TYPE="JOURNAL_ARTICLE">
<AU>Di Chiara G, Imperato A</AU>
<TI>Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1988</YR>
<VL>85</VL>
<NO>14</NO>
<PG>5274-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drevets-1999" MODIFIED="2015-05-04 12:27:30 +0200" MODIFIED_BY="[Empty name]" NAME="Drevets 1999" TYPE="JOURNAL_ARTICLE">
<AU>Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, et al</AU>
<TI>PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>6</NO>
<PG>694-709</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drevets-2001" MODIFIED="2015-05-04 12:28:12 +0200" MODIFIED_BY="[Empty name]" NAME="Drevets 2001" TYPE="JOURNAL_ARTICLE">
<AU>Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, et al</AU>
<TI>Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>2</NO>
<PG>81-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMCDDA-2014" MODIFIED="2015-05-14 10:35:01 +0200" MODIFIED_BY="[Empty name]" NAME="EMCDDA 2014" TYPE="OTHER">
<TI>The state of the drugs problem in the European Union and Norway</TI>
<SO>European Monitoring Centre for Drug and Drug Abuse, Luxemburg 2014</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faggiano-2003" MODIFIED="2015-05-03 20:23:43 +0200" MODIFIED_BY="[Empty name]" NAME="Faggiano 2003" TYPE="COCHRANE_REVIEW">
<AU>Faggiano F, Vigna-Taglianti F, Versino E, Lemma P</AU>
<TI>Methadone maintenance at different dosages for opioid dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002208"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gardner-1999" MODIFIED="2015-05-04 12:28:19 +0200" MODIFIED_BY="[Empty name]" NAME="Gardner 1999" TYPE="BOOK_SECTION">
<AU>Gardner EL</AU>
<TI>Neurobiology and genetics of addiction: implications of "reward deficiency syndrome" for therapeutic strategies in chemical dependency</TI>
<SO>Addiction: Entries and Exits</SO>
<YR>1999</YR>
<PG>57-119</PG>
<ED>Elster J</ED>
<PB>Russell Sage Foundation</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gold-1997" MODIFIED="2011-05-02 13:34:29 +0200" MODIFIED_BY="[Empty name]" NAME="Gold 1997" TYPE="BOOK_SECTION">
<AU>Gold MS</AU>
<TI>Cocaine (and Crack): Clinical Aspects</TI>
<SO>Substance Abuse: A Comprehensive Textbook</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>181-99</PG>
<EN>3rd</EN>
<ED>Lowinson JH, Ruiz P, Millman RB, Langrod JG</ED>
<PB>Lippincott, Williams &amp; Wilkins</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gorelick-2004" MODIFIED="2015-05-04 12:28:27 +0200" MODIFIED_BY="[Empty name]" NAME="Gorelick 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gorelick DA, Gardner EL, Xi ZX</AU>
<TI>Agents in development for the management of cocaine abuse</TI>
<SO>Drugs</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>14</NO>
<PG>1547-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-05-03 20:28:06 +0200" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2015-05-04 12:28:35 +0200" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-1994" MODIFIED="2015-05-04 12:28:42 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 1994" TYPE="JOURNAL_ARTICLE">
<AU>Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badjer GJ</AU>
<TI>Incentives improve outcome in outpatient behavioral treatment of cocaine dependence</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>7</NO>
<PG>568-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-05-04 12:28:55 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kimmel-2007" MODIFIED="2015-05-04 13:02:13 +0200" MODIFIED_BY="[Empty name]" NAME="Kimmel 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kimmel HL, O&#8217;Connor JA, Carroll FI, Howell LL</AU>
<TI>Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys</TI>
<SO>Pharmacology, Biochemistry, and Behavior</SO>
<YR>2007</YR>
<VL>86</VL>
<NO>1</NO>
<PG>45-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knapp-2007" MODIFIED="2015-05-03 20:31:03 +0200" MODIFIED_BY="[Empty name]" NAME="Knapp 2007" TYPE="COCHRANE_REVIEW">
<AU>Knapp WP, Soares BGO, Farrel M, Lima MS</AU>
<TI>Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003023.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martinez-2009" MODIFIED="2015-05-04 13:02:05 +0200" MODIFIED_BY="[Empty name]" NAME="Martinez 2009" TYPE="JOURNAL_ARTICLE">
<AU>Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R, et al</AU>
<TI>Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>10</NO>
<PG>1170-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mattick-2008" MODIFIED="2015-05-04 13:02:36 +0200" MODIFIED_BY="[Empty name]" NAME="Mattick 2008" TYPE="COCHRANE_REVIEW">
<AU>Mattick RP, Kimber J, Breen C, Davoli M</AU>
<TI>Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002207.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mattick-2009" MODIFIED="2015-05-04 13:02:44 +0200" MODIFIED_BY="[Empty name]" NAME="Mattick 2009" TYPE="COCHRANE_REVIEW">
<AU>Mattick RP, Breen C, Kimber J, Davoli M</AU>
<TI>Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-05-03 20:33:18 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-03 20:33:18 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002209.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pani-2010" MODIFIED="2015-05-03 20:34:59 +0200" MODIFIED_BY="[Empty name]" NAME="Pani 2010" TYPE="COCHRANE_REVIEW">
<AU>Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M</AU>
<TI>Disulfiram for the treatment of cocaine dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-05-03 20:34:59 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-03 20:34:59 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007024.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pani-2011" MODIFIED="2015-05-03 20:35:28 +0200" MODIFIED_BY="[Empty name]" NAME="Pani 2011" TYPE="COCHRANE_REVIEW">
<AU>Pani PP, Trogu E, Vecchi S, Amato L</AU>
<TI>Antidepressants for cocaine dependence and problematic cocaine use</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2015-05-03 20:35:28 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-03 20:35:28 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002950.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rush-2009" MODIFIED="2015-05-04 13:03:08 +0200" MODIFIED_BY="[Empty name]" NAME="Rush 2009" TYPE="JOURNAL_ARTICLE">
<AU>Rush CR, Stoops WW, Hays LR</AU>
<TI>Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2009</YR>
<VL>99</VL>
<NO>1-3</NO>
<PG>261-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rush-2010" MODIFIED="2015-05-04 13:03:16 +0200" MODIFIED_BY="[Empty name]" NAME="Rush 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rush CR, Stoops WW, Sevak RJ, Hays LR</AU>
<TI>Cocaine choice in humans during D-amphetamine maintenance</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>2</NO>
<PG>152-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-R_x00f6_sner-2010a" MODIFIED="2015-05-04 13:03:24 +0200" MODIFIED_BY="[Empty name]" NAME="Rösner 2010a" TYPE="COCHRANE_REVIEW">
<AU>Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M</AU>
<TI>Acamprosate for alcohol dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2015-03-31 12:38:45 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-31 12:38:45 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004332.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-R_x00f6_sner-2010b" MODIFIED="2015-05-03 20:51:50 +0200" MODIFIED_BY="[Empty name]" NAME="Rösner 2010b" TYPE="COCHRANE_REVIEW">
<AU>Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M</AU>
<TI>Opioid antagonists for alcohol dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>12</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001867.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SAMHSA-2014" MODIFIED="2015-05-14 10:35:42 +0200" MODIFIED_BY="[Empty name]" NAME="SAMHSA 2014" TYPE="OTHER">
<TI>2014 National Survey on Drug Use &amp; Health</TI>
<SO>Substance Abuse &amp; Mental Health Services Administration. Rockville, MD</SO>
<YR>2014 (accessed 12 January 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2006" MODIFIED="2015-05-04 13:03:55 +0200" MODIFIED_BY="[Empty name]" NAME="Schünemann 2006" TYPE="JOURNAL_ARTICLE">
<AU>Schünemann HJ, Jaeschke R, Cook DJ, Bria W, El-Solh AA, Ernst A, et al</AU>
<TI>An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2006</YR>
<VL>174</VL>
<NO>5</NO>
<PG>605-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Self-1995" MODIFIED="2015-05-03 20:41:11 +0200" MODIFIED_BY="[Empty name]" NAME="Self 1995" TYPE="JOURNAL_ARTICLE">
<AU>Self DW, Nestler EJ</AU>
<TI>Molecular mechanisms of drug reinforcement and addiction</TI>
<SO>Annual Review of Neuroscience</SO>
<YR>1995</YR>
<VL>18</VL>
<PG>463-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sorensen-1991" MODIFIED="2015-05-04 13:04:47 +0200" MODIFIED_BY="[Empty name]" NAME="Sorensen 1991" TYPE="BOOK">
<AU>Sorensen JL, Wermuth LA, Gibson DR, Choi K, Guydish JR</AU>
<SO>Preventing AIDS in Drug Abusers and Their Sexual Partners</SO>
<YR>1991</YR>
<PB>Guilford</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNODC-2014" MODIFIED="2015-05-04 13:05:04 +0200" MODIFIED_BY="[Empty name]" NAME="UNODC 2014" TYPE="BOOK">
<AU>United Nations Office on Drugs and Crime</AU>
<SO>World Drug Report 2014</SO>
<YR>2014</YR>
<VL>Sales No. E.14.XI.7</VL>
<PB>United Nations</PB>
<CY>Vienna</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volkow-1995" MODIFIED="2015-05-04 13:05:49 +0200" MODIFIED_BY="[Empty name]" NAME="Volkow 1995" TYPE="JOURNAL_ARTICLE">
<AU>Volkow ND, Ding Y-S, Fowler JS, Wang GJ, Logan J, Gatley JS, et al</AU>
<TI>Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>6</NO>
<PG>456-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volkow-1997" MODIFIED="2015-05-04 13:05:58 +0200" MODIFIED_BY="[Empty name]" NAME="Volkow 1997" TYPE="JOURNAL_ARTICLE">
<AU>Volkow ND, Wang G-J, Fowler JS, Logan J, Gatley SJ, Hitzemann R, et al</AU>
<TI>Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects</TI>
<SO>Nature</SO>
<YR>1997</YR>
<VL>386</VL>
<NO>6627</NO>
<PG>830-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volkow-1999a" MODIFIED="2015-05-04 13:06:07 +0200" MODIFIED_BY="[Empty name]" NAME="Volkow 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Volkow ND, Fowler JS, Wang GJ</AU>
<TI>Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>4</NO>
<PG>337-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volkow-1999b" MODIFIED="2015-05-04 13:06:14 +0200" MODIFIED_BY="[Empty name]" NAME="Volkow 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, et al</AU>
<TI>Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1999</YR>
<VL>291</VL>
<NO>1</NO>
<PG>409-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volkow-2003a" MODIFIED="2015-05-04 11:46:10 +0200" MODIFIED_BY="[Empty name]" NAME="Volkow 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Volkow ND, Fowler JS, Wang GJ</AU>
<TI>The addicted human brain: insights for imaging studies</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>10</NO>
<PG>1444-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volkow-2003b" MODIFIED="2015-05-04 11:46:25 +0200" MODIFIED_BY="[Empty name]" NAME="Volkow 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Volkow ND, Swanson JM</AU>
<TI>Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>11</NO>
<PG>1909-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volkow-2006" MODIFIED="2015-05-03 20:47:21 +0200" MODIFIED_BY="[Empty name]" NAME="Volkow 2006" TYPE="JOURNAL_ARTICLE">
<AU>Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, et al</AU>
<TI>Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction</TI>
<SO>Journal of Neuroscience</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>24</NO>
<PG>6583-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volkow-2010" MODIFIED="2015-05-03 20:47:40 +0200" MODIFIED_BY="[Empty name]" NAME="Volkow 2010" TYPE="JOURNAL_ARTICLE">
<AU>Volkow ND, Wang GJ, Tomasi D, Telang F, Fowler JS, Pradhan K, et al</AU>
<TI>Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers</TI>
<SO>PLoS One</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>7</NO>
<PG>e11509</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wise-2005" MODIFIED="2015-05-04 11:46:32 +0200" MODIFIED_BY="[Empty name]" NAME="Wise 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wise RA</AU>
<TI>Forebrain substrates of reward and motivation</TI>
<SO>Journal of Comparative Neurology</SO>
<YR>2005</YR>
<VL>493</VL>
<NO>1</NO>
<PG>115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-05-04 11:46:17 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amato-2011" MODIFIED="2015-05-04 11:46:02 +0200" MODIFIED_BY="[Empty name]" NAME="Amato 2011" TYPE="COCHRANE_REVIEW">
<AU>Amato L, Minozzi S, Pani PP, Solimini R, Vecchi S, Zuccaro P, et al</AU>
<TI>Dopamine agonists for the treatment of cocaine dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2015-03-30 16:10:13 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-30 16:10:13 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003352.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Soares-2003" MODIFIED="2015-05-04 11:46:17 +0200" MODIFIED_BY="[Empty name]" NAME="Soares 2003" TYPE="COCHRANE_REVIEW">
<AU>Soares B, Lima Reisser AARL, Farrell M, Silva de Lima M</AU>
<TI>Dopamine agonists for cocaine dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-05-03 20:54:33 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-03 20:54:33 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003352.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-05-14 10:32:39 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-05-14 10:32:39 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-05-04 12:17:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alterman-1992">
<CHAR_METHODS MODIFIED="2011-04-05 14:45:18 +0200" MODIFIED_BY="Laura Amato">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:17:35 +0200" MODIFIED_BY="[Empty name]">
<P>N = 42 cocaine dependents (DSM-III-R); mean age: 35 years; sex: male 100%; Race: African-American 90%, less than 20% currently married.<BR/>History: 15 days of cocaine use last month, cocaine regular use for ~3 years. Recent use of alcohol and cannabis were also reported, but not a dependence on these drugs.</P>
<P>Inclusion criteria: cocaine dependence according to the DSM III criteria.</P>
<P>Exclusion criteria: patients with significant cardiovascular, hepatic, renal, neurological or endocrinological abnormalities; dependence on a substance other than cocaine or nicotine; inability to understand self-medication instructions; taking neuroleptic medications; not having used cocaine in the past week; unstable housing arrangements.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:17:35 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Amantadine 200 mg, N = 21;</LI>
<LI>Placebo, N = 21.</LI>
</OL>
<P>Setting: outpatient; Duration: 10 days, follow-up 1 month; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:17:35 +0200" MODIFIED_BY="[Empty name]">
<P>No retention in treatment; Positive urine for cocaine metabolites; BDI; Side effects (total number of side effects); ASI (related to follow-up period- 30 days);<BR/>CSR - craving; HDRS: SCL-90</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The subjects received 27 hours per week of day hospital treatment.<BR/>Participants were paid for completing each assessments.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:18:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ciraulo-2005">
<CHAR_METHODS MODIFIED="2011-04-05 14:56:49 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:18:31 +0200" MODIFIED_BY="[Empty name]">
<P>60 subjects; age 43 on the average; males 43/60; black 55/60; married 29/60.</P>
<P>Inclusion criteria: age between 18 and 60years; meet DSM-IV criteria for cocaine dependence and reported use of cocaine on at least six occasions or days within 28 days prior to screening and 3/6 urine positive.</P>
<P>Exclusion criteria: current dependence on any psychoactive substance other than cocaine and nicotine or physiological dependence on alcohol requiring medical detoxification; neurological or psychiatric disorders that require treatment; serious medical illness; pregnancy or lactation; renal stone formation; asthma or actively using beta-adrenergic agonist medications.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:18:31 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pramipexole (dopamine agonist) 1.5 mg daily, N = 20;</LI>
<LI>Venlafaxine (antidepressant (150 mg daily), N = 20;</LI>
<LI>Placebo, N = 20.</LI>
</OL>
<P>Setting: outpatient; duration: 8 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:18:31 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; use of cocaine (urine BE); ASI; CGI-O; HAM-D; HAM-A; BSCS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:18:31 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:18:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eiler-1995">
<CHAR_METHODS MODIFIED="2015-05-03 23:08:10 +0200" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:18:51 +0200" MODIFIED_BY="[Empty name]">
<P>N = 63<BR/>Mean 35.6 years; male 100%; black 86%, Caucasian 15%; unemployed 60%, married 24%; 55% intranasal use and 3% intravenously. Duration of use average 7.9 years, average amount of cocaine used in a typical week 9.2 g. Alcohol abuse could be present, but not alcohol dependence.</P>
<P>Inclusion criteria: meet DSM-III-R criteria for cocaine dependence, last cocaine use was within 6 days.</P>
<P>Exclusion criteria: other drug dependence,alcohol dependence, psychotropic medication other than Halcion for sleep prescribed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:18:51 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Bromocriptine 2.5 to 10 mg/day, N = 32;</LI>
<LI>Placebo, N = 31.</LI>
</OL>
<P>Setting: inpatient; duration: 18 to 21 days; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:18:51 +0200" MODIFIED_BY="[Empty name]">
<P>Dropouts; dropouts due to adverse effects; BDI; craving; withdrawal symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:18:52 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:19:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Focchi-2005">
<CHAR_METHODS MODIFIED="2011-04-05 16:25:02 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:19:03 +0200" MODIFIED_BY="[Empty name]">
<P>N = 42</P>
<P>All male; average age 26.5 years; white 35/42; married 14/42; working 29/42; cocaine smoked 3/42, inhaled 20/42, smoked and inhaled 19/42.</P>
<P>Inclusion criteria: male, between 18 and 50 years, cocaine dependents (DSM-IV), living in São Paulo, at least primary school education.</P>
<P>Exclusion criteria: active psychiatric illness or psychosis, hypersensitivity to pergolide or other ergot derivatives, without permanent address or telephone number.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:19:03 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pergolide 0.05 mg/day in the first week and 0.1 mg/day in the second week, until 0.2 mg/day in the fourth week, N = 22;</LI>
<LI>Placebo, N = 20.</LI>
</OL>
<P>Setting: outpatient; duration: 4 weeks, follow-up 3 months; country of origin: Brazil.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:19:03 +0200" MODIFIED_BY="[Empty name]">
<P>HAM-D; Minnesota Cocaine Craving Scale; adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:19:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giannini-1989">
<CHAR_METHODS MODIFIED="2011-04-08 10:36:35 +0200" MODIFIED_BY="Laura Amato">
<P>RCT<BR/>3 parallel groups<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:19:23 +0200" MODIFIED_BY="[Empty name]">
<P>N = 30<BR/>All male; age: range 24 to 32 years; Caucasians 100%.<BR/>All subjects had abused cocaine intranasally on a daily basis for at least 4 weeks before study entry, confirmed by urine drug screen before and during the study; 2 subjects in the bromocriptine group and one each in the amantadine and placebo group met DSM-III-R criteria for antisocial personality disorder.</P>
<P>Inclusion criteria: not reported.</P>
<P>Exclusion criteria: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:19:23 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Amantadine 400 mg/day, N = 10;</LI>
<LI>Bromocriptine 10 mg/day, N = 10;</LI>
<LI>Placebo, N = 10.</LI>
</OL>
<P>Setting: outpatient; duration: 30 days; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:19:23 +0200" MODIFIED_BY="[Empty name]">
<P>Side effects; BPRS; craving</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-08 10:40:13 +0200" MODIFIED_BY="Laura Amato"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:19:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gorelick-2006">
<CHAR_METHODS MODIFIED="2011-05-13 09:42:01 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:19:57 +0200" MODIFIED_BY="[Empty name]">
<P>N = 70</P>
<P>All men; mean age 34 years; 86% African-American; mean 39 months of regular cocaine use (predominantly smoked).</P>
<P>Inclusion criteria: met DSM IV criteria for current cocaine abuse or dependence; age 18 to 65 years, living within 25 miles of the hospital, no other current substance abuse or dependence except nicotine.</P>
<P>Exclusion criteria: myocardial infarction within the past 6 months, current serious or unstable medical or psychiatric condition, allergy or hypersensitivity to bromocriptine or ergot alkaloids, current treatment with dopamine affecting medications (i.e. disulfiram, amantadine, anti-depressants, neuroleptics), inability to give informed consent or inability to cooperate with study procedures.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:19:57 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Bromocriptine max dose 2.5 mg, N = 35;</LI>
<LI>Placebo, N = 35.</LI>
</OL>
<P>Setting: inpatient; duration: 4 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:19:57 +0200" MODIFIED_BY="[Empty name]">
<P>Compliance; retention; use of cocaine (urine samples); craving (0-5 Likert scale); BDI; HAM-D; adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:19:57 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:20:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Handelsman-1995">
<CHAR_METHODS MODIFIED="2011-04-08 11:56:30 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:20:20 +0200" MODIFIED_BY="[Empty name]">
<P>N = 67 methadone-maintained patients in treatment for heroine dependence (59 analysed).<BR/>Age: ~36 years; sex: male 100%; race: unclear.<BR/>Inclusion criteria: male, age between 21 and 50, fulfil DSM-III criteria for cocaine dependence including active dependence in the 3-month period prior to research, reported cocaine use on 3 or more days per week during the prior 3 months.</P>
<P>Exclusion criteria: any serious medical illness, assuming a systematically active medication, abnormal electrocardiogram, fulfilled criteria for any psychoactive substance use disorder other than heroin, cocaine, nicotine or caffeine, fulfilled DSM III criteria for any current major psychiatric disorder including psychotic, affective or panic disorders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:20:20 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Amantadine 200 mg/day, N = 19;</LI>
<LI>Amantadine 400 mg/day, N = 23;</LI>
<LI>Placebo, N = 25.</LI>
</OL>
<P>Setting: outpatient; duration: 9 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:20:20 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; BDI; SCL-90; Positive urine sample for cocaine metabolites; craving; compliance; adverse effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:20:20 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:20:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Handelsman-1997">
<CHAR_METHODS MODIFIED="2011-05-13 09:45:38 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:20:34 +0200" MODIFIED_BY="[Empty name]">
<P>N = 60.</P>
<P>Methadone-maintained patients with cocaine abuse or dependence (DSM-III-R).</P>
<P>Age: ~39 years; male 100%; 24% black.<BR/>Inclusion criteria: older than 21 years of age, using cocaine in the last 30 days and at least one positive urine for cocaine metabolite.</P>
<P>Exclusion criteria: serious medical illness, history of alcohol or sedative dependence that need medical detoxification, any psychotic disorder, female.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:20:34 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Bromocriptine 5 mg, N = 30;</LI>
<LI>Placebo, N = 30.</LI>
</OL>
<P>For both groups intensive cognitive behavioral therapy.</P>
<P>Setting: outpatient; duration: 5 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:20:34 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; use of cocaine (self report and urine based); craving, POMS; PANAS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-08 13:12:03 +0200" MODIFIED_BY="Laura Amato">
<P>Patients were paid for participation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:20:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kampman-1996">
<CHAR_METHODS MODIFIED="2011-05-13 09:46:45 +0200" MODIFIED_BY="Laura Amato">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:20:52 +0200" MODIFIED_BY="[Empty name]">
<P>N = 61<BR/>Cocaine use within 10 days of entering the stud. Age: ~35 years; male in amantadine group 87%; in placebo group 77%; African-American in amantadine group 67%; in placebo group 71%.</P>
<P>Inclusion criteria: not reported.<BR/>Exclusion criteria: dependents on any drug except cocaine, marijuana and alcohol, pregnancy, breast feeding, psychosis, dementia, epilepsy, use of psychotropic medication. Alcohol and marijuana dependent were not excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:20:52 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Amantadine 300 mg, N = 30;</LI>
<LI>Placebo, N = 31.</LI>
</OL>
<P>For all 50 minutes individual counselling sessions and twice weekly 90 minutes therapy sessions.</P>
<P>Setting: outpatient; duration: 4 weeks, follow-up at 8 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:20:52 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; abstinence; ASI; BDI; BAI; craving; adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:20:52 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:21:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kampman-2006">
<CHAR_METHODS MODIFIED="2011-05-13 09:47:30 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:21:04 +0200" MODIFIED_BY="[Empty name]">
<P>N = 199</P>
<P>Mean age: 42.2 years, male: 65.5% African American: 85%, Caucasian: 17%, Hispanic: 2.5%. Days of cocaine use in past 30 days: 15.4. Year of cocaine use: 11.6.</P>
<P>Inclusion criteria: aged between 18 and 60 years, cocaine dependents, patients addicted also to alcohol were also admitted.</P>
<P>Exclusion criteria: other addictions, except nicotine, psychosis, dementia, use of psychotropic medications, pregnancy, breastfeeding, hyperthyroidism, bronchoplastic disease, heart disease, history of chest pain.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:21:04 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Propanolol 20 mg twice daily for the first 3 days, then 40 mg twice daily, N = 50;</LI>
<LI>Amantadine 100 mg three times daily, N = 50;</LI>
<LI>Amantadine + Propanolol, N = 50;</LI>
<LI>Placebo, N = 49.</LI>
</OL>
<P>For all twice-weekly individual cognitive behavioural therapy</P>
<P>Setting: outpatient; Duration:10 weeks; Country of origin: USA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-13 09:47:30 +0200" MODIFIED_BY="Laura Amato">
<P>Retention; Use of cocaine based on urine test, CSSA, ASI, Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:21:04 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:21:49 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2015-05-03 21:53:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;Please replace the term &amp;quot;and/or&amp;quot; with another term.&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 12:21:49 +0200" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolar-1992">
<CHAR_METHODS MODIFIED="2011-05-13 09:49:11 +0200" MODIFIED_BY="Laura Amato">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:21:49 +0200" MODIFIED_BY="[Empty name]">
<P>N = 24<BR/>Mean 34.8 years, 85% male, African-American 68%<BR/>Patients had used cocaine on average for 10 years. Other diagnosis were found such as attention deficit disorder, affective and anxiety disorders. Patients were required to be stabilized on a daily methadone dose of 40 mg or greater for a minimum of six weeks.</P>
<P>Inclusion criteria: DSM III criteria for cocaine dependence, stabilized on daily methadone dose of 40 mg or greater for a minimum of 6 weeks.</P>
<P>Exclusion criteria: current use or dependence on any substance other than marijuana, nicotine, and caffeine or took prescribed medication; currently medically ill, psychotic, and/or pregnant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:21:49 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Desipramine 200 mg, N = 8;</LI>
<LI>Amantadine 200 mg followed by placebo, N = 5;</LI>
<LI>Placebo, N = 9.</LI>
</OL>
<P>For all weekly group counselling sessions as well as weekly or more frequent individual counselling sessions.</P>
<P>Setting: outpatient; duration:12 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:21:49 +0200" MODIFIED_BY="[Empty name]">
<P>No retention in treatment; use of cocaine; BDI; craving; adverse effects; participants presenting at least one adverse effect.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:21:49 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 12:22:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosten-1992">
<CHAR_METHODS MODIFIED="2011-05-13 09:51:17 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:22:47 +0200" MODIFIED_BY="[Empty name]">
<P>N = 94<BR/>Opioid and cocaine dependents (DSM-III-R) Sex: male 52%, at least 3/6 urine positive for cocaine metabolites during the 3 months before the onset of the study; patients had been receiving methadone maintenance for a mean of 7.6 months before entering the study. Additional diagnosis: antisocial personality disorder (20%); major depression (5%), dysthymia (22%). Mean 32 years, 82% white.</P>
<P>Inclusion criteria: meeting the DSM III criteria for a and opioid dependence, with at least three urine toxicology screening positive for cocaine metabolites during the 3 months before the study.<BR/>Exclusion criteria: taking zidovudine for HIV syndrome, asthma, renal dysfunction, high blood pressure, diabetes, current alcoholism, refuse to use adequate birth control.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:22:47 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Desipramine 150 mg, N = 30;</LI>
<LI>Amantadine 300 mg, N = 33;</LI>
<LI>Placebo, N = 31.</LI>
</OL>
<P>For all weekly group relapse prevention therapy.</P>
<P>Setting: outpatient; duration:12 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:22:48 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; use of cocaine (urine based); dropout due to adverse effects; craving.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:22:48 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-14 10:32:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-2000">
<CHAR_METHODS MODIFIED="2011-05-13 09:52:50 +0200" MODIFIED_BY="Laura Amato">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 12:23:06 +0200" MODIFIED_BY="[Empty name]">
<P>N = 464<BR/>Age: range 18 to 52 years, male 79%, black 52%, mean years of cocaine use ~8.</P>
<P>Inclusion criteria: able to give informed consent, met DSM-III-R criteria for cocaine dependence with or without comorbid alcohol dependence, crack or cocaine as their primary drug of choice.</P>
<P>Exclusion criteria: past or present major Axis I disorders, previous treatment with dopamine agonists, treatment with anxiolytics, antidepressants or antipsychotic within 30 days of entering the study, females of childbearing potential without reliable birth control measures, patients with unstable medical conditions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 12:23:06 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>High dose pergolide 0.25 mg bid, N = 156;</LI>
<LI>Low dose pergolide 0.05 mg bid, N = 155;</LI>
<LI>Placebo (sucrose powder), N = 153.</LI>
</OL>
<P>Setting: outpatient; duration: 12 weeks + 6 months follow-up; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 12:23:06 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment(12 weeks); positive urine samples; adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 12:23:06 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were paid USD 25 at weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:56:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mooney-2007a">
<CHAR_METHODS MODIFIED="2011-05-13 09:55:28 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:56:32 +0200" MODIFIED_BY="[Empty name]">
<P>Two trials</P>
<P>N = 67</P>
<P>Mean age: 35 years; male 67.5%; white 45.5%, black 47.5%, Hispanic 7%; mean years of cocaine use: 8.5.</P>
<P>Inclusion criteria: age between 18 and 55 years, current users of cocaine.</P>
<P>Exclusion criteria: pregnancy or nursing, current dependence on substances other than cannabis or nicotine, current psychotic, affective or anxiety disorder, serious medical conditions including movement disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:56:32 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>400/100mg L-dopa/Carbidopa, N = 31;</LI>
<LI>Placebo, N = 36.</LI>
</OL>
<P>For all supportive behavioural counselling for 1 h each week.</P>
<P>Setting: outpatient; duration: 1, 5 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:56:32 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; adverse effects; cocaine use; craving; mood.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:56:32 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:56:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mooney-2007b">
<CHAR_METHODS MODIFIED="2011-05-13 09:56:18 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:56:15 +0200" MODIFIED_BY="[Empty name]">
<P>N = 122</P>
<P>Mean age: 39.7, male 67.5%; white 28.5%, black 65.4%, Hispanic 6%; mean years of cocaine use: 10.6.</P>
<P>Inclusion criteria: age between 18 and 55 years, current users of cocaine.</P>
<P>Exclusion criteria: pregnancy or nursing, current dependence on substances other than cannabis or nicotine, current psychotic, affective or anxiety disorder, serious medical conditions including movement disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:56:15 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>400/100 mg L-dopa/carbidopa, N = 43;</LI>
<LI>800/200mg L-dopa/carbidopa, N = 39;</LI>
<LI>Placebo, N = 40.</LI>
</OL>
<P>For all supportive behavioural counselling for 1 h each week.</P>
<P>Setting: outpatient; duration: 2, 9 week; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:56:15 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; adverse effects; cocaine use; craving; mood.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:56:15 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:57:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moscovitz-1993">
<CHAR_METHODS MODIFIED="2011-05-13 09:57:06 +0200" MODIFIED_BY="Laura Amato">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:57:10 +0200" MODIFIED_BY="[Empty name]">
<P>N = 29<BR/>Diagnosis: cocaine users, age: ~37 years, male 100%.<BR/>Participants used cocaine at least four times per week for the previous month.</P>
<P>Inclusion criteria: frequent cocaine use defined as intranasal, inhalational (crack), or intravenous administration of cocaine more than three times per week for the previous four weeks. A positive urine test for benzoylecgonine, a cocaine metabolite, was also required for entry into the study.<BR/>
</P>
<P>Exclusion criteria: use of narcotics, dependence on other substances, consumption more than the equivalent of a pint of hard<BR/>liquor per day, use of neuroleptic or antidepressant medications; a history of schizophrenia, cardiovascular disease, or hypertension; and a prior adverse reaction to bromocriptine.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:57:10 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Bromocriptine 3.75 mg/day, N = 14;</LI>
<LI>Placebo, N = 15.</LI>
</OL>
<P>Setting: outpatient; duration: 2 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:57:10 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment, positive urine sample for cocaine metabolites, participants presenting at least one adverse effect.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:57:10 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:56:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oliveto-1995">
<CHAR_METHODS MODIFIED="2011-05-13 09:58:09 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:56:02 +0200" MODIFIED_BY="[Empty name]">
<P>N = 21<BR/>Opioid dependents on methadone maintenance and cocaine abusers, mean age: 33.1 years; 52.9% male; 94.1% white; education: mean 11.6 years; e<BR/>mployed full-time: 35.3%; heroin use: mean 8.8 years, 22.9 days last month; cocaine use: 8.4 days last month.</P>
<P>Inclusion criteria: opioid dependence, cocaine use, no current alcohol or sedative physical dependence, no current use of medications for psychiatric conditions, women who have negative pregnancy test and agree to effective birth control.</P>
<P>Exclusion criteria: significant medical contra-indications (e.g. cerebral, renal, thyroid, hepatic or cardiac pathology), acute suicidality or severity of clinical conditions such that inpatient treatment is indicated, illiteracy or inability to comprehend the consent for study procedure or both, concurrent treatment with AZT or other medications for the treatment of AIDS.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:56:02 +0200" MODIFIED_BY="[Empty name]">
<P>Buprenorphine 8 mg/day and:</P>
<OL>
<LI>Amantadine 300 mg/day, N = 5;</LI>
<LI>Desipramine 150 mg/day, N = 8;</LI>
<LI>Fluoxetine 60 mg/day, N = 4.</LI>
</OL>
<P>For all at least once-weekly group relapse prevention.</P>
<P>Setting: outpatient; duration: 12 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:56:02 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; positive urine sample; cocaine craving; BDI.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:56:02 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:55:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<CHAR_METHODS MODIFIED="2011-05-13 10:04:42 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:55:44 +0200" MODIFIED_BY="[Empty name]">
<P>N = 42<BR/>Heroin and cocaine dependents, mean age: ~31 years; 77% male; race: unclear; education: mean ~8 years; employment: unclear; heroin use: mean ~10 years; cocaine use: mean 20 days last month.</P>
<P>Inclusion criteria: 18 to 45 years old, meet DSM-III-R criteria for heroin dependence and for current cocaine abuse or dependence, urine toxicology test positive for BE on the first day of hospitalisation.</P>
<P>Exclusion criteria: pregnancy, DSM-III-R diagnosis of dependence on alcohol, hypnotics or sedative, as well as schizophrenia or other psychotic disorders, presence of severe physical alterations that contraindicated participation in the trial (e.g. impaired renal function, peptic ulcere disease and seizures).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:55:44 +0200" MODIFIED_BY="[Empty name]">
<P>Methadone maintenance, on the first or second day of hospitalisation never higher than 50 mg/day, tapered at a rate of 5 mg/day and:</P>
<OL>
<LI>Amantadine 200 to 300 mg/day, N = 19;</LI>
<LI>Placebo N = 21.</LI>
</OL>
<P>Setting: inpatient; duration: 14 days; country of origin: Spain.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:55:44 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; craving; BDI; STAI; adverse effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-05-13 10:04:42 +0200" MODIFIED_BY="Laura Amato"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:55:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitz-2008">
<CHAR_METHODS MODIFIED="2011-05-13 10:05:48 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:55:27 +0200" MODIFIED_BY="[Empty name]">
<P>N = 161</P>
<P>Mean age: 41.1 years, male: 83.2%; white: 24.1% black :67.7%, Hispanic: 7.4%; mean education years: 12.7, mean years of cocaine use: 11.7.</P>
<P>Inclusion criteria: meet DSM-IV criteria for current cocaine dependence and self reporting recent use of cocaine (confirmed by BE positive urine).</P>
<P>Exclusion criteria: dependence on drugs other than cannabis or nicotine, current non substance induced psychotic, depressive or anxiety disorder, presence of significant suicidal or homicidal ideation, major medical illness or condition (e.g. severe pulmonary or cardiovascular disease, renal function impairment), concomitant medications interacting with levodopa/carbidopa (e.g. MAO inhibitors, anticonvulsants), pregnancy, inability to read, write or speak English.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:55:27 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Levodopa/carbidopa + Clinical Management, N = 25;</LI>
<LI>Levodopa/carbidopa + CBT, N = 28;</LI>
<LI>Levodopa/carbidopa + VBRT, N = 23;</LI>
<LI>Placebo + Clinical Management, N = 27;</LI>
<LI>Placebo + CBT, N = 31;</LI>
<LI>Placbo + VBRT, N = 27.</LI>
</OL>
<P>Levodopa/carbidopa sustained release tablet, days 1.2, 50/12.5 BId; days 3 to 4 100/25 BID, days 5 to 6 200/50 BID, day 7 400/100 BID, followed by maintenance for 11 weeks and a 7-day dose reduction at week 12.</P>
<P>For all brief clinical management and CBT or CBT plus VBRT.</P>
<P>Setting: outpatient; duration: 12 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:55:27 +0200" MODIFIED_BY="[Empty name]">
<P>Cocaine use; craving; compliance; adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:55:27 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:54:40 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2015-05-03 21:35:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;&amp;quot;BID&amp;quot;. Please replace this term (according to P9 Cochrane Style Guide, Abbreviations to avoid).&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 11:54:40 +0200" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitz-2010">
<CHAR_METHODS MODIFIED="2011-05-13 10:06:30 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:54:40 +0200" MODIFIED_BY="[Empty name]">
<P>N = 136</P>
<P>83% male, 71% African American, mean age 41 years, mean education of 12.8 years, 53% employed, 64% previous drug treatment, recent cocaine use 13.4 days in the past 30, lifetime cocaine use 12.0 years.</P>
<P>Inclusion criteria: meet DSM-Iv criteria for current cocaine dependence and self reporting recent use of cocaine (confirmed by BE positive urine).</P>
<P>Exclusion criteria: dependence on drugs other than cannabis or nicotine, current non substance induced psychotic, depressive or anxiety disorder, presence of significant suicidal or homicidal ideation, major medical illness or condition (e.g. severe pulmonary or cardiovascular disease, renal function impairment), concomitant medications interacting with levodopa/carbidopa (e.g. MAO inhibitors, anticonvulsants), pregnancy, inability to read, write or speak English.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:54:40 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Levodopa/carbidopa+CM-Clinical attendance, N = 23;</LI>
<LI>Levodopa/carbidopa+CM-Urine, N = 23;</LI>
<LI>Levodopa/carbidopa+CM-Medication, N = 22;</LI>
<LI>Placebo+CM-Clinical Attendance, N = 21;</LI>
<LI>Placebo+CM-Urine, N = 27;</LI>
<LI>Placebo+CM-Medication, N = 20.</LI>
</OL>
<UL>
<LI>CM-Clinical Attendance: subjects received cash-valued vouchers contingent on attending thrice weekly clinic visits;</LI>
<LI>CM-Urine: subjects received cash-valued vouchers contingent on cocaine negative urine toxicology results;</LI>
<LI>CM-Medication: subjects received cash-valued vouchers contingent on medication event monitoring system and riboflavin based evidence of pill taking behavior.</LI>
</UL>
<P>Levodopa/carbidopa sustained release tablet, days 1.2, 50/12.5 BId; days 3 to 4 100/25 BID, days 5 to 6 200/50 BID, day 7 400/100 BID, followed by maintenance for 11 weeks and a 7-day dose reduction at week 12.</P>
<P>Setting: outpatient; duration: 12 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:54:40 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment, attendance, compliance, cocaine use.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:54:40 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:54:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitz-2014">
<CHAR_METHODS MODIFIED="2015-05-03 22:33:07 +0200" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:54:18 +0200" MODIFIED_BY="[Empty name]">
<P>N = 81.</P>
<P>82% male, 70% African American, mean age 42.1 years, with a 13-year history of cocaine use and recent use reported on 15.2 of the past 30 days.</P>
<P>Inclusion criteria: meet DSM-Iv criteria for current cocaine dependence (Diagnostic and Statistical Manual, Fourth Edition (DSM-IV)) and submitting at least one cocaine-positive urine result during<BR/>screening.</P>
<P>Exclusion criteria: acutely unstable medical or psychiatric disorders or substance dependence aside from cocaine, cannabis, or nicotine; subjects currently enrolled in drug-abuse treatment and women who were pregnant, nursing, or of childbearing potential and unwilling to use acceptable birth control methods during study participation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:54:18 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Placebo, N = 18;</LI>
<LI>Modafinil, N = 22;</LI>
<LI>Levodopa, N = 25;</LI>
<LI>Naltrexone, N = 16.</LI>
</OL>
<P>For all subjects cognitive behavioral therapy and contingency management targeting medication compliance.</P>
<P>Setting: outpatient; duration: 12 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:54:18 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment, adverse events, compliance, cocaine use.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:54:18 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:54:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shoptaw-2002">
<CHAR_METHODS MODIFIED="2011-05-13 10:07:39 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:54:01 +0200" MODIFIED_BY="[Empty name]">
<P>N = 69<BR/>Cocaine dependence (SCID) - 85% smoking coca, mean age: 36.4 years, male 79%, 39.4% Latino; 33.3%, African American, mean education years: 12.6, mean years of cocaine use: 9.</P>
<P>Inclusion criteria: not reported.</P>
<P>Exclusion criteria: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:54:01 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Amantadine 100 mg BID, N = 34;</LI>
<LI>Placebo, N = 35.</LI>
</OL>
<P>Associated with 3 times/ week group counselling.</P>
<P>Setting: outpatient; duration: 16 weeks + 9 months follow-up; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:54:01 +0200" MODIFIED_BY="[Empty name]">
<P>At 16 weeks: retention in treatment, non-abstinent for consecutive 3 weeks, adverse events, craving, clinical global impression rated by staff, compliance.<BR/>At 9 months follow-up: positive urine sample.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:54:01 +0200" MODIFIED_BY="[Empty name]">
<P>Subjects paid US$ 25 for the 9 months follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:53:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shoptaw-2005">
<CHAR_METHODS MODIFIED="2011-05-13 10:08:10 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:53:44 +0200" MODIFIED_BY="[Empty name]">
<P>N = 60</P>
<P>Mean age: 38.1 years, male: 69.8%; African-American: 59.5%, Caucasian: 15%, Hispanic: 16.8%. Days used cocaine in last 30 days: 14.1, years of cocaine use: 9.1.</P>
<P>Inclusion criteria: current cocaine dependence (DSM-IV-R), two substantiated episodes of cocaine use in a 2-week baseline period, seeking treatment for cocaine dependence, if female and of childbearing potential, used reliable birth control method, access to sufficient resources to attend clinic reliably (e.g. bus, car).</P>
<P>Exclusion criteria: concurrent dependence upon substances other than cocaine, nicotine or caffeine, participation in a clinical trial in the past 30 days, medical conditions that would preclude safe study participation or that would alter metabolism or excretion of study medication, psychiatric condition that required medical or behavioural intervention, recent therapy (past 60 days) with any opiate substitution, suicide risk, known sensitivity to hydergine, levodopa/carbidopa or cabergoline, history of asthma or seizures.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:53:44 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Hydergine 1 mg three times daily, N = 15;</LI>
<LI>Levodopa/carbidopa 25/100 mg three times daily, N = 15;</LI>
<LI>Cabergoline 0.5 mg per week, N = 15;</LI>
<LI>Placebo three times daily, N = 15.</LI>
</OL>
<P>For all 1 hour per week of cognitive behavioural drug counselling.</P>
<P>Setting: outpatient; duration: 8 weeks + 4 weeks follow-up; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:53:44 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment; use of cocaine; craving: Clinical Global Impression Scale (self and observer), HIV risk behaviours.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:53:44 +0200" MODIFIED_BY="[Empty name]">
<P>Participants received $5 in grocery vouchers each for six screening and 23 medication phase research visits and an additional USD 20 for completing visits for a maximum value of USD 165 in vouchers.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-04 11:53:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weddington-1991">
<CHAR_METHODS MODIFIED="2011-05-13 10:10:14 +0200" MODIFIED_BY="Laura Amato">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-04 11:53:31 +0200" MODIFIED_BY="[Empty name]">
<P>N = 83<BR/>Age: ~30 years; sex: male 76%; race: white 69%; diagnosis: cocaine dependence (DSM-III-R); history: cocaine use was 1 g or more per week for 12 weeks. Additional diagnosis: attention deficit disorder, affective and anxiety disorders.</P>
<P>Inclusion criteria: cocaine addicts applied for treatment, minimum 1 g cocaine per week for 12 weeks prior to treatment.</P>
<P>Exclusion criteria: current abuse/dependence on any substance other than nicotine, medical illness, pregnancy, psychosis, mandated treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-04 11:53:31 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Desipramine 200 mg/day, N = 32 per 12 weeks;</LI>
<LI>Amantadine 400 mg/day, N = 23, per 4 weeks followed placebo per 8 weeks;</LI>
<LI>Placebo, N = 28 per 12 weeks.</LI>
</OL>
<P>For all individual interpersonal psychotherapy (both supportive and psychodynamic) twice per week.</P>
<P>Setting: outpatient; duration: 12 weeks; country of origin: USA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-04 11:53:31 +0200" MODIFIED_BY="[Empty name]">
<P>Retention in treatment, cocaine use, craving, depression, duration of treatment, participants presenting at least one side effect.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-04 11:53:31 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviations: ASI - Addiction Severity Index; BAI - Beck Anxiety Inventory; BE- benzoylecgonine; BDI - Beck Depression Inventory; BSCS- Brief Substance Craving Scale; BPRS- Brief Psychiatric Rating Scale; CBT- Cognitive Behavioral Therapy; CGI-O- Clinical Global Inventory-Observer; CM - Contingency Management; CSR - Cocaine Status Report; CSSA- Cocaine Selective Severity Assessment; DSM- Diagnostic and Statistic Manual (American Psychiatric Association); HAM-A -Hamilton Anxiety Scale; HAM-D -Hamilton Depression Scale; PANAS - Positive Affect Negative Affect Scale; POMS - Profile of Mood States; SCL-90 R - Symptom Checklist 90-Revised; STAI - State Anxiety Inventory; VBRT - voucher-based reinforcement therapy.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-05-04 11:53:23 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:53:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collins-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:53:23 +0200" MODIFIED_BY="[Empty name]">
<P>Study design and outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:53:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collins-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:53:20 +0200" MODIFIED_BY="[Empty name]">
<P>Study design and outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:53:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cunningham-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:53:17 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:53:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dackis-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:53:13 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:53:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dackis-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:53:11 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:53:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elkashef-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:53:08 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:53:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ersche-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:53:03 +0200" MODIFIED_BY="[Empty name]">
<P>Types of intervention and outcome not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:53:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ersche-2011b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:53:00 +0200" MODIFIED_BY="[Empty name]">
<P>Types of intervention and outcome not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Extein-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:57 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fairbairn-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:54 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gawin-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:52 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gawin-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:49 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haney-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:47 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-03 21:11:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-03 21:11:50 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-03 21:11:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kjome-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-03 21:11:49 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosten-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:43 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:41 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumor-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:38 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:51:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:51:30 +0200" MODIFIED_BY="[Empty name]">
<P>Outcome measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:35 +0200" MODIFIED_BY="[Empty name]">
<P>Type of comparison not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McDougle-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:33 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montoya-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morgan-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:28 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Preston-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:25 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robbins-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:22 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rotheram_x002d_Fuller-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:17 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shoptaw-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:14 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sule-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:12 +0200" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tennant-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:09 +0200" MODIFIED_BY="[Empty name]">
<P>Type of comparison not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 12:53:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tennant-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 12:53:26 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention and study design not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winhusen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:05 +0200" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-04 11:52:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolfsohn-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-04 11:52:02 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes measures not in the inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-04-01 12:31:44 +0200" MODIFIED_BY="Laura Amato" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-04-01 12:31:59 +0200" MODIFIED_BY="Laura Amato" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterman-1992">
<DESCRIPTION>
<P>"random assignment was completed by a research technician using a constrained block randomisation procedure; the procedure ensured equal subjects numbers for each group within series of 10 subjects."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:18:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ciraulo-2005">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eiler-1995">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Focchi-2005">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannini-1989">
<DESCRIPTION>
<P>Randomised using a "Texas Instrument Programable 68" random computer programme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gorelick-2006">
<DESCRIPTION>
<P>"subjects were randomly assigned". No other details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Handelsman-1995">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Handelsman-1997">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kampman-1996">
<DESCRIPTION>
<P>Randomised, utilizing a stratified block procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:21:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kampman-2006">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kolar-1992">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:22:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kosten-1992">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-2000">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:56:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mooney-2007a">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:56:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mooney-2007b">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moscovitz-1993">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oliveto-1995">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2008">
<DESCRIPTION>
<P>"urn randomisation procedure to ensure even distribution of treatment groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:54:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2010">
<DESCRIPTION>
<P>"urn randomisation procedure to ensure even distribution of treatment groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:54:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2014">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:53:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoptaw-2002">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoptaw-2005">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:51:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weddington-1991">
<DESCRIPTION>
<P>Stated as "random assignment", no further details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alterman-1992">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:18:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ciraulo-2005">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eiler-1995">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Focchi-2005">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannini-1989">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorelick-2006">
<DESCRIPTION>
<P>"treatment assignment was done by the pharmaceutical company which provided the medication".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Handelsman-1995">
<DESCRIPTION>
<P>"randomised after one week period of placebo use". No further details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Handelsman-1997">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kampman-1996">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:21:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kampman-2006">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolar-1992">
<DESCRIPTION>
<P>"assignment done by study pharmacist who had no client contact".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:22:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kosten-1992">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-2000">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:56:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mooney-2007a">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:56:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mooney-2007b">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moscovitz-1993">
<DESCRIPTION>
<P>"A pharmacist who had no contact with the subjects or the test data, coded the study medications".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oliveto-1995">
<DESCRIPTION>
<P>"the pharmacist and the principal investigator held the code".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2008">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:54:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2010">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:54:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2014">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:53:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoptaw-2002">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoptaw-2005">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:51:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weddington-1991">
<DESCRIPTION>
<P>Stated as "random assignment", no further details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterman-1992">
<DESCRIPTION>
<P>"both research/clinical personnel and the subjects were unaware of drug group assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterman-1992">
<DESCRIPTION>
<P>"both research/clinical personnel and the subjects were unaware of drug group assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:18:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciraulo-2005">
<DESCRIPTION>
<P>"Medications and placebo were supplied by the manufacturer in identically appearing tablets; Participants, therapists and research staff were not told the specific medication that a participants was taking".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:18:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciraulo-2005">
<DESCRIPTION>
<P>"Medications and placebo were supplied by the manufacturer in identically appearing tablets; Participants, therapists and research staff were not told the specific medication that a participants was taking".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:19:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eiler-1995">
<DESCRIPTION>
<P>"the patients, ward staff, research assistant and physician prescribing the medication were blind to whether the patient was receiving the active drug or placebo".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:18:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eiler-1995">
<DESCRIPTION>
<P>"the patients, ward staff, research assistant and physician prescribing the medication were blind to whether the patient was receiving the active drug or placebo".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:19:15 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Focchi-2005">
<DESCRIPTION>
<P>Single blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:19:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Focchi-2005">
<DESCRIPTION>
<P>No blinding or incomplete blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:19:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannini-1989">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:19:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannini-1989">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:20:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorelick-2006">
<DESCRIPTION>
<P>"the study medication capsules or the matching placebo capsules were provided by Sandoz Pharmaceuticals CO. the medication was not known to either the investigators or clinical staff".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:20:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorelick-2006">
<DESCRIPTION>
<P>"the study medication capsules or the matching placebo capsules were provided by Sandoz Pharmaceuticals CO. the medication was not known to either the investigators or clinical staff".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:20:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1995">
<DESCRIPTION>
<P>"medication was administered in a double blind fashion except during the first week of the nine week trial. In the first week placebo was administered under single blind condition".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:20:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1995">
<DESCRIPTION>
<P>"medication was administered in a double blind fashion except during the first week of the nine week trial. In the first week placebo was administered under single blind condition".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:20:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Handelsman-1997">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:20:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1997">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kampman-1996">
<DESCRIPTION>
<P>Stated as double blinded, but no details were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:20:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kampman-1996">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:21:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kampman-2006">
<DESCRIPTION>
<P>Stated as double blinded, no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:21:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kampman-2006">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolar-1992">
<DESCRIPTION>
<P>"subjects, study nurse, research assistant were blind to treatment condition".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 14:12:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolar-1992">
<DESCRIPTION>
<P>"subjects, study nurse, research assistant were blind to treatment condition".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 12:22:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kosten-1992">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 12:22:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kosten-1992">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-2000">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:56:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2000">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:56:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mooney-2007a">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:56:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mooney-2007a">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:57:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mooney-2007b">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:57:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mooney-2007b">
<DESCRIPTION>
<P>No information about blinding, but the outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moscovitz-1993">
<DESCRIPTION>
<P>Stated as double blind, no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:57:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moscovitz-1993">
<DESCRIPTION>
<P>No information about blinding, but the outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:55:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oliveto-1995">
<DESCRIPTION>
<P>"To maintain the blind, the dosages of Amantidine, desipramine and fluoxitine were placed in seize 00 blue opaque capsules with lactose filter".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:55:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oliveto-1995">
<DESCRIPTION>
<P>"To maintain the blind, the dosages of Amantidine, desipramine and fluoxitine were placed in seize 00 blue opaque capsules with lactose filter".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:55:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<DESCRIPTION>
<P>"to preserve the clinical trial double blind conditions...identical opaque capsules were used".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:55:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<DESCRIPTION>
<P>"to preserve the clinical trial double blind conditions...identical opaque capsules were used".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:55:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2008">
<DESCRIPTION>
<P>Stated as double blind, no details provided: "double blind for medical conditions".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:55:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2008">
<DESCRIPTION>
<P>No information about blinding, but the outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:54:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2010">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:54:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2010">
<DESCRIPTION>
<P>No information about blinding, but the outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:54:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2014">
<DESCRIPTION>
<P>All active and placebo capsules were identical in appearance, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance. All investigators and staff, except the pharmacist, were blinded to medication assignment.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:54:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2014">
<DESCRIPTION>
<P>All active and placebo capsules were identical in appearance, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance. All investigators and staff, except the pharmacist, were blinded to medication assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:53:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoptaw-2002">
<DESCRIPTION>
<P>Stated as double blinded, no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:53:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2002">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2005">
<DESCRIPTION>
<P>"in order to maximize protection of the modified blind in the clinic, personnel charged with administering and counting medications were kept isolated from clinical staff and research team during clinic hours".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:53:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2005">
<DESCRIPTION>
<P>"in order to maximize protection of the modified blind in the clinic, personnel charged with administering and counting medications were kept isolated from clinical staff and research team during clinic hours".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-04 11:51:40 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weddington-1991">
<DESCRIPTION>
<P>Only participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-05-04 11:51:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weddington-1991">
<DESCRIPTION>
<P>Only participants were blinded but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterman-1992">
<DESCRIPTION>
<P>"both research/clinical personnel and the subjects were unaware of drug group assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterman-1992">
<DESCRIPTION>
<P>"both research/clinical personnel and the subjects were unaware of drug group assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:18:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciraulo-2005">
<DESCRIPTION>
<P>"Participants, therapists and research staff were not told the specific medication that a participants was taking".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:18:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciraulo-2005">
<DESCRIPTION>
<P>" Participants, therapists and research staff were not told the specific medication that a participants was taking".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:19:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eiler-1995">
<DESCRIPTION>
<P>"the patients, ward staff, research assistant and physician prescribing the medication were blind to whether the patient was receiving the active drug or placebo".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:19:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eiler-1995">
<DESCRIPTION>
<P>""the patients, ward staff, research assistant and physician prescribing the medication were blind to whether the patient was receiving the active drug or placebo".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:19:15 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Focchi-2005">
<DESCRIPTION>
<P>Single blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:19:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Focchi-2005">
<DESCRIPTION>
<P>No blinding or incomplete blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-13 09:41:33 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Giannini-1989">
<DESCRIPTION>
<P>"subject response was measured by two experienced research psychologists without knowledge of the purpose of the study or the medications used".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-03-25 12:53:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannini-1989">
<DESCRIPTION>
<P>"subject response was measured by two experienced research psychologists without knowledge of the purpose of the study or the medications used".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:20:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorelick-2006">
<DESCRIPTION>
<P>"the medication was not known to either the investigators or clinical staff".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:20:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorelick-2006">
<DESCRIPTION>
<P>"the medication was not known to either the investigators or clinical staff".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:20:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Handelsman-1995">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:20:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1995">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:20:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Handelsman-1997">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:20:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1997">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kampman-1996">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kampman-1996">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:21:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kampman-2006">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:21:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kampman-2006">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolar-1992">
<DESCRIPTION>
<P>"subjects, study nurse, research assistant were blind to treatment condition".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolar-1992">
<DESCRIPTION>
<P>"subjects, study nurse, research assistant were blind to treatment condition".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 12:22:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kosten-1992">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 12:22:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kosten-1992">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-2000">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2000">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:56:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mooney-2007a">
<DESCRIPTION>
<P>Stated as double blinded, but no details were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:56:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mooney-2007a">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:56:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mooney-2007b">
<DESCRIPTION>
<P>Stated as double blinded, but no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:57:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mooney-2007b">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moscovitz-1993">
<DESCRIPTION>
<P>Stated as double blind, no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moscovitz-1993">
<DESCRIPTION>
<P>No information about blinding, but the outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:55:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oliveto-1995">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:55:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oliveto-1995">
<DESCRIPTION>
<P>No information about blinding, but the outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:55:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:55:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:55:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2008">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:55:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2008">
<DESCRIPTION>
<P>No information about blinding, but the outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:54:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2010">
<DESCRIPTION>
<P>Stated as double blind, no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:54:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2010">
<DESCRIPTION>
<P>No information about blinding, but the outcome is not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:54:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2014">
<DESCRIPTION>
<P>All investigators and staff, except the pharmacist, were blinded to medication assignment.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:54:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2014">
<DESCRIPTION>
<P>All investigators and staff, except the pharmacist, were blinded to medication assignment.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:53:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoptaw-2002">
<DESCRIPTION>
<P>Stated as double blinded, no details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:53:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2002">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoptaw-2005">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2005">
<DESCRIPTION>
<P>No information about blinding, but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-04 11:51:40 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weddington-1991">
<DESCRIPTION>
<P>Only participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-05-04 11:51:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weddington-1991">
<DESCRIPTION>
<P>Only participants were blinded but the outcome is unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterman-1992">
<DESCRIPTION>
<P>Dropout: 25%; no difference between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:18:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciraulo-2005">
<DESCRIPTION>
<P>No significant differences in the attrition rate between groups; mean attrition rate: 20%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:19:33 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eiler-1995">
<DESCRIPTION>
<P>Only 50% of patients completed the study; there was no significant difference in the attrition rate between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:19:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Focchi-2005">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:19:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannini-1989">
<DESCRIPTION>
<P>None lost at follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:20:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gorelick-2006">
<DESCRIPTION>
<P>71% of attrition in the bromocriptine group, 54% in the placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:20:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1995">
<DESCRIPTION>
<P>"67 completed enrolment, 8 dropped out after the clinical trial began, statistical analysis were restricted to 59 subjects".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:20:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1997">
<DESCRIPTION>
<P>16.6% dropout from the study; no significant differences in the attrition rate between groups; reason for dropout reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kampman-1996">
<DESCRIPTION>
<P>38% of patients dropped out from the study; no significant difference in the attrition rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:21:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kampman-2006">
<DESCRIPTION>
<P>Missing urine counted as positives.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolar-1992">
<DESCRIPTION>
<P>24 participants, data on 22 analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 12:22:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kosten-1992">
<DESCRIPTION>
<P>Missing urine counted as positives. Dropout rate of 21%; no significant differences between groups. Principle of analysis: ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Malcolm-2000">
<DESCRIPTION>
<P>27% dropped out in the first week; 357 analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:56:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mooney-2007a">
<DESCRIPTION>
<P>ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:57:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mooney-2007b">
<DESCRIPTION>
<P>ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moscovitz-1993">
<DESCRIPTION>
<P>65% dropped out from the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:55:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oliveto-1995">
<DESCRIPTION>
<P>4/21 (19%) participants left the studies for administrative reasons.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:55:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<DESCRIPTION>
<P>Only two patients (4.76%) dropped out from the studies.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:55:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2008">
<DESCRIPTION>
<P>Principle of analysis: ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:54:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2010">
<DESCRIPTION>
<P>136 randomised, 101 received initial dose of treatment; data on these 101 (74%) patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:54:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2014">
<DESCRIPTION>
<P>Principle of analysis: ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:53:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2002">
<DESCRIPTION>
<P>Sixty-nine randomised, analysis on 68 who completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2005">
<DESCRIPTION>
<P>No details provided but data on all randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-04 11:51:40 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weddington-1991">
<DESCRIPTION>
<P>Results only on 54/83 subjects that continued in treatment for 14 days (dropout 35%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alterman-1992">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:18:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciraulo-2005">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eiler-1995">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Focchi-2005">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:19:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannini-1989">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorelick-2006">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1995">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:20:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Handelsman-1997">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kampman-1996">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:21:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kampman-2006">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 14:14:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kolar-1992">
<DESCRIPTION>
<P>Not all the outcome measures were clearly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 12:22:57 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kosten-1992">
<DESCRIPTION>
<P>Outcomes not pre-defined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:56:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2000">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:56:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mooney-2007a">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:57:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mooney-2007b">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moscovitz-1993">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oliveto-1995">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:55:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2008">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:54:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2010">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:54:12 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schmitz-2014">
<DESCRIPTION>
<P>Results for cocaine use in each group not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:53:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2002">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:58:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoptaw-2005">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-04 11:51:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weddington-1991">
<DESCRIPTION>
<P>All outcomes stated in the methods section were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-05-12 09:12:06 +0200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-05-12 09:12:06 +0200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-02-22 11:16:12 +0100" MODIFIED_BY="Grade Profiler">Any dopamine agonist versus placebo for the treatment of cocaine dependence</TITLE>
<TABLE COLS="7" ROWS="24">
<TR>
<TD COLSPAN="7">
<P>
<B>Any dopamine agonist versus placebo for the treatment of cocaine dependence</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with the treatment of cocaine dependence<BR/>
<B>Settings: </B>Outpatient<BR/>
<B>Intervention:</B> any dopamine agonist versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Any dopamine agonist versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropouts</B>
<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.94 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1656<BR/>(20 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>456 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>474 per 1000</B>
<BR/>(428 to 519)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>416 per 1000</B>
<BR/>(376 to 456)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events as N of participants with at least one adverse event</B>
<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.27 </B>
<BR/>(0.66 to 2.44)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>252<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>272 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>345 per 1000</B>
<BR/>(180 to 664)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>254 per 1000</B>
<BR/>(132 to 488)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Abstinence (objective)</B>
<BR/>Participants abstinent at the end of treatment (N)<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.12 </B>
<BR/>(0.85 to 1.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>731<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>308 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>345 per 1000</B>
<BR/>(262 to 453)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>355 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>398 per 1000</B>
<BR/>(302 to 522)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Abstinence at follow-up (objective)</B>
<BR/>N of subjects abstinent at follow-up<BR/>Follow-up: mean 4 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.1 </B>
<BR/>(0.61 to 1.98)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>136<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>625 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>688 per 1000</B>
<BR/>(381 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>541 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>595 per 1000</B>
<BR/>(330 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Severity of dependence (difference before and after)</B>
<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean severity of dependence (difference before and after) in the intervention groups was<BR/>
<B>1.69 standard deviations higher</B>
<BR/>(0.17 to 3.2 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>202<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD 1.69 (0.17 to 3.2)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Most studies were classified as at unclear risk of bias for sequence generation and method of allocation concealment.<BR/>
<SUP>2</SUP>Significant heterogeneity.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-05-12 09:11:53 +0200" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-02-22 11:16:31 +0100" MODIFIED_BY="Grade Profiler">Amantadine versus placebo for the treatment of cocaine dependence</TITLE>
<TABLE COLS="6" ROWS="23">
<TR>
<TD COLSPAN="6">
<P>
<B>Amantadine versus placebo for the treatment of cocaine dependence</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> patients with the treatment of cocaine dependence<BR/>
<B>Settings: </B>Outpatient<BR/>
<B>Intervention:</B> amantadine versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Amantadine versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropouts</B>
<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.77 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>484<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>378 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>371 per 1000</B>
<BR/>(291 to 476)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>286 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>280 per 1000</B>
<BR/>(220 to 360)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events as N of participants with at least one adverse event</B>
<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.19 </B>
<BR/>(0.69 to 2.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>128<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>329 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>391 per 1000</B>
<BR/>(227 to 677)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>357 per 1000</B>
<BR/>(207 to 618)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Abstinence (objective)</B>
<BR/>N of subjects abstinent at the end of the study<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.13 </B>
<BR/>(0.59 to 2.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>275<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>307 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>347 per 1000</B>
<BR/>(181 to 654)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>355 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>401 per 1000</B>
<BR/>(209 to 756)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Abstinence at follow-up (objective)</B>
<BR/>N of subjects abstinent at follow-up<BR/>Follow-up: mean 4 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.49 </B>
<BR/>(1.03 to 2.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>76<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>512 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>763 per 1000</B>
<BR/>(528 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>526 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>784 per 1000</B>
<BR/>(542 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Most were classified as at unclear risk of bias for sequence generation and method of allocation concealment.<BR/>
<SUP>2</SUP>Significant heterogeneity.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2015-05-12 09:11:25 +0200" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2015-02-22 11:16:44 +0100" MODIFIED_BY="Grade Profiler">Amantidine versus antidepressants for the treatment of cocaine dependence</TITLE>
<TABLE COLS="6" ROWS="19">
<TR>
<TD COLSPAN="6">
<P>
<B>Amantidine versus antidepressants for the treatment of cocaine dependence</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> patients with the treatment of cocaine dependence<BR/>
<B>Settings: </B>Outpatient<BR/>
<B>Intervention:</B> amantidine versus antidepressants<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Amantidine versus antidepressants</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropouts</B>
<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.48 to 1.53)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>153<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>329 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>283 per 1000</B>
<BR/>(158 to 504)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>267 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>230 per 1000</B>
<BR/>(128 to 409)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events as N of participants with at least one adverse event</B>
<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.56 </B>
<BR/>(0.18 to 1.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>44<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>320 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>179 per 1000</B>
<BR/>(58 to 566)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>335 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>188 per 1000</B>
<BR/>(60 to 593)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Abstinence (objective)</B>
<BR/>N of subjects abstinent at the end of the study<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.25 </B>
<BR/>(0.12 to 0.53)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>68<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>775 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>194 per 1000</B>
<BR/>(93 to 411)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>859 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>215 per 1000</B>
<BR/>(103 to 455)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Most studies were classified as at unclear risk of bias for sequence generation and method of allocation concealment.<BR/>
<SUP>2</SUP>Only 2 studies with 44 participants.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-05-04 11:49:03 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-05-04 11:49:03 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-05-04 11:49:03 +0200" MODIFIED_BY="[Empty name]">'Risk of bias' assessment of included studies</TITLE>
<TABLE COLS="3" ROWS="25">
<TR>
<TH ALIGN="LEFT">
<P>
<B> Item</B>
</P>
</TH>
<TH ALIGN="LEFT">
<P>
<B>Judgment</B>
</P>
</TH>
<TH ALIGN="LEFT">
<P>
<B> Description</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>1. Random sequence generation (selection bias)</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The investigators describe a random component in the sequence generation process such as: random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; or minimization.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The investigators describe a non-random component in the sequence generation process such as: odd or even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgement of the clinician; results of a laboratory test or a series of tests; or availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Insufficient information about the sequence generation process to permit judgement of low or high risk.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>2. Allocation concealment (selection bias)</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based, and pharmacy-controlled, randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Investigators enrolling participants could possibly foresee assignments because one of the following method was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Insufficient information to permit judgement of low or high risk. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>3. Blinding of participants and providers (performance bias)</P>
<P>subjective outcomes</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low risk</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding;</LI>
<LI>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;</LI>
<LI>Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>Insufficient information to permit judgement of low or high risk.</LI>
</UL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>4. Blinding of participants and providers (performance bias)</P>
<P>objective outcomes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding;</LI>
<LI>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;</LI>
<LI>Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>Insufficient information to permit judgement of low or high risk.</LI>
</UL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>5. Blinding of outcome assessor (detection bias)</P>
<P>Subjective outcomes </P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low risk</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;</LI>
<LI>Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding;</LI>
<LI>Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>Insufficient information to permit judgement of low or high risk.</LI>
</UL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>6. Blinding of outcome assessor (detection bias)</P>
<P>objective outcomes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;</LI>
<LI>Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding;</LI>
<LI>Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>Insufficient information to permit judgement of low or high risk.</LI>
</UL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>7. Incomplete outcome data (attrition bias)</P>
<P>For all outcomes except retention in treatment or dropout</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low risk</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>No missing outcome data;</LI>
<LI>Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);</LI>
<LI>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;</LI>
<LI>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;</LI>
<LI>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;</LI>
<LI>Missing data have been imputed using appropriate methods</LI>
<LI>All randomised patients are reported/analysed in the group they were allocated to by randomisation irrespective of non-compliance and co-interventions (ITT).</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;</LI>
<LI>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;</LI>
<LI>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;</LI>
</UL>
<UL>
<LI>'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomisation.</LI>
</UL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>Insufficient information to permit judgement of low or high risk (e.g. number randomised not stated, no reasons for missing data provided; number of dropouts not reported for each group).</LI>
</UL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>8. Selective reporting (reporting bias)</P>
<P> </P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Low risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way;</LI>
<LI>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>High risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>Not all of the study's pre-specified primary outcomes have been reported;</LI>
<LI>One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified;</LI>
<LI>One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);</LI>
<LI>One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;</LI>
<LI>The study report fails to include results for a key outcome that would be expected to have been reported for such a study.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unclear risk</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<UL>
<LI>Insufficient information to permit judgement of low or high risk.</LI>
</UL>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-05-12 14:12:31 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-05-12 14:12:31 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Any dopamine agonist versus placebo</NAME>
<DICH_OUTCOME CHI2="18.072219044555872" CI_END="1.1376757114945337" CI_START="0.9438154076715991" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="1.036221919012665" ESTIMABLE="YES" EVENTS_1="489" EVENTS_2="323" I2="0.3996135968572594" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.05601848633062973" LOG_CI_START="-0.025112937130667014" LOG_EFFECT_SIZE="0.015452774599981352" METHOD="MH" MODIFIED="2015-02-22 11:38:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4509047055136114" P_Q="1.0" P_Z="0.4552972950003241" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.9732971655083697E-4" TOTALS="YES" TOTAL_1="947" TOTAL_2="709" WEIGHT="100.00000000000001" Z="0.7466128507316774">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.876500413900387" CI_START="0.2718912705018658" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.27334866454160545" LOG_CI_START="-0.5656047358980814" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2011-05-13 10:25:00 +0200" MODIFIED_BY="Laura Amato" ORDER="275" O_E="0.0" SE="0.49280538030458115" STUDY_ID="STD-Ciraulo-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.24285714285714288" WEIGHT="0.934436466422255"/>
<DICH_DATA CI_END="1.528507180413739" CI_START="0.6139824362787565" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.18426748323661857" LOG_CI_START="-0.21184405220788508" LOG_EFFECT_SIZE="-0.013788284485633297" MODIFIED="2015-02-22 11:37:57 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.23267787670382498" STUDY_ID="STD-Eiler-1995" TOTAL_1="32" TOTAL_2="31" VAR="0.05413899430740038" WEIGHT="4.179873529901916"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 10:25:20 +0200" MODIFIED_BY="Laura Amato" ORDER="293" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannini-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 10:25:26 +0200" MODIFIED_BY="Laura Amato" ORDER="277" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannini-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.1507401619812847" CI_START="0.3173857406797927" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4984125888703692" LOG_CI_START="-0.49841258887036916" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-22 11:37:56 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.5855400437691199" STUDY_ID="STD-Gorelick-2006" TOTAL_1="35" TOTAL_2="35" VAR="0.34285714285714286" WEIGHT="0.6620492681409318"/>
<DICH_DATA CI_END="3.800127344141452" CI_START="0.258988681998383" EFFECT_SIZE="0.9920634920634921" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.579798150282936" LOG_CI_START="-0.5867192145019491" LOG_EFFECT_SIZE="-0.003460532109506474" MODIFIED="2011-05-13 10:25:43 +0200" MODIFIED_BY="Laura Amato" ORDER="279" O_E="0.0" SE="0.6852180744287248" STUDY_ID="STD-Handelsman-1995" TOTAL_1="42" TOTAL_2="25" VAR="0.4695238095238095" WEIGHT="0.4835187168011796"/>
<DICH_DATA CI_END="4.78265312007099" CI_START="0.4704501755641861" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6796688831713416" LOG_CI_START="-0.3274863650599791" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2011-05-13 10:25:54 +0200" MODIFIED_BY="Laura Amato" ORDER="280" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Handelsman-1997" TOTAL_1="30" TOTAL_2="30" VAR="0.35" WEIGHT="0.6485456719036577"/>
<DICH_DATA CI_END="1.7433912020755034" CI_START="0.48197890225523043" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.24139485001278624" LOG_CI_START="-0.3169719717915858" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2011-05-13 10:25:59 +0200" MODIFIED_BY="Laura Amato" ORDER="281" O_E="0.0" SE="0.32798743508823264" STUDY_ID="STD-Kampman-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.1075757575757576" WEIGHT="2.107381055939151"/>
<DICH_DATA CI_END="1.6330013476958798" CI_START="0.6999108564812302" EFFECT_SIZE="1.069090909090909" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.21298654315469778" LOG_CI_START="-0.1549572699909085" LOG_EFFECT_SIZE="0.029014636581894643" MODIFIED="2011-05-13 10:26:07 +0200" MODIFIED_BY="Laura Amato" ORDER="282" O_E="0.0" SE="0.21613201719297861" STUDY_ID="STD-Kampman-2006" TOTAL_1="50" TOTAL_2="49" VAR="0.046713048855906006" WEIGHT="4.84155040763706"/>
<DICH_DATA CI_END="2.444274179582082" CI_START="0.21208749997458762" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.38814992006514243" LOG_CI_START="-0.6734849272026054" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2011-05-13 10:26:16 +0200" MODIFIED_BY="Laura Amato" ORDER="283" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Kolar-1992" TOTAL_1="5" TOTAL_2="9" VAR="0.38888888888888884" WEIGHT="0.5837239964805888"/>
<DICH_DATA CI_END="5.619107773239197" CI_START="0.6281858323292917" EFFECT_SIZE="1.878787878787879" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7496673618464961" LOG_CI_START="-0.2019118626057632" LOG_EFFECT_SIZE="0.27387774962036643" MODIFIED="2011-05-13 10:26:26 +0200" MODIFIED_BY="Laura Amato" ORDER="284" O_E="0.0" SE="0.5589623468363863" STUDY_ID="STD-Kosten-1992" TOTAL_1="33" TOTAL_2="31" VAR="0.3124389051808407" WEIGHT="0.7264639768145512"/>
<DICH_DATA CI_END="1.4247872856058912" CI_START="1.0514320718768138" EFFECT_SIZE="1.2239554925275444" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="89" LOG_CI_END="0.15375003095277304" LOG_CI_START="0.02178122018734212" LOG_EFFECT_SIZE="0.0877656255700576" MODIFIED="2015-02-22 11:37:57 +0100" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.077519132699763" STUDY_ID="STD-Malcolm-2000" TOTAL_1="309" TOTAL_2="153" VAR="0.006009215934523465" WEIGHT="36.593457177032896"/>
<DICH_DATA CI_END="1.3042928925437542" CI_START="0.6617385875968038" EFFECT_SIZE="0.9290322580645162" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.11537512769363956" LOG_CI_START="-0.17931353984372317" LOG_EFFECT_SIZE="-0.03196920607504181" MODIFIED="2011-05-13 10:26:50 +0200" MODIFIED_BY="Laura Amato" ORDER="286" O_E="0.0" SE="0.17310158204387732" STUDY_ID="STD-Mooney-2007a" TOTAL_1="31" TOTAL_2="36" VAR="0.02996415770609319" WEIGHT="7.53009821158142"/>
<DICH_DATA CI_END="1.1972320992137464" CI_START="0.6439600654062293" EFFECT_SIZE="0.8780487804878049" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="25" LOG_CI_END="0.07817835227483688" LOG_CI_START="-0.19114106417973334" LOG_EFFECT_SIZE="-0.05648135595244823" MODIFIED="2011-05-13 10:27:00 +0200" MODIFIED_BY="Laura Amato" ORDER="287" O_E="0.0" SE="0.1581995583780268" STUDY_ID="STD-Mooney-2007b" TOTAL_1="82" TOTAL_2="40" VAR="0.02502710027100271" WEIGHT="9.003928438103626"/>
<DICH_DATA CI_END="1.6376184684738955" CI_START="0.5678043797601031" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.21421272749951165" LOG_CI_START="-0.24580126186597548" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2015-02-22 11:37:55 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.2702144944592592" STUDY_ID="STD-Moscovitz-1993" TOTAL_1="14" TOTAL_2="15" VAR="0.07301587301587302" WEIGHT="3.102158545501019"/>
<DICH_DATA CI_END="4.097836633283934" CI_START="0.8280837193440393" EFFECT_SIZE="1.8421052631578947" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6125546405762676" LOG_CI_START="-0.08192575378137429" LOG_EFFECT_SIZE="0.26531444339744664" MODIFIED="2011-05-13 10:27:20 +0200" MODIFIED_BY="Laura Amato" ORDER="289" O_E="0.0" SE="0.40794122137907396" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001" TOTAL_1="19" TOTAL_2="21" VAR="0.16641604010025063" WEIGHT="1.3631496845037963"/>
<DICH_DATA CI_END="1.3859503032655651" CI_START="0.7215265927240017" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" LOG_CI_END="0.14174765783387902" LOG_CI_START="-0.14174765783387905" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 10:27:35 +0200" MODIFIED_BY="Laura Amato" ORDER="290" O_E="0.0" SE="0.16652655174768616" STUDY_ID="STD-Schmitz-2008" TOTAL_1="68" TOTAL_2="68" VAR="0.027731092436974792" WEIGHT="8.132180230282582"/>
<DICH_DATA CI_END="2.8291962599086804" CI_START="0.7329290050973454" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.4516630752897763" LOG_CI_START="-0.134938091099277" LOG_EFFECT_SIZE="0.15836249209524964" MODIFIED="2015-02-13 08:14:58 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.34457242885953415" STUDY_ID="STD-Schmitz-2014" TOTAL_1="25" TOTAL_2="18" VAR="0.11873015873015871" WEIGHT="1.9097263842552046"/>
<DICH_DATA CI_END="0.9916767064445412" CI_START="0.5882208668079231" EFFECT_SIZE="0.7637571157495257" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="-0.003629887816715405" LOG_CI_START="-0.23045957320060315" LOG_EFFECT_SIZE="-0.11704473050865927" MODIFIED="2011-05-13 13:08:06 +0200" MODIFIED_BY="Laura Amato" ORDER="455" O_E="0.0" SE="0.133240880019547" STUDY_ID="STD-Shoptaw-2002" TOTAL_1="34" TOTAL_2="35" VAR="0.017753132108383324" WEIGHT="12.652541461880762"/>
<DICH_DATA CI_END="1.407812928533899" CI_START="0.5154460246782401" EFFECT_SIZE="0.8518518518518519" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" LOG_CI_END="0.14854494919309227" LOG_CI_START="-0.28781680547588107" LOG_EFFECT_SIZE="-0.06963592814139442" MODIFIED="2015-02-15 10:27:08 +0100" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.25632105471807703" STUDY_ID="STD-Shoptaw-2005" TOTAL_1="45" TOTAL_2="15" VAR="0.06570048309178743" WEIGHT="3.446532636226572"/>
<DICH_DATA CI_END="2.9665786559764356" CI_START="0.49957940097627185" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4722558677261181" LOG_CI_START="-0.3013954770768654" LOG_EFFECT_SIZE="0.08543019532462637" MODIFIED="2015-02-22 11:37:54 +0100" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.4544466295731929" STUDY_ID="STD-Weddington-1991" TOTAL_1="23" TOTAL_2="28" VAR="0.20652173913043476" WEIGHT="1.0986841405908312"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.647746256489272" CI_END="2.440529347703011" CI_START="0.6576079320860655" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2668510005278173" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="34" I2="48.48788883379702" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.3874840344751626" LOG_CI_START="-0.18203295696369923" LOG_EFFECT_SIZE="0.10272553875573173" METHOD="MH" MODIFIED="2015-02-13 08:24:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07030466520192946" P_Q="1.0" P_Z="0.47953571287843955" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.33823903630098956" TOTALS="YES" TOTAL_1="127" TOTAL_2="125" WEIGHT="99.99999999999999" Z="0.7070495148706079">
<NAME>Adverse events as N of participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3143959948185437" CI_START="0.7681389795686892" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.3644376690716105" LOG_CI_START="-0.11456019585501069" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-05-13 10:29:12 +0200" MODIFIED_BY="Laura Amato" ORDER="296" O_E="0.0" SE="0.2813657169355689" STUDY_ID="STD-Gorelick-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.07916666666666666" WEIGHT="26.812060887297257"/>
<DICH_DATA CI_END="22.223594687240784" CI_START="1.4503994958656774" EFFECT_SIZE="5.67741935483871" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.346814307825689" LOG_CI_START="0.16148764013406525" LOG_EFFECT_SIZE="0.7541509739798772" MODIFIED="2011-05-13 10:29:21 +0200" MODIFIED_BY="Laura Amato" ORDER="297" O_E="0.0" SE="0.696266752063694" STUDY_ID="STD-Kampman-2006" TOTAL_1="31" TOTAL_2="22" VAR="0.4847873900293255" WEIGHT="13.597992439409586"/>
<DICH_DATA CI_END="1.8872445087136351" CI_START="0.010221316510778171" EFFECT_SIZE="0.1388888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.27582817038537544" LOG_CI_START="-1.9904931632479126" LOG_EFFECT_SIZE="-0.8573324964312684" MODIFIED="2011-05-13 10:29:28 +0200" MODIFIED_BY="Laura Amato" ORDER="298" O_E="0.0" SE="1.331248369847724" STUDY_ID="STD-Kolar-1992" TOTAL_1="3" TOTAL_2="4" VAR="1.7722222222222224" WEIGHT="5.30287257227604"/>
<DICH_DATA CI_END="1.390712605070853" CI_START="0.20636168455792922" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.14323739100745675" LOG_CI_START="-0.6853709355805327" LOG_EFFECT_SIZE="-0.27106677228653797" MODIFIED="2011-05-13 10:29:36 +0200" MODIFIED_BY="Laura Amato" ORDER="299" O_E="0.0" SE="0.48672863271515265" STUDY_ID="STD-Moscovitz-1993" TOTAL_1="14" TOTAL_2="15" VAR="0.23690476190476195" WEIGHT="19.458624360703396"/>
<DICH_DATA CI_END="6.561662515924027" CI_START="0.4233344477922461" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8170138896829089" LOG_CI_START="-0.37331639045019605" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2011-05-13 10:29:44 +0200" MODIFIED_BY="Laura Amato" ORDER="300" O_E="0.0" SE="0.6992058987801011" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001" TOTAL_1="9" TOTAL_2="15" VAR="0.48888888888888893" WEIGHT="13.530563751797827"/>
<DICH_DATA CI_END="24.60565788465784" CI_START="0.36576953325892164" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.391034981313078" LOG_CI_START="-0.4367924718737531" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-02-13 08:24:34 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="1.0736748938937604" STUDY_ID="STD-Schmitz-2014" TOTAL_1="24" TOTAL_2="18" VAR="1.1527777777777777" WEIGHT="7.505956349384729"/>
<DICH_DATA CI_END="3.7905915461329793" CI_START="0.25563137806644765" EFFECT_SIZE="0.984375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5787069896974779" LOG_CI_START="-0.5923858387580889" LOG_EFFECT_SIZE="-0.006839424530305466" MODIFIED="2011-05-13 10:29:54 +0200" MODIFIED_BY="Laura Amato" ORDER="301" O_E="0.0" SE="0.6879057244377936" STUDY_ID="STD-Weddington-1991" TOTAL_1="16" TOTAL_2="21" VAR="0.47321428571428564" WEIGHT="13.791929639131158"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.143161156711965" CI_END="1.4668029272107344" CI_START="0.853916010721802" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1191633053843626" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="103" I2="54.83932971797556" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.16637176798491143" LOG_CI_START="-0.06858484344899803" LOG_EFFECT_SIZE="0.04889346226795671" METHOD="MH" MODIFIED="2015-05-12 14:11:44 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.014391690714091632" P_Q="1.0" P_Z="0.41466020001091775" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08797271622010655" TOTALS="YES" TOTAL_1="397" TOTAL_2="334" WEIGHT="100.0" Z="0.8157201837379995">
<NAME>Abstinence (objective)</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dopamine agonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.402721000225571" CI_START="1.0070886658053861" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.3807033442133355" LOG_CI_START="0.0030677082644907667" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2011-05-13 10:32:07 +0200" MODIFIED_BY="Laura Amato" ORDER="305" O_E="0.0" SE="0.22182504188289742" STUDY_ID="STD-Alterman-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0492063492063492" WEIGHT="13.885537782765667"/>
<DICH_DATA CI_END="1.7960365838106658" CI_START="0.7189844158462394" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.25431517864825864" LOG_CI_START="-0.14328052294859586" LOG_EFFECT_SIZE="0.05551732784983141" MODIFIED="2011-05-13 10:32:14 +0200" MODIFIED_BY="Laura Amato" ORDER="306" O_E="0.0" SE="0.23354968324845687" STUDY_ID="STD-Focchi-2005" TOTAL_1="22" TOTAL_2="20" VAR="0.054545454545454536" WEIGHT="13.365349034102413"/>
<DICH_DATA CI_END="2.150820783495779" CI_START="0.5908180781048261" EFFECT_SIZE="1.1272727272727272" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.33260422443606596" LOG_CI_START="-0.22854622442804595" LOG_EFFECT_SIZE="0.05202900000401" MODIFIED="2015-02-22 11:42:07 +0100" MODIFIED_BY="[Empty name]" ORDER="307" O_E="0.0" SE="0.3296225514023" STUDY_ID="STD-Kampman-1996" TOTAL_1="30" TOTAL_2="31" VAR="0.1086510263929619" WEIGHT="9.687564027971733"/>
<DICH_DATA CI_END="3.97726640852818" CI_START="0.34668164745870733" EFFECT_SIZE="1.1742424242424243" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5995846822303067" LOG_CI_START="-0.4600691483014235" LOG_EFFECT_SIZE="0.06975776696444164" MODIFIED="2011-05-13 10:32:33 +0200" MODIFIED_BY="Laura Amato" ORDER="308" O_E="0.0" SE="0.6224459054253957" STUDY_ID="STD-Kosten-1992" TOTAL_1="33" TOTAL_2="31" VAR="0.3874389051808407" WEIGHT="4.006643948606974"/>
<DICH_DATA CI_END="1.8845362042965843" CI_START="0.7973322313415958" EFFECT_SIZE="1.2258064516129032" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2752044852057322" LOG_CI_START="-0.09836067964065723" LOG_EFFECT_SIZE="0.08842190278253749" MODIFIED="2011-05-13 10:32:42 +0200" MODIFIED_BY="Laura Amato" ORDER="309" O_E="0.0" SE="0.21943402700815834" STUDY_ID="STD-Mooney-2007a" TOTAL_1="31" TOTAL_2="36" VAR="0.04815129220901716" WEIGHT="13.993160486273208"/>
<DICH_DATA CI_END="1.5367119908220481" CI_START="0.5340604562356996" EFFECT_SIZE="0.9059233449477352" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.18659248004544782" LOG_CI_START="-0.2724095775717965" LOG_EFFECT_SIZE="-0.04290854876317436" MODIFIED="2011-05-13 10:32:51 +0200" MODIFIED_BY="Laura Amato" ORDER="310" O_E="0.0" SE="0.2696200807411985" STUDY_ID="STD-Mooney-2007b" TOTAL_1="82" TOTAL_2="40" VAR="0.07269498793889037" WEIGHT="11.855556821167605"/>
<DICH_DATA CI_END="9.92750288457511" CI_START="0.4625369328100079" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9968400219262878" LOG_CI_START="-0.33485358384343905" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2015-02-22 11:42:06 +0100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="0.7822434160188003" STUDY_ID="STD-Moscovitz-1993" TOTAL_1="14" TOTAL_2="15" VAR="0.611904761904762" WEIGHT="2.721626506809367"/>
<DICH_DATA CI_END="257.558417132434" CI_START="0.8735882232274597" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4108757474002007" LOG_CI_START="-0.05869322928883823" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2011-05-13 10:33:06 +0200" MODIFIED_BY="Laura Amato" ORDER="312" O_E="0.0" SE="1.4506370414707312" STUDY_ID="STD-Schmitz-2008" TOTAL_1="68" TOTAL_2="68" VAR="2.1043478260869564" WEIGHT="0.8688533721346403"/>
<DICH_DATA CI_END="10.44403692989508" CI_START="0.9131715347093972" EFFECT_SIZE="3.088235294117647" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0188683988097822" LOG_CI_START="-0.039447634754416296" LOG_EFFECT_SIZE="0.48971038202768297" MODIFIED="2011-05-13 13:08:34 +0200" MODIFIED_BY="Laura Amato" ORDER="456" O_E="0.0" SE="0.6216600768644658" STUDY_ID="STD-Shoptaw-2002" TOTAL_1="34" TOTAL_2="35" VAR="0.3864612511671335" WEIGHT="4.014900337919533"/>
<DICH_DATA CI_END="1.0880162093687014" CI_START="0.7523730779556697" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="14" LOG_CI_END="0.03663536557074866" LOG_CI_START="-0.12356675313292921" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2015-02-15 10:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="0.09410351753981751" STUDY_ID="STD-Shoptaw-2005" TOTAL_1="45" TOTAL_2="15" VAR="0.008855472013366741" WEIGHT="19.672010090601365"/>
<DICH_DATA CI_END="0.7843624772444756" CI_START="0.11809284856315935" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.10548319052114606" LOG_CI_START="-0.9277764014855258" LOG_EFFECT_SIZE="-0.516629796003336" MODIFIED="2015-02-22 11:42:06 +0100" MODIFIED_BY="[Empty name]" ORDER="314" O_E="0.0" SE="0.4830191025375178" STUDY_ID="STD-Weddington-1991" TOTAL_1="23" TOTAL_2="28" VAR="0.2333074534161491" WEIGHT="5.9287975916475055"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.415925918437157" CI_END="1.9847429131056262" CI_START="0.6051441329846556" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0959267901409946" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="35" I2="79.1896821822373" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.29770425988982574" LOG_CI_START="-0.21814117294300175" LOG_EFFECT_SIZE="0.039781543473411944" METHOD="MH" MODIFIED="2015-05-12 14:11:51 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.002390357329751791" P_Q="1.0" P_Z="0.762422328777564" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2619656389019151" TOTALS="YES" TOTAL_1="80" TOTAL_2="56" WEIGHT="100.00000000000003" Z="0.3023013774847946">
<NAME>Abstinence at follow-up (objective)</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dopamine agonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.543399155741051" CI_START="0.9856669326895386" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.40541452279166035" LOG_CI_START="-0.0062698129812521685" LOG_EFFECT_SIZE="0.1995723549052041" MODIFIED="2011-05-13 10:34:35 +0200" MODIFIED_BY="Laura Amato" ORDER="317" O_E="0.0" SE="0.24182541670333726" STUDY_ID="STD-Alterman-1992" TOTAL_1="18" TOTAL_2="19" VAR="0.058479532163742715" WEIGHT="28.652376690677805"/>
<DICH_DATA CI_END="2.444274179582082" CI_START="0.21208749997458762" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.38814992006514243" LOG_CI_START="-0.6734849272026054" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2011-05-13 10:34:41 +0200" MODIFIED_BY="Laura Amato" ORDER="318" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Kolar-1992" TOTAL_1="5" TOTAL_2="9" VAR="0.38888888888888884" WEIGHT="14.106863143822233"/>
<DICH_DATA CI_END="3.18168428516712" CI_START="0.8299456398959771" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5026570829119638" LOG_CI_START="-0.08095035228217735" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2011-05-13 10:34:48 +0200" MODIFIED_BY="Laura Amato" ORDER="319" O_E="0.0" SE="0.34281389633643433" STUDY_ID="STD-Shoptaw-2002" TOTAL_1="12" TOTAL_2="13" VAR="0.11752136752136755" WEIGHT="24.19454578068158"/>
<DICH_DATA CI_END="0.91435170393993" CI_START="0.5579954403039772" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="-0.03888672144295675" LOG_CI_START="-0.2533693499135193" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2015-02-15 10:31:04 +0100" MODIFIED_BY="[Empty name]" ORDER="322" O_E="0.0" SE="0.12598815766974236" STUDY_ID="STD-Shoptaw-2005" TOTAL_1="45" TOTAL_2="15" VAR="0.015873015873015858" WEIGHT="33.0462143848184"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="57.66001942988468" CI_END="3.2025584972660495" CI_START="0.17306120771275157" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="1.6878098524894005" ESTIMABLE="YES" I2="94.79708812160905" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2015-05-12 14:12:31 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.857847209407737E-12" P_Q="1.0" P_Z="0.028970229836962916" Q="0.0" RANDOM="YES" SCALE="7.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.158568663202231" TOTALS="YES" TOTAL_1="116" TOTAL_2="86" UNITS="" WEIGHT="99.99999999999999" Z="2.183891390190919">
<NAME>Severity of dependence (difference before and after)</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2335538682308065" CI_START="-0.007138773891183892" EFFECT_SIZE="0.6132075471698113" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="-0.13" MODIFIED="2011-05-13 12:33:07 +0200" MODIFIED_BY="Laura Amato" ORDER="438" SD_1="0.08" SD_2="0.08" SE="0.3165090409590216" STUDY_ID="STD-Alterman-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="26.44340912752491"/>
<CONT_DATA CI_END="8.896745434704707" CI_START="5.3769836626911065" EFFECT_SIZE="7.136864548697907" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="-0.7" MODIFIED="2011-05-13 12:33:37 +0200" MODIFIED_BY="Laura Amato" ORDER="439" SD_1="0.08" SD_2="0.09" SE="0.8979149106251523" STUDY_ID="STD-Ciraulo-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="20.145899056313908"/>
<CONT_DATA CI_END="0.7529336845018828" CI_START="-0.263238108980852" EFFECT_SIZE="0.24484778776051544" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="-0.1" MODIFIED="2011-05-13 12:34:14 +0200" MODIFIED_BY="Laura Amato" ORDER="440" SD_1="0.07" SD_2="0.09" SE="0.2592322617910758" STUDY_ID="STD-Kampman-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="26.83518990959909"/>
<CONT_DATA CI_END="0.6679598253186527" CI_START="-0.501144722696385" EFFECT_SIZE="0.08340755131113392" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.08" MODIFIED="2015-02-15 10:32:53 +0100" MODIFIED_BY="[Empty name]" ORDER="443" SD_1="0.13" SD_2="0.07" SE="0.2982464364745437" STUDY_ID="STD-Shoptaw-2005" TOTAL_1="45" TOTAL_2="15" WEIGHT="26.57550190656208"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.04085172303363946" CI_END="5.376712168453729" CI_START="0.2741925675083969" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2141888297221186" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.7305167880117828" LOG_CI_START="-0.5619443217341012" LOG_EFFECT_SIZE="0.08428623313884077" METHOD="MH" MODIFIED="2015-05-12 14:12:31 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9797813404191535" P_Q="1.0" P_Z="0.7982340843064057" Q="0.0" RANDOM="YES" SCALE="300.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="206" TOTAL_2="162" WEIGHT="100.0" Z="0.25563319483888314">
<NAME>Dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.803951985514043" CI_START="0.07574695856384728" EFFECT_SIZE="1.1612903225806452" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2505164143874776" LOG_CI_START="-1.1206348005214486" LOG_EFFECT_SIZE="0.06494080693301461" MODIFIED="2011-05-13 10:30:39 +0200" MODIFIED_BY="Laura Amato" ORDER="302" O_E="0.0" SE="1.3928259610253153" STUDY_ID="STD-Mooney-2007a" TOTAL_1="31" TOTAL_2="36" VAR="1.9399641577060933" WEIGHT="29.710945038701574"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 10:30:48 +0200" MODIFIED_BY="Laura Amato" ORDER="303" O_E="0.0" SE="0.0" STUDY_ID="STD-Mooney-2007b" TOTAL_1="82" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.663782872221153" CI_START="0.06384153867284795" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.194896654409919" LOG_CI_START="-1.194896654409919" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 10:30:56 +0200" MODIFIED_BY="Laura Amato" ORDER="304" O_E="0.0" SE="1.403776419268438" STUDY_ID="STD-Schmitz-2008" TOTAL_1="68" TOTAL_2="68" VAR="1.9705882352941178" WEIGHT="29.249219818900436"/>
<DICH_DATA CI_END="14.693157457367857" CI_START="0.14112691611837302" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1671151326836093" LOG_CI_START="-0.8503901484931098" LOG_EFFECT_SIZE="0.15836249209524964" MODIFIED="2015-02-13 08:27:15 +0100" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="1.1850925889754118" STUDY_ID="STD-Schmitz-2014" TOTAL_1="25" TOTAL_2="18" VAR="1.4044444444444444" WEIGHT="41.039835142398"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.447333418249656" CI_END="0.7403661442481293" CI_START="-0.346551802630793" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.19690717080866812" ESTIMABLE="YES" I2="63.28478823602755" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2015-05-12 14:12:01 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.06563385637172614" P_Q="1.0" P_Z="0.4776184609373417" Q="0.0" RANDOM="YES" SCALE="7.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.14566866844192353" TOTALS="YES" TOTAL_1="76" TOTAL_2="75" UNITS="" WEIGHT="99.99999999999999" Z="0.7101381740744358">
<NAME>Craving at the end of treatment</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0345116124800668" CI_START="-0.21927616781292325" EFFECT_SIZE="0.40761772233357174" ESTIMABLE="YES" MEAN_1="3.85" MEAN_2="2.55" MODIFIED="2011-05-13 12:06:56 +0200" MODIFIED_BY="Laura Amato" ORDER="435" SD_1="3.05" SD_2="3.2" SE="0.3198496988165874" STUDY_ID="STD-Ciraulo-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="31.005149422234314"/>
<CONT_DATA CI_END="1.177458655858484" CI_START="-0.05940176154622312" EFFECT_SIZE="0.5590284471561304" ESTIMABLE="YES" MEAN_1="2.06" MEAN_2="0.96" MODIFIED="2011-05-13 12:07:53 +0200" MODIFIED_BY="Laura Amato" ORDER="436" SD_1="2.37" SD_2="1.28" SE="0.31553141464866297" STUDY_ID="STD-Focchi-2005" TOTAL_1="22" TOTAL_2="20" WEIGHT="31.35205235999564"/>
<CONT_DATA CI_END="0.19611588848807965" CI_START="-0.7526218311444837" EFFECT_SIZE="-0.278252971328202" ESTIMABLE="YES" MEAN_1="0.77" MEAN_2="1.39" MODIFIED="2011-05-13 12:08:31 +0200" MODIFIED_BY="Laura Amato" ORDER="437" SD_1="1.7" SD_2="2.6" SE="0.2420293758242716" STUDY_ID="STD-Shoptaw-2002" TOTAL_1="34" TOTAL_2="35" WEIGHT="37.642798217770036"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.01887790402987162" CI_END="0.43257372927293286" CI_START="-0.5046284486979844" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.03602735971252576" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2015-02-15 10:34:18 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8907171000172781" P_Q="1.0" P_Z="0.8802222327221466" Q="0.0" RANDOM="YES" SCALE="7.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="35" UNITS="" WEIGHT="100.00000000000001" Z="0.1506875019166057">
<NAME>Clinical global evaluation (end of treatment)</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dopamine agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6122077866551162" CI_START="-0.6273872283861653" EFFECT_SIZE="-0.00758972086552461" ESTIMABLE="YES" MEAN_1="-1.42" MEAN_2="-1.41" MODIFIED="2011-05-13 12:39:50 +0200" MODIFIED_BY="Laura Amato" ORDER="444" SD_1="1.23" SD_2="1.35" SE="0.3162290289053903" STUDY_ID="STD-Ciraulo-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="57.161936902446314"/>
<CONT_DATA CI_END="0.6419856099826299" CI_START="-0.7899331406080862" EFFECT_SIZE="-0.07397376531272817" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.4" MODIFIED="2015-02-15 10:34:18 +0100" MODIFIED_BY="[Empty name]" ORDER="447" SD_1="1.5" SD_2="1.1" SE="0.3652921078870603" STUDY_ID="STD-Shoptaw-2005" TOTAL_1="15" TOTAL_2="15" WEIGHT="42.8380630975537"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="42.157707511623855" CI_END="1.2818537769817548" CI_START="-0.349812620154226" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.46602057841376443" ESTIMABLE="YES" I2="90.51181803731356" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2015-05-04 11:45:32 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.547213923647206E-8" P_Q="1.0" P_Z="0.2628964494807636" Q="0.0" RANDOM="YES" SCALE="7.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.7832656443763897" TOTALS="YES" TOTAL_1="170" TOTAL_2="122" UNITS="" WEIGHT="100.0" Z="1.1195714410111524">
<NAME>Depression (difference before and after)</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8521583117948529" CI_START="-0.36254761291645476" EFFECT_SIZE="0.24480534943919907" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="-0.08" MODIFIED="2011-05-13 12:45:40 +0200" MODIFIED_BY="Laura Amato" ORDER="448" SD_1="0.17" SD_2="0.15" SE="0.30987965449690735" STUDY_ID="STD-Alterman-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="19.704885515952693"/>
<CONT_DATA CI_END="1.5071454579408292" CI_START="0.45766748772085675" EFFECT_SIZE="0.9824064728308429" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-9.5" MODIFIED="2011-05-13 12:48:01 +0200" MODIFIED_BY="Laura Amato" ORDER="449" SD_1="3.0" SD_2="2.61" SE="0.2677288915761005" STUDY_ID="STD-Focchi-2005" TOTAL_1="32" TOTAL_2="31" WEIGHT="20.266030508840114"/>
<CONT_DATA CI_END="-0.2969477052279711" CI_START="-1.3269005302501848" EFFECT_SIZE="-0.811924117739078" ESTIMABLE="YES" MEAN_1="-11.1" MEAN_2="-4.0" MODIFIED="2011-05-13 12:49:22 +0200" MODIFIED_BY="Laura Amato" ORDER="450" SD_1="8.1" SD_2="9.5" SE="0.26274789566194845" STUDY_ID="STD-Handelsman-1995" TOTAL_1="42" TOTAL_2="25" WEIGHT="20.328859155236806"/>
<CONT_DATA CI_END="2.1770699755408143" CI_START="1.0059512653458857" EFFECT_SIZE="1.59151062044335" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="-0.32" MODIFIED="2011-05-13 12:48:52 +0200" MODIFIED_BY="Laura Amato" ORDER="451" SD_1="0.18" SD_2="0.14" SE="0.2987602627988482" STUDY_ID="STD-Kampman-1996" TOTAL_1="30" TOTAL_2="30" WEIGHT="19.857725971845575"/>
<CONT_DATA CI_END="0.9289599057691664" CI_START="-0.2465432191869878" EFFECT_SIZE="0.34120834329108934" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="-1.2" MODIFIED="2015-02-22 08:44:27 +0100" MODIFIED_BY="[Empty name]" ORDER="453" SD_1="10.6" SD_2="6.9" SE="0.29987875650480644" STUDY_ID="STD-Shoptaw-2005" TOTAL_1="45" TOTAL_2="15" WEIGHT="19.842498848124798"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-04-30 14:56:08 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Amantadine versus placebo</NAME>
<DICH_OUTCOME CHI2="8.705592693665842" CI_END="1.2614158394686998" CI_START="0.7677874522165702" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9841235966946931" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="90" I2="19.591919283184765" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.10085828008259276" LOG_CI_START="-0.11475898974092813" LOG_EFFECT_SIZE="-0.006950354829167739" METHOD="MH" MODIFIED="2015-02-22 10:09:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2744900914189021" P_Q="1.0" P_Z="0.8994488283134275" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.024408742828241247" TOTALS="YES" TOTAL_1="246" TOTAL_2="238" WEIGHT="100.00000000000001" Z="0.1263576443212782">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 16:48:18 +0200" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannini-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.800127344141452" CI_START="0.258988681998383" EFFECT_SIZE="0.9920634920634921" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.579798150282936" LOG_CI_START="-0.5867192145019491" LOG_EFFECT_SIZE="-0.003460532109506474" MODIFIED="2011-05-13 16:48:27 +0200" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.6852180744287248" STUDY_ID="STD-Handelsman-1995" TOTAL_1="42" TOTAL_2="25" VAR="0.4695238095238095" WEIGHT="3.2476905399017078"/>
<DICH_DATA CI_END="1.7433912020755034" CI_START="0.48197890225523043" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.24139485001278624" LOG_CI_START="-0.3169719717915858" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2011-05-13 16:48:37 +0200" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.32798743508823264" STUDY_ID="STD-Kampman-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.1075757575757576" WEIGHT="12.154003483083674"/>
<DICH_DATA CI_END="1.6330013476958798" CI_START="0.6999108564812302" EFFECT_SIZE="1.069090909090909" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.21298654315469778" LOG_CI_START="-0.1549572699909085" LOG_EFFECT_SIZE="0.029014636581894643" MODIFIED="2011-05-13 16:48:47 +0200" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.21613201719297861" STUDY_ID="STD-Kampman-2006" TOTAL_1="50" TOTAL_2="49" VAR="0.046713048855906006" WEIGHT="22.554832205961095"/>
<DICH_DATA CI_END="2.444274179582082" CI_START="0.21208749997458762" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.38814992006514243" LOG_CI_START="-0.6734849272026054" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2011-05-13 16:48:58 +0200" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Kolar-1992" TOTAL_1="5" TOTAL_2="9" VAR="0.38888888888888884" WEIGHT="3.8813193072472503"/>
<DICH_DATA CI_END="5.619107773239197" CI_START="0.6281858323292917" EFFECT_SIZE="1.878787878787879" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7496673618464961" LOG_CI_START="-0.2019118626057632" LOG_EFFECT_SIZE="0.27387774962036643" MODIFIED="2011-05-13 16:49:07 +0200" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.5589623468363863" STUDY_ID="STD-Kosten-1992" TOTAL_1="33" TOTAL_2="31" VAR="0.3124389051808407" WEIGHT="4.7622124931090815"/>
<DICH_DATA CI_END="4.097836633283934" CI_START="0.8280837193440393" EFFECT_SIZE="1.8421052631578947" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6125546405762676" LOG_CI_START="-0.08192575378137429" LOG_EFFECT_SIZE="0.26531444339744664" MODIFIED="2011-05-13 16:49:18 +0200" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.40794122137907396" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001" TOTAL_1="19" TOTAL_2="21" VAR="0.16641604010025063" WEIGHT="8.406350857605235"/>
<DICH_DATA CI_END="0.9916767064445412" CI_START="0.5882208668079231" EFFECT_SIZE="0.7637571157495257" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="-0.003629887816715405" LOG_CI_START="-0.23045957320060315" LOG_EFFECT_SIZE="-0.11704473050865927" MODIFIED="2011-05-13 16:49:35 +0200" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.133240880019547" STUDY_ID="STD-Shoptaw-2002" TOTAL_1="34" TOTAL_2="35" VAR="0.017753132108383324" WEIGHT="38.047171290046194"/>
<DICH_DATA CI_END="2.9665786559764356" CI_START="0.49957940097627185" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4722558677261181" LOG_CI_START="-0.3013954770768654" LOG_EFFECT_SIZE="0.08543019532462637" MODIFIED="2011-05-13 16:49:48 +0200" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.4544466295731929" STUDY_ID="STD-Weddington-1991" TOTAL_1="23" TOTAL_2="28" VAR="0.20652173913043476" WEIGHT="6.94641982304577"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.29068325869372" CI_END="2.060306993968388" CI_START="0.6928814032449463" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1948005695915087" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" I2="8.83352288391045" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.3139319368026086" LOG_CI_START="-0.15934109486010417" LOG_EFFECT_SIZE="0.07729542097125222" METHOD="MH" MODIFIED="2015-02-13 08:17:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34894153289314567" P_Q="1.0" P_Z="0.522038345697754" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03802870356797205" TOTALS="YES" TOTAL_1="58" TOTAL_2="70" WEIGHT="100.0" Z="0.6402065240915019">
<NAME>Adverse events as N of participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3143959948185437" CI_START="0.7681389795686892" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.3644376690716105" LOG_CI_START="-0.11456019585501069" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-05-13 16:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.2813657169355689" STUDY_ID="STD-Kampman-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.07916666666666666" WEIGHT="65.94597058647493"/>
<DICH_DATA CI_END="1.8872445087136351" CI_START="0.010221316510778171" EFFECT_SIZE="0.1388888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.27582817038537544" LOG_CI_START="-1.9904931632479126" LOG_EFFECT_SIZE="-0.8573324964312684" MODIFIED="2011-05-13 16:59:47 +0200" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="1.331248369847724" STUDY_ID="STD-Kolar-1992" TOTAL_1="3" TOTAL_2="4" VAR="1.7722222222222224" WEIGHT="4.26933212863345"/>
<DICH_DATA CI_END="6.561662515924027" CI_START="0.4233344477922461" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8170138896829089" LOG_CI_START="-0.37331639045019605" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2011-05-13 17:00:00 +0200" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.6992058987801011" STUDY_ID="STD-P_x00e9_rez-de-los-Cobos-2001" TOTAL_1="9" TOTAL_2="15" VAR="0.48888888888888893" WEIGHT="14.66749743983404"/>
<DICH_DATA CI_END="3.7905915461329793" CI_START="0.25563137806644765" EFFECT_SIZE="0.984375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5787069896974779" LOG_CI_START="-0.5923858387580889" LOG_EFFECT_SIZE="-0.006839424530305466" MODIFIED="2011-05-13 17:00:15 +0200" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.6879057244377936" STUDY_ID="STD-Weddington-1991" TOTAL_1="16" TOTAL_2="21" VAR="0.47321428571428564" WEIGHT="15.11719984505759"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.490698282824633" CI_END="2.133486333125672" CI_START="0.5940563136340056" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1257935095945297" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="43" I2="67.97616987114155" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.32908986516246636" LOG_CI_START="-0.22617238407389048" LOG_EFFECT_SIZE="0.05145874054428792" METHOD="MH" MODIFIED="2015-02-13 08:17:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.014052029116836118" P_Q="1.0" P_Z="0.7163972307051736" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.33429130888776476" TOTALS="YES" TOTAL_1="135" TOTAL_2="140" WEIGHT="99.99999999999997" Z="0.3632779944802758">
<NAME>Abstinence (objective)</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amantadine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.402721000225571" CI_START="1.0070886658053861" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.3807033442133355" LOG_CI_START="0.0030677082644907667" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2011-05-13 17:01:04 +0200" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.22182504188289742" STUDY_ID="STD-Alterman-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0492063492063492" WEIGHT="27.74014863890547"/>
<DICH_DATA CI_END="2.150820783495779" CI_START="0.5908180781048261" EFFECT_SIZE="1.1272727272727272" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.33260422443606596" LOG_CI_START="-0.22854622442804595" LOG_EFFECT_SIZE="0.05202900000401" MODIFIED="2011-05-13 17:01:15 +0200" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.3296225514023" STUDY_ID="STD-Kampman-1996" TOTAL_1="30" TOTAL_2="31" VAR="0.1086510263929619" WEIGHT="24.017306973966647"/>
<DICH_DATA CI_END="3.97726640852818" CI_START="0.34668164745870733" EFFECT_SIZE="1.1742424242424243" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5995846822303067" LOG_CI_START="-0.4600691483014235" LOG_EFFECT_SIZE="0.06975776696444164" MODIFIED="2011-05-13 17:01:25 +0200" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.6224459054253957" STUDY_ID="STD-Kosten-1992" TOTAL_1="33" TOTAL_2="31" VAR="0.3874389051808407" WEIGHT="14.73997046379941"/>
<DICH_DATA CI_END="10.44403692989508" CI_START="0.9131715347093972" EFFECT_SIZE="3.088235294117647" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0188683988097822" LOG_CI_START="-0.039447634754416296" LOG_EFFECT_SIZE="0.48971038202768297" MODIFIED="2011-05-13 17:01:32 +0200" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.6216600768644658" STUDY_ID="STD-Shoptaw-2002" TOTAL_1="34" TOTAL_2="35" VAR="0.3864612511671335" WEIGHT="14.759964275940378"/>
<DICH_DATA CI_END="0.7843624772444756" CI_START="0.11809284856315935" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.10548319052114606" LOG_CI_START="-0.9277764014855258" LOG_EFFECT_SIZE="-0.516629796003336" MODIFIED="2011-05-13 17:01:48 +0200" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.4830191025375178" STUDY_ID="STD-Weddington-1991" TOTAL_1="23" TOTAL_2="28" VAR="0.2333074534161491" WEIGHT="18.742609647388083"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5212411856189194" CI_END="2.148303871975017" CI_START="1.0266061879643356" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4850798121977467" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.3320957111933068" LOG_CI_START="0.011403877683039116" LOG_EFFECT_SIZE="0.17174979443817298" METHOD="MH" MODIFIED="2015-04-30 14:56:08 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4673764053440338" P_Q="1.0" P_Z="0.03578539351108624" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="41" WEIGHT="100.0" Z="2.09935755311461">
<NAME>Abstinence at follow-up (objective)</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amantadine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.543399155741051" CI_START="0.9856669326895386" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.40541452279166035" LOG_CI_START="-0.0062698129812521685" LOG_EFFECT_SIZE="0.1995723549052041" MODIFIED="2011-05-13 17:02:12 +0200" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.24182541670333726" STUDY_ID="STD-Alterman-1992" TOTAL_1="18" TOTAL_2="19" VAR="0.058479532163742715" WEIGHT="60.68021567814185"/>
<DICH_DATA CI_END="2.444274179582082" CI_START="0.21208749997458762" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.38814992006514243" LOG_CI_START="-0.6734849272026054" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2011-05-13 17:02:19 +0200" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.6236095644623235" STUDY_ID="STD-Kolar-1992" TOTAL_1="5" TOTAL_2="9" VAR="0.38888888888888884" WEIGHT="9.124844462878476"/>
<DICH_DATA CI_END="3.18168428516712" CI_START="0.8299456398959771" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5026570829119638" LOG_CI_START="-0.08095035228217735" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2011-05-13 17:02:36 +0200" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.34281389633643433" STUDY_ID="STD-Shoptaw-2002" TOTAL_1="12" TOTAL_2="13" VAR="0.11752136752136755" WEIGHT="30.19493985897968"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8106670364318507" CI_END="0.7858132708512466" CI_START="-3.311417466104194E-4" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3927410645523181" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2015-03-09 00:54:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3679231717235073" P_Q="1.0" P_Z="0.05019331711232398" Q="0.0" RANDOM="YES" SCALE="700.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" UNITS="" WEIGHT="100.0" Z="1.95831282252266">
<NAME>Severity of dependence (difference before and after)</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2335538682308065" CI_START="-0.007138773891183892" EFFECT_SIZE="0.6132075471698113" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="-0.13" MODIFIED="2011-05-13 17:03:11 +0200" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="0.08" SD_2="0.08" SE="0.3165090409590216" STUDY_ID="STD-Alterman-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="40.14914034827401"/>
<CONT_DATA CI_END="0.7529336845018828" CI_START="-0.263238108980852" EFFECT_SIZE="0.24484778776051544" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="-0.1" MODIFIED="2011-05-13 17:03:39 +0200" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="0.07" SD_2="0.09" SE="0.2592322617910758" STUDY_ID="STD-Kampman-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="59.850859651726"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.765204193533641" CI_END="0.7389439253337085" CI_START="-1.3316027627190155" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.29632941869265345" ESTIMABLE="YES" I2="85.21848016123703" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2015-02-13 08:17:54 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.009295279322346972" P_Q="1.0" P_Z="0.5747931660256194" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.4758076549284902" TOTALS="YES" TOTAL_1="63" TOTAL_2="46" UNITS="" WEIGHT="100.0" Z="0.5610064158886543">
<NAME>Depression (difference before and after)</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8521583117948529" CI_START="-0.36254761291645476" EFFECT_SIZE="0.24480534943919907" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="-0.08" MODIFIED="2011-05-13 17:05:33 +0200" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="0.17" SD_2="0.15" SE="0.30987965449690735" STUDY_ID="STD-Alterman-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="48.791551202143246"/>
<CONT_DATA CI_END="-0.2969477052279711" CI_START="-1.3269005302501848" EFFECT_SIZE="-0.811924117739078" ESTIMABLE="YES" MEAN_1="-11.1" MEAN_2="-4.0" MODIFIED="2011-05-13 17:06:03 +0200" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="8.1" SD_2="9.5" SE="0.26274789566194845" STUDY_ID="STD-Handelsman-1995" TOTAL_1="42" TOTAL_2="25" WEIGHT="51.208448797856754"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-03-09 00:59:42 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Bromocriptine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.5374041175877572" CI_END="1.3773303428433659" CI_START="0.7288785548582093" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0019513710026224" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.13903811517920248" LOG_CI_START="-0.1373448274415362" LOG_EFFECT_SIZE="8.466438688331967E-4" METHOD="MH" MODIFIED="2015-03-09 00:59:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9106003946601633" P_Q="1.0" P_Z="0.9904192999684999" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="121" WEIGHT="100.0" Z="0.012007915357654568">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour bromocriptine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.528507180413739" CI_START="0.6139824362787565" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.18426748323661857" LOG_CI_START="-0.21184405220788508" LOG_EFFECT_SIZE="-0.013788284485633297" MODIFIED="2011-05-13 17:08:40 +0200" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.23267787670382498" STUDY_ID="STD-Eiler-1995" TOTAL_1="32" TOTAL_2="31" VAR="0.05413899430740038" WEIGHT="48.684138901196846"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-09 00:59:42 +0100" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannini-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.1507401619812847" CI_START="0.3173857406797927" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4984125888703692" LOG_CI_START="-0.49841258887036916" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 17:08:58 +0200" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.5855400437691199" STUDY_ID="STD-Gorelick-2006" TOTAL_1="35" TOTAL_2="35" VAR="0.34285714285714286" WEIGHT="7.687488429928373"/>
<DICH_DATA CI_END="4.78265312007099" CI_START="0.4704501755641861" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6796688831713416" LOG_CI_START="-0.3274863650599791" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2011-05-13 17:09:16 +0200" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Handelsman-1997" TOTAL_1="30" TOTAL_2="30" VAR="0.35" WEIGHT="7.530600910950244"/>
<DICH_DATA CI_END="1.6376184684738955" CI_START="0.5678043797601031" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.21421272749951165" LOG_CI_START="-0.24580126186597548" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2011-05-13 17:09:32 +0200" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.2702144944592592" STUDY_ID="STD-Moscovitz-1993" TOTAL_1="14" TOTAL_2="15" VAR="0.07301587301587302" WEIGHT="36.097771757924534"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.655583331712913" CI_END="2.223916632363973" CI_START="0.38121850352553854" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9207595617507044" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" I2="62.3434901078786" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.3471185028817313" LOG_CI_START="-0.4188260278028365" LOG_EFFECT_SIZE="-0.03585376246055258" METHOD="MH" MODIFIED="2015-02-22 10:09:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1031869532541062" P_Q="1.0" P_Z="0.8544125357596587" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.26164129438677286" TOTALS="YES" TOTAL_1="44" TOTAL_2="45" WEIGHT="100.0" Z="0.1834913112314574">
<NAME>Adverse events as N of participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Bromocriptine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour Bromocriptine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3143959948185437" CI_START="0.7681389795686892" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.3644376690716105" LOG_CI_START="-0.11456019585501069" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-05-13 17:10:42 +0200" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.2813657169355689" STUDY_ID="STD-Gorelick-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.07916666666666666" WEIGHT="59.396398419408825"/>
<DICH_DATA CI_END="1.390712605070853" CI_START="0.20636168455792922" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.14323739100745675" LOG_CI_START="-0.6853709355805327" LOG_EFFECT_SIZE="-0.27106677228653797" MODIFIED="2011-05-13 17:11:14 +0200" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.48672863271515265" STUDY_ID="STD-Moscovitz-1993" TOTAL_1="14" TOTAL_2="15" VAR="0.23690476190476195" WEIGHT="40.603601580591175"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-05-04 11:44:57 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>L dopa/carbidopa versus placebo</NAME>
<DICH_OUTCOME CHI2="1.7865803077329854" CI_END="1.1664547967754504" CI_START="0.7768535759670214" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9519267724351983" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.06686791339006476" LOG_CI_START="-0.10966083080282239" LOG_EFFECT_SIZE="-0.021396458706378838" METHOD="MH" MODIFIED="2015-02-13 08:30:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6178596915075443" P_Q="1.0" P_Z="0.6347004766467752" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="109" WEIGHT="100.00000000000003" Z="0.4751213594470324">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Ldopa/carbidopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ldopa/carbidopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favour placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3042928925437542" CI_START="0.6617385875968038" EFFECT_SIZE="0.9290322580645162" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.11537512769363956" LOG_CI_START="-0.17931353984372317" LOG_EFFECT_SIZE="-0.03196920607504181" MODIFIED="2011-05-13 17:15:32 +0200" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.17310158204387732" STUDY_ID="STD-Mooney-2007a" TOTAL_1="31" TOTAL_2="36" VAR="0.02996415770609319" WEIGHT="35.88425988043497"/>
<DICH_DATA CI_END="1.1972320992137464" CI_START="0.6439600654062293" EFFECT_SIZE="0.8780487804878049" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="25" LOG_CI_END="0.07817835227483688" LOG_CI_START="-0.19114106417973334" LOG_EFFECT_SIZE="-0.05648135595244823" MODIFIED="2011-05-13 17:15:42 +0200" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.1581995583780268" STUDY_ID="STD-Mooney-2007b" TOTAL_1="82" TOTAL_2="40" VAR="0.02502710027100271" WEIGHT="42.96309243103162"/>
<DICH_DATA CI_END="2.8291962599086804" CI_START="0.7329290050973454" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.4516630752897763" LOG_CI_START="-0.134938091099277" LOG_EFFECT_SIZE="0.15836249209524964" MODIFIED="2015-02-13 08:30:11 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.34457242885953415" STUDY_ID="STD-Schmitz-2014" TOTAL_1="25" TOTAL_2="18" VAR="0.11873015873015871" WEIGHT="9.056179438515846"/>
<DICH_DATA CI_END="1.7938216794284925" CI_START="0.5574690123706152" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2537792684241523" LOG_CI_START="-0.2537792684241523" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 17:15:55 +0200" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="0.29814239699997197" STUDY_ID="STD-Shoptaw-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.08888888888888889" WEIGHT="12.096468250017592"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.040851723033639466" CI_END="5.376712168453729" CI_START="0.2741925675083969" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2141888297221186" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.7305167880117828" LOG_CI_START="-0.5619443217341012" LOG_EFFECT_SIZE="0.08428623313884077" METHOD="MH" MODIFIED="2015-02-13 08:32:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9797813404191535" P_Q="1.0" P_Z="0.7982340843064057" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="206" TOTAL_2="162" WEIGHT="100.00000000000001" Z="0.25563319483888314">
<NAME>Dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Ldopa/carbidopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ldopa/carbidopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favour placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.803951985514043" CI_START="0.07574695856384728" EFFECT_SIZE="1.1612903225806452" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2505164143874776" LOG_CI_START="-1.1206348005214486" LOG_EFFECT_SIZE="0.06494080693301461" MODIFIED="2011-05-13 17:18:04 +0200" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="1.3928259610253153" STUDY_ID="STD-Mooney-2007a" TOTAL_1="31" TOTAL_2="36" VAR="1.9399641577060933" WEIGHT="29.71094503870158"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 17:18:14 +0200" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.0" STUDY_ID="STD-Mooney-2007b" TOTAL_1="82" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.663782872221153" CI_START="0.06384153867284795" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.194896654409919" LOG_CI_START="-1.194896654409919" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-13 17:18:23 +0200" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="1.403776419268438" STUDY_ID="STD-Schmitz-2008" TOTAL_1="68" TOTAL_2="68" VAR="1.9705882352941178" WEIGHT="29.24921981890044"/>
<DICH_DATA CI_END="14.693157457367857" CI_START="0.14112691611837302" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1671151326836093" LOG_CI_START="-0.8503901484931098" LOG_EFFECT_SIZE="0.15836249209524964" MODIFIED="2015-02-13 08:32:17 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="1.1850925889754118" STUDY_ID="STD-Schmitz-2014" TOTAL_1="25" TOTAL_2="18" VAR="1.4044444444444444" WEIGHT="41.039835142398"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.65006780222026" CI_END="1.5198019119068393" CI_START="0.8046594140841877" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1058584520448291" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="46" I2="46.903292048617274" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.1817869865158602" LOG_CI_START="-0.09438790333788238" LOG_EFFECT_SIZE="0.04369954158898892" METHOD="MH" MODIFIED="2015-02-22 10:11:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.129933523812787" P_Q="1.0" P_Z="0.535089445545234" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04574830457668601" TOTALS="YES" TOTAL_1="196" TOTAL_2="159" WEIGHT="99.99999999999999" Z="0.6202557205739238">
<NAME>Abstinence (objective)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ldopa/carbidopa</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8845362042965843" CI_START="0.7973322313415958" EFFECT_SIZE="1.2258064516129032" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2752044852057322" LOG_CI_START="-0.09836067964065723" LOG_EFFECT_SIZE="0.08842190278253749" MODIFIED="2011-05-13 17:22:42 +0200" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.21943402700815834" STUDY_ID="STD-Mooney-2007a" TOTAL_1="31" TOTAL_2="36" VAR="0.04815129220901716" WEIGHT="28.027209227307647"/>
<DICH_DATA CI_END="1.5367119908220481" CI_START="0.5340604562356996" EFFECT_SIZE="0.9059233449477352" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.18659248004544782" LOG_CI_START="-0.2724095775717965" LOG_EFFECT_SIZE="-0.04290854876317436" MODIFIED="2011-05-13 17:22:51 +0200" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.2696200807411985" STUDY_ID="STD-Mooney-2007b" TOTAL_1="82" TOTAL_2="40" VAR="0.07269498793889037" WEIGHT="22.219440118372503"/>
<DICH_DATA CI_END="257.558417132434" CI_START="0.8735882232274597" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4108757474002007" LOG_CI_START="-0.05869322928883823" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2011-05-13 17:23:01 +0200" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="1.4506370414707312" STUDY_ID="STD-Schmitz-2008" TOTAL_1="68" TOTAL_2="68" VAR="2.1043478260869564" WEIGHT="1.2240120838971142"/>
<DICH_DATA CI_END="1.2804299640342376" CI_START="0.8924246613620915" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.10735582875111621" LOG_CI_START="-0.04942843688048306" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2011-05-13 17:23:14 +0200" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.09209585372663295" STUDY_ID="STD-Shoptaw-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.008481646273637372" WEIGHT="48.52933857042273"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-02-13 08:18:54 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Amantidine versus antidepressants</NAME>
<DICH_OUTCOME CHI2="5.0109964028761835" CI_END="1.5302925344189509" CI_START="0.47981934355881495" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8568920348082694" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" I2="20.175556348352146" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.18477445953650407" LOG_CI_START="-0.3189222477572765" LOG_EFFECT_SIZE="-0.0670738941103862" METHOD="MH" MODIFIED="2015-02-13 08:18:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2861711265933332" P_Q="1.0" P_Z="0.601677033667336" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08997285236815625" TOTALS="YES" TOTAL_1="71" TOTAL_2="82" WEIGHT="99.99999999999999" Z="0.5219903757779973">
<NAME>Dropouts</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Antidepressants</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antidepressant</GRAPH_LABEL_2>
<DICH_DATA CI_END="130.3403286691407" CI_START="0.43156251464415496" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.115078811787816" LOG_CI_START="-0.364956285004416" LOG_EFFECT_SIZE="0.8750612633917001" MODIFIED="2011-05-13 17:26:57 +0200" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="1.456784892227477" STUDY_ID="STD-Kolar-1992" TOTAL_1="5" TOTAL_2="8" VAR="2.1222222222222222" WEIGHT="3.9572182808460408"/>
<DICH_DATA CI_END="2.1187015539555953" CI_START="0.39007206062069866" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.32606978512105667" LOG_CI_START="-0.40885515543750683" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2011-05-13 17:27:04 +0200" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.43169854802122787" STUDY_ID="STD-Kosten-1992" TOTAL_1="33" TOTAL_2="30" VAR="0.18636363636363637" WEIGHT="31.679271999664266"/>
<DICH_DATA CI_END="1.7947789186084" CI_START="0.1584843913059728" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.25401095968775117" LOG_CI_START="-0.8000135038152266" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2011-05-13 17:27:20 +0200" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Oliveto-1995" TOTAL_1="5" TOTAL_2="4" VAR="0.3833333333333333" WEIGHT="18.49572022176736"/>
<DICH_DATA CI_END="26.781226600425146" CI_START="0.3823573935869481" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4278304641471176" LOG_CI_START="-0.4175305075073055" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2011-05-13 17:27:12 +0200" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="1.08397416943394" STUDY_ID="STD-Oliveto-1995" TOTAL_1="5" TOTAL_2="8" VAR="1.175" WEIGHT="6.920416334293649"/>
<DICH_DATA CI_END="1.333347733500969" CI_START="0.3161654574590053" EFFECT_SIZE="0.6492753623188405" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.12494342701797845" LOG_CI_START="-0.500085580496201" LOG_EFFECT_SIZE="-0.18757107673911136" MODIFIED="2011-05-13 17:27:41 +0200" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.3671451329573147" STUDY_ID="STD-Weddington-1991" TOTAL_1="23" TOTAL_2="32" VAR="0.13479554865424428" WEIGHT="38.94737316342868"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20657814353703627" CI_END="1.7697257874045076" CI_START="0.18037491593614355" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5649903894165931" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.24790597921897048" LOG_CI_START="-0.743823858301651" LOG_EFFECT_SIZE="-0.24795893954134027" METHOD="MH" MODIFIED="2015-02-13 08:18:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6494627553040209" P_Q="1.0" P_Z="0.3270433570230976" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="25" WEIGHT="100.0" Z="0.980086658198718">
<NAME>Adverse events as N of participants with at least one adverse event</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Antidepressant</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antidepressant</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.8748017365037075" CI_START="0.021193954567824642" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.6879569571641216" LOG_CI_START="-1.6737880009699102" LOG_EFFECT_SIZE="-0.49291552190289434" MODIFIED="2011-05-13 17:29:15 +0200" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="1.3873006792340203" STUDY_ID="STD-Kolar-1992" TOTAL_1="3" TOTAL_2="8" VAR="1.9246031746031744" WEIGHT="17.63277905704767"/>
<DICH_DATA CI_END="2.2431036866475615" CI_START="0.18118032279078272" EFFECT_SIZE="0.6375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3508493491505589" LOG_CI_START="-0.7418889709385734" LOG_EFFECT_SIZE="-0.19551981089400725" MODIFIED="2011-05-13 17:29:57 +0200" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.6418798983622782" STUDY_ID="STD-Weddington-1991" TOTAL_1="16" TOTAL_2="17" VAR="0.4120098039215686" WEIGHT="82.36722094295233"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.011176809253489009" CI_END="0.5348387584238923" CI_START="0.11556239506317764" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24861063512263762" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.271777128037387" LOG_CI_START="-0.9371834658591408" LOG_EFFECT_SIZE="-0.604480296948264" METHOD="MH" MODIFIED="2015-02-13 08:18:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9158041717585018" P_Q="1.0" P_Z="3.6942974347836747E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="40" WEIGHT="100.0" Z="3.5610109012819264">
<NAME>Abstinence (objective)</NAME>
<GROUP_LABEL_1>Amantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>Antidepressant</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antidepressant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amantadine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.068009528127923" CI_START="0.06560728374312448" EFFECT_SIZE="0.2647058823529412" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.02857512721961751" LOG_CI_START="-1.183047942425478" LOG_EFFECT_SIZE="-0.5772364076029303" MODIFIED="2011-05-13 17:31:57 +0200" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.7117133887404524" STUDY_ID="STD-Kolar-1992" TOTAL_1="5" TOTAL_2="8" VAR="0.5065359477124183" WEIGHT="30.16051816389749"/>
<DICH_DATA CI_END="0.6051560303071264" CI_START="0.09674782934743753" EFFECT_SIZE="0.24196597353497165" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="23" LOG_CI_END="-0.2181326346619119" LOG_CI_START="-1.0143587701127228" LOG_EFFECT_SIZE="-0.6162457023873174" MODIFIED="2011-05-13 17:32:34 +0200" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.46770717334674267" STUDY_ID="STD-Weddington-1991" TOTAL_1="23" TOTAL_2="32" VAR="0.21874999999999997" WEIGHT="69.83948183610251"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-05-14 10:44:01 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram present update.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAgoAAAJaCAYAAABOT2+iAABMIklEQVR42u2dAWRdSfv/l7WqoqpU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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZQAAAScCAIAAAAjzO49AABSP0lEQVR42u2dv04rSbe3W0JCBA4I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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtUAAAEZCAMAAABvrykLAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Any dopamine agonist versus placebo, outcome: 1.1 Dropouts.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3oAAAHQCAMAAADAlejrAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Any dopamine agonist versus placebo, outcome: 1.2 Adverse events as number of participants with at least one adverse event.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3oAAADwCAMAAABhTuZpAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-05-14 10:46:22 +0200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Amantadine versus placebo, outcome: 2.2 Adverse events as number of participants with at least one adverse event.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzoAAADACAMAAAD7juZkAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-05-04 14:32:55 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-05-04 14:32:55 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-03-31 10:13:32 +0200" MODIFIED_BY="[Empty name]">Search strategies June 2011</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-04 14:32:28 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2015-04-29 17:53:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;Please insert date in June 2011&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-05-04 14:32:28 +0200" NOTES_MODIFIED_BY="[Empty name]">
<OL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL - the Cochrane Library, most recent);</LI>
<LI>PubMed (1966 to 1 June 2011);</LI>
<LI>EMBASE (1988 - to 1 June 2011);</LI>
<LI>CINAHL (1982 to 1 June 2011);</LI>
<LI>PsycINFO (1967 to 1 June 2011).</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<OL>
<LI>MESH DESCRIPTOR¬ COCAINE-RELATED DISORDERS EXPLODE ALL TREES</LI>
<LI>( (DRUG OR SUBSTANCE) NEAR2 (ABUSE* OR¬ MISUSE* OR ADDICT* OR DEPENDEN*):TI,AB</LI>
<LI>#1 OR #2</LI>
<LI>MESH DESCRIPTOR¬ COCAINE EXPLODE ALL TREES</LI>
<LI>COCAINE :TI,AB</LI>
<LI>#4 OR #5</LI>
<LI>MESH DESCRIPTOR DOPAMINE AGONISTS EXPLODE ALL TREES</LI>
<LI>MeSH descriptor Levodopa explode all trees</LI>
<LI>DOPAMINE OR AMANTADINE OR BROMOCRIPTINE OR MAZINDOL OR PERGOLIDE OR LEVODOPA</LI>
<LI>#7 OR #8 OR #9</LI>
<LI>#3 AND #6 AND #10</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE, PubMed on platform STN (Scientific &amp; Technical Information Network)</HEADING>
<OL>
<LI>COCAINE&#8211;RELATED DISORDER/CT</LI>
<LI>COCAINE DEPENDENCE/CT</LI>
<LI>(ADDICT? OR ABUSE? OR DEPENDEN? OR DISORDER?)/TI,AB¬</LI>
<LI>(COCAINE/CT OR COCAINE/TI,AB)</LI>
<LI>1 OR 2 OR 3</LI>
<LI>4 AND 5</LI>
<LI>DOPAMINE AGONIST/CT</LI>
<LI>DOPAMINE AGONIST#</LI>
<LI>LEVODOPA/CT</LI>
<LI>AMANTADINE*NT/CT OR AMANTADINE/TI,AB</LI>
<LI>BROMOCRIPTINE/CT OR BROMOCRIPTINE/TI,AB</LI>
<LI>PERGOLIDE/CT OR PERGOLIDE/TI,AB</LI>
<LI>LEVODOPA/TI,AB</LI>
<LI>DOPAMINE(S)AGONIST#/TI,AB</LI>
<LI>DOPAMINE RECEPTOR STIMULATING AGENT/CT</LI>
<LI>6 AND (7-15)</LI>
<LI>RANDOMIZED CONTROLLED TRIAL/DT</LI>
<LI>RANDOMIZED CONTROLLED TRIAL/CT</LI>
<LI>CONTROLLED CLINICAL TRIAL/DT</LI>
<LI>PHASE 2 CLINICAL TRIAL/CT</LI>
<LI>PHASE 3 CLINICAL TRIAL/CT</LI>
<LI>DOUBLE BLIND PROCEDURE/CT</LI>
<LI>SINGLE BLIND PROCEDURE/CT</LI>
<LI>CROSSOVER PROCEDURE/CT</LI>
<LI>LATIN SQUARE DESIGN/CT</LI>
<LI>PLACEBO/CT</LI>
<LI>MULTICENTER STUDY/CT</LI>
<LI>DRUG THERAPY+NT/CT</LI>
<LI>RANDOM?/TI,AB</LI>
<LI>PLACEBO/TI,AB OR PLACEBOS/TI,AB</LI>
<LI>CROSSOVER?/TI,AB</LI>
<LI>TRIAL# OR GROUP#)/TI,AB</LI>
<LI>(SINGL? OR DOUBL? OR TREBL? OR TRIPL?)/TI,AB(S)(BLIND? OR MASK?)/TI,AB</LI>
<LI>16 AND (17-33)</LI>
<LI>34/HUMAN</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">PsycINFO</HEADING>
<OL>
<LI>COCAINE-DEPENDENCE.KW.</LI>
<LI>COCAINE-RELATED-DISORDERS.KW</LI>
<LI>(ADDICT$4 OR DISORDER$1 OR DEPENDEN$3 OR ABUSE$1).TI,AB.</LI>
<LI>COCAINE.KW,TI,AB.</LI>
<LI>4 AND (1 OR 2 OR 3)</LI>
<LI>MENTAL-HEALTH-PROGRAMME-EVALUATION.KW.</LI>
<LI>TREATMENT-EFFECTIVENESS-EVALUATION</LI>
<LI>PLACEBO.KW.</LI>
<LI>PLACEBO$1.TI,AB.</LI>
<LI>RANDOM$6.KW,TI,AB.</LI>
<LI>((SINGL$2 OR DOUBL$3 OR TREVL$3 OR TRIPL$4) NEAR (BLIND$4 OR MASK$4 OR DUMMY)).TI,AB.</LI>
<LI>(FACTORIAL$1 OR ALLOCAT$5 OR ASSIGN$5 OR VOLUNTEER$1).TI,AB.</LI>
<LI>(CROSSOVER$).TI,AB.¬ OR (CROSS ADJ OVER$1).TI,AB.</LI>
<LI>(QUASI ADJ EXPERIMENTAL).TI,AB.</LI>
<LI>((CONTROL$5 NEAR (TRIAL$1 OR STUDY OR STUDIES OR GROUP$1))).TI,AB.</LI>
<LI>7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15</LI>
<LI>5 AND 16</LI>
<LI>(DOPAMINE-AGONIST.KW.)</LI>
<LI>(DOPAMINE ADJ AGONIST$1).TI,AB.</LI>
<LI>(DOPAMINE ADJ RECEPTOR$1 ADJ STIMULATING ADJ AGENT$1).TI,AB.</LI>
<LI>AMANTADINE.KW,TI,AB.</LI>
<LI>BROMOCRIPTINE.KW,TI,AB.</LI>
<LI>PERGOLIDE.KW,TI,AB.</LI>
<LI>LEVODOPA.KW,TI,AB.</LI>
<LI>17 AND (18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24)</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL (EBSCO)</HEADING>
<OL>
<LI>MH SUBSTANCE ABUSE</LI>
<LI>((DRUG OR SUBSTANCE OR COCAINE) AND (ABUSE* OR DEPENDEN* OR ADDICT* OR DISORDER*))</LI>
<LI>S1 OR S2</LI>
<LI>TX COCAINE OR MH COCAINE</LI>
<LI>S3 AND S4</LI>
<LI>(MH &#8220;DOPAMINE AGONISTS&#8221;)</LI>
<LI>TX DOPAMINE OR TX AMANTADINE OR TX BROMOCRIPTINE OR TX MAZINDOL OR TX PERGOLIDE OR TX LEVODOPA</LI>
<LI>S6 OR S7</LI>
<LI>TX RANDOM*</LI>
<LI>TX (CLINICAL AND TRIAL*)</LI>
<LI>TX ((SINGL* OR DOUBL* OR TRIPL* OR TREBL*) AND (MASK* OR BLIND*))</LI>
<LI>TX (CROSSOVER* OR ALLOCAT* OR¬ ASSIGN*)</LI>
<LI>MH RANDOM ASSIGNMENT/</LI>
<LI>MH CLINICAL TRIALS/</LI>
<LI>S9 OR S10 OR S11 OR S12 OR S13 OR S14</LI>
<LI>S5 AND S8 AND S15</LI>
</OL>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-05-04 11:42:07 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-03-31 12:54:09 +0200" MODIFIED_BY="[Empty name]">Search strategies 2015</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-04 11:42:07 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CDAG Specialized Register (via CRS)</HEADING>
<OL>
<LI>((dopamine OR amantadine OR bromocriptine OR mazindol OR pergolide OR levodopa)ti,ab,kw) AND (INREGISTER)</LI>
<LI>(cocaine :ti,ab,ky,xdi) AND (INREGISTER)</LI>
<LI>#1 AND #2</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<OL>
<LI>MeSH descriptor: [Cocaine-Related Disorders] explode all trees</LI>
<LI>((drug* or substance) near/2 (abus* or misus* or addict* or dependen*)):ti,ab</LI>
<LI>#1 or #2</LI>
<LI>cocaine:ti,ab,kw (Word variations have been searched)</LI>
<LI>#3 and #4</LI>
<LI>(DOPAMINE or AMANTADINE or BROMOCRIPTINE or MAZINDOL or PERGOLIDE or LEVODOPA):ti,ab,kw (Word variations have been searched)</LI>
<LI>#5 and #6</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (via PubMed)</HEADING>
<OL>
<LI>"Cocaine-Related Disorders"[Mesh]</LI>
<LI>((cocaine*[tiab]) AND (abuse*[tiab] OR addict*[tiab] OR dependen*[tiab]))</LI>
<LI>#1 OR #2</LI>
<LI>"Dopamine Agonists"[Mesh]</LI>
<LI>dopamine OR amantadine OR bromocriptine OR mazindol OR pergolide OR levodopa</LI>
<LI>#4 OR #5</LI>
<LI>randomized controlled trial [pt]</LI>
<LI>controlled clinical trial [pt]</LI>
<LI>randomized [tiab]</LI>
<LI>placebo [tiab]</LI>
<LI>clinical trials as topic [mesh: noexp]</LI>
<LI>randomly [tiab]</LI>
<LI>trial [ti]</LI>
<LI>#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13</LI>
<LI>animals [mh] NOT humans [mh]</LI>
<LI>#14 NOT #15</LI>
<LI>#3 AND #6 AND #16</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (via embase.com)</HEADING>
<P>'cocaine dependence'/exp OR (cocaine:ab,ti AND (abus*:ab,ti OR dependen*:ab,ti OR disorder*:ab,ti OR addict*:ab,ti)) AND ('dopamine receptor stimulating agent'/exp OR 'dopamine' OR 'amantadine' OR 'mazindol' OR pergolide OR 'levodopa') AND ('randomized controlled trial'/exp OR 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR 'controlled clinical trial'/exp OR 'clinical trial'/exp OR placebo:ab,ti OR 'double blind':ab,ti OR 'single blind':ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR random*:ab,ti OR factorial*:ab,ti OR crossover:ab,ti OR (cross:ab,ti AND over:ab,ti))</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL (via EBSCOHOST)</HEADING>
<OL>
<LI>(MH "Substance Abuse+")</LI>
<LI>TX((drug* or substance or cocaine) N3 (abus* or depend* or addict* or disorder*))</LI>
<LI>S1 OR S2</LI>
<LI>TI cocaine OR AB cocaine OR MH cocaine</LI>
<LI>S3 AND S4</LI>
<LI>(MH "Dopamine Agonists+")</LI>
<LI>TX DOPAMINE OR TX AMANTADINE OR TX BROMOCRIPTINE OR TX MAZINDOL OR TX PERGOLIDE OR TX LEVODOPA</LI>
<LI>S6 OR S7</LI>
<LI>S5 AND S8</LI>
<LI>MH "Clinical Trials+"</LI>
<LI>PT Clinical trial</LI>
<LI>TI clinic* N1 trial* or AB clinic* N1 trial*</LI>
<LI>TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )</LI>
<LI>AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )</LI>
<LI>TI randomi?ed control* trial* or AB randomi?ed control* trial*</LI>
<LI>MH "Random Assignment"</LI>
<LI>TI random* allocat* or AB random* allocat*</LI>
<LI>MH "Placebos"</LI>
<LI>TI placebo* or AB placebo*</LI>
<LI>MH "Quantitative Studies"</LI>
<LI>S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20</LI>
<LI>S9 AND S21</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Web of Science</HEADING>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI Timespan=All years</I>
</P>
<OL>
<LI>TS=((( cocaine* OR crack) AND (abuse* OR depend* OR addict* OR disorder* OR detox* OR withdraw* OR abstinen* OR abstain*)))</LI>
<LI>TS=(dopamine OR amantadine OR bromocriptine OR mazindol OR pergolide OR levodopa)</LI>
<LI>TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR TS=controlled trial* OR TS=follow-up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*)</LI>
<LI>#1 AND #2 AND #3</LI>
</OL>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;22 of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;23 of studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;50 of full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;442 of records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;823 of records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;5 of additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;392 of records excluded on the basis of title and abstract&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;27 of full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>